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Lipohypertrophy (LH) is a common insulin injection site problem that occurs with 
repeated exposure to insulin injections in the subcutaneous tissue. Subcutaneous 
insulin exposure can increase tissue density with hypertrophy and hyperplasia of 
adipocytes. The effect of insulin when injected into an LH area can be attenuated, 
potentially leading to glucose variability. Thereby, potentially increasing the risks of 
diabetes complications, hypoglycaemia and individual distress. The aim of this study 
was to explore the association between ultrasonographically characterised LH lesions 
with time in range (TIR 4 to 10 mmol/L) and glucose variability (GV) in adults with Type 
1 diabetes (T1DM). The study also aimed to characterise the LH observed in 
participants. 
Methods 
The study involved two integrated arms, the glucose variability arm (the GV study) and 
LH characterisation arm (the LH characterisation study). All participants were recruited 
from clinics at Guys and St Thomas’ Hospitals. The main screening criteria were: 
people with T1DM using insulin; with evident GV based on the standard deviation (SD) 
of the mean glucose from their self-monitored blood glucose downloads (SD³ 
4.0mmol/L). In the GV study participants TIR and GV (SD of glucose, coefficient of 
variation (CV), mean amplitude of glucose excursions (MAGE), continuous 
overlapping net glycaemic action (CONGA), means of the daily differences (MODD), 
and mean absolute glucose (MAG)) were assessed in two conditions using blind 
continuous glucose monitoring (CGM): Condition 1, usual insulin injecting behaviour; 
and Condition 2, injecting in areas assessed to be free of LH- participants insulin doses 
were reduced at this stage, to reduce the risk of hypoglycaemia. Additional outcomes 
included: glycaemic control; insulin satisfaction; diabetes distress; and quality of life. 
Data were also collected on participant injecting behaviours; and at the end of the 
3 
study interviews were conducted to explore participants’ views of the study. In the LH 
characterisation study, the participants injection areas were screened using 
ultrasound (US) with a blind comparison to physical clinical assessment (digital 
palpation) following a standard protocol for the assessment and recording the LH. 
These participants were shown were their LH lesions were and given advise on insulin 
site management (avoiding LH affected tissue) and insulin doses were reviewed to 
reduce the risk of potential hypoglycaemia.  
Findings 
A total of 27 participants were enrolled into the GV study, of which 15 completed the 
study and were included in the analysis. The median age of the completing participants 
was 32 (IQR, 25-60) years (range 20-71 years), with a median duration of T1DM of 14 
(IQR, 10-23) years. In terms of the impact of LH on TIR and GV, one third of those 
participants demonstrated improvement in TIR (4-10mmol/L) ³10%, the remainder 
showed limited improvement and one participant showed a reduction in TIR >10% 
(p=0.02). No significant changes were seen in the GV measures. The findings showed 
a significant improvement in the median percentage of effective bolus insulin injections 
(based on the glucose response to the insulin), with an increase of 17% from  69% 
(IQR, 62-73) to  86% (IQR, 82-93) (p<0.001). In some participants there were large 
reductions in the total daily insulin dose, in five participants these were  25, 20, 9, 8, 6 
units respectively; of the remainder most had minimal dose changes, with two having 
a modest increase of 3 and 4 units. The LH characterisation study involved the US 
assessment and digital palpation of 74 participants. The US images showed that the 
LH was heterogenous in its morphology, with the main presenting features being: LH 
nodules; and areas of diffuse (dense) subcutaneous tissue. Additional observations 
included hypoechogenic tissue within nodules which could indicate necrotic tissue; 
inflammatory changes; and disruption to dermal tissue. The US screening identified 
740 LH nodules in the participants, with 304 diffuse areas. The most common areas 
where LH were observed where in the lower abdominal and thigh areas. LH areas 
were graded from 1-5 (1 = diffuse LH; 2 = nodules <6mm; 3 = nodules >6mm to <8mm; 
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4 = >8mm to <10mm; and 5 = >10mm). Palpation was shown to have a moderate level 
of accuracy (Cohen’s kappa 0.44) in detecting LH compared to US, missing over half 
of the areas detected via US.  
Conclusion 
The finding from this study provide some important new insights into the morphology 
of LH and its impact on clinical management. Overall, the study identified that the 
interaction between LH and glucose regulation is complex and challenging to study. 
The current data shows that changing injection sites in a small sample of participants 
with T1DM led to improvements in TIR for some participants and reductions in insulin 
doses. The study has also revealed that LH is complex and heterogenous in 
presentation, and a potential method for grading LH has been presented which could 
be adopted clinically with further validation. As the study was unable to identify a clear 
estimation of the association between LH and GV, determining the clinical significance 
of LH remains an important objective for future studies.  
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Chapter 1. Introduction   
Type 1 diabetes mellitus (T1DM) is an autoimmune disease that results in destruction 
of beta-cells in the pancreas with subsequent loss of insulin production and 
hyperglycaemia (Atkinson et al. 2014, Eisenbarth 1986). The only treatment for the 
condition is to compensate for the loss of endogenous insulin supply with insulin 
therapy. Most people with T1DM either follow a multiple daily injection (MDI) regimen 
involving ≥ 4 injections per day or use a continuous subcutaneous insulin infusion 
(CSII) device (insulin pump). Hence, people with T1DM are exposed to high levels of 
subcutaneous insulin. The development of lipohypertrophy (LH) due to the anabolic 
effect of insulin on the local tissues is a potential consequence of this exposure. This 
can lead to significant dense subcutaneous lesions, which may impact on and impede 
the absorption of insulin, potentially leading to erratic blood glycaemic control. While 
LH is a well-recognised phenomenon in the context of insulin use, currently there is a 
lack of knowledge about its effects on glucose regulation and the extent to which this 
contributes to clinically important events, such as excess hyperglycaemia or 
hypoglycaemia.  
 
This thesis presents an exploratory study designed to contribute new knowledge on: 
the morphology of LH lesions using ultrasound technology as a means of 
characterising their presentation in people with T1DM; and to estimate the impact of 
LH on glucose regulation by comparing Time in range and glucose variability in 2 
conditions (1. insulin is injected into LH affected area; and 2. participant avoids LH 
affected injection sites). This chapter introduces some of the key elements relevant to 
the conduct of the study, with consideration given to the following areas: 
 
• Type 1 Diabetes mellitus 
• Insulin therapy in people with type 1 diabetes mellitus  







1.1 Type 1 Diabetes Mellitus 
T1DM is a condition characterised by hyperglycaemia due to an absolute deficiency 
of endogenous insulin production (Daneman 2006) caused by the autoimmune 
destruction of insulin-producing beta cells in the pancreas (Bluestone et al. 2010, 
Maahs et al. 2010, Atkinson & Eisenbarth 2001). The factors that precipitate this 
process are not fully understood, but a combination of genetic susceptibility and 
environmental triggers, such as a viral exposure or dietary factors, have been 
postulated (Peng & Hagopian 2006). The incidence of T1DM onset peaks in childhood 
and adolescence, although 42% of cases occur in adulthood (Thomas et al. 2018). 
The prevalence of T1DM is increasing across the globe and it currently accounts for 
10% of the total diabetes population (International Diabetes Federation [IDF] 2017a). 
There are national variations in the prevalence; Finland currently has the highest 
incidence with 57.2 cases per 100,000 people each year (IDF 2017b), and the lowest 
levels are reported in China and Venezuela (0.1 cases per 100,000 people each year) 
(Karvonen et al. 2000). In the UK, based on estimates from IDF report, a rate of 25.9 
cases per 100,000 among children (aged <20) each year (IDF 2017b). It is also 
estimated that 29,000 children and up to 370,000 adults have T1DM in UK (The 
National Institute for Health and Care Excellence [NICE] 2015).  
 
The hyperglycaemia that is a consequence of T1DM drives a range of potential 
microvascular and macrovascular complications that include: retinopathy, 
nephropathy; neuropathy; vascular disease and increased risk of mortality (Chawla et 
al. 2016). A landmark study, the Diabetes Control and Complications Trial, showed 
that intensifying insulin therapy to achieve near normal glucose levels (with a glycated 
haemoglobin target measured by HbA1c of 46 mmol/mol [6.4%]) led to a significant 
reduction in the development and progression of these complications (Diabetes 
Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complications [DCCT/EDIC] 2005, Diabetes Control and Complications Trial [DCCT] 
1995). The intensive insulin treatment involved the administration of insulin (long and 
quick acting) up to four times a day or via a continuous subcutaneous insulin infusion 






glucose (SMBG), adjusting for food intake and activity levels. Hence, the findings of 
this trial and the subsequent follow-up of participants indicates that intensive insulin 
management with tight glucose control over a prolonged period can significantly 
reduce diabetes complications and mortality hazard. However, it has also been 
observed that intensive insulin therapy can lead to problems, such as: weight gain 
(Russell-Jones & Khan 2007); hypoglycaemia (Diabetes Control & Complications Trial 
Research Group 1993, Reichard et al. 1990); and local tissue changes, such as the 
formation of LH (Blanco et al. 2013). Therefore, it is important to understand how to 
reduce these potential problems in the use of insulin in people with T1DM, such that 
insulin will have the maximum effect without these hazards. While there have been 
significant investigations on strategies to manage and reduce hypoglycaemia and, to 
a lesser extent, weight gain related to insulin use, there has been much less 
investigation of managing local tissue changes such as LH. 
 
1.2 Insulin therapy in people with Type 1 Diabetes Mellitus  
Prior to the discovery of insulin in 1921, T1DM was a fatal disease (Rosenfeld 2002). 
Since the discovery of insulin and its clinical application in the treatment of T1DM, 
there have been many advances in both the formulation of insulin and the method of 
delivering it. Initially, animal insulins were the main source of insulin; subsequently, 
human and more recently analogue insulins have become more popular (Shah et al. 
2013). In terms of insulin delivery, there are multiple potential models for delivery, this 
includes using twice-daily mixed insulin, MDI models or CSII methods (with or without 
glucose sensors) (Shah et al. 2016). The most common model in the UK is MDI 
followed by CSII, although the latter is increasing particularly in paediatric diabetes 
(Olsen et al. 2015, Danne et al. 2007). 
 
The advantage of the MDI and CSII models is that they provide more flexibility in 
intensifying insulin delivery in order to try and mimic normal insulin physiology. While 
insulin is the most important hormone in reducing hyperglycaemia systemically, it also 






of local tissue through an immunological reaction to the animal proteins (Schernthaner 
1993), the most common reaction observed in exposure to human and analogue 
insulin is an increase in local tissue synthesis and density in response to the anabolic 
effect of the insulin on fat and protein (Chowdhury & Escudier 2003, Hauner et al. 
1996). Therefore, the most important and common localised tissue effect of insulin is 
the development of LH lesions which may have potentially detrimental effects on 
insulin delivery and absorption, with adverse consequences for managing diabetes. 
 
1.3 Insulin related Lipohypertrophy 
LH is characterised by the enlargement (hypertrophy) and to lesser extent proliferation 
(hyperplasia) of adipocytes in the subcutaneous tissue arising from the anabolic effect 
of exogenous insulin exposure (Hambridge 2007, Chowdhury & Escudier 2003, 
Richardson & Kerr 2003, Hauner et al. 1996). The anabolic effect of the insulin is 
related to the effect of the insulin on insulin growth factor (IGF) receptors (Clemmons 
2012). It has also been suggested that local inflammation due to insulin exposure and 
injections may also increase the density of the subcutaneous tissue by stimulating an 
inflammatory response with the accumulation of macrophages into dense plaques of 
tissue (Anderson et al. 2008, Anderson & Shive 1997), although this hypothesis has 
not been confirmed in studies directly studying insulin exposed tissue. LH has also 
been associated with sub-optimal glycaemia control (Al Hayek et al. 2016). The 
prevalence of LH in the diabetes population has been varyingly reported with ranges 
from 30-64.4% (Blanco et al. 2013, Pavlovic et al. 2007) reflecting the methods used 
for LH case definition, although the pooled prevalence from a meta-analysis of 26 
studies estimated it to be 38% (Deng et al. 2018), suggesting that it is a common 
problem. 
 
According to the First Injection Techniques guidelines (FIT 2016) (which was founded 
by a group of diabetes nurses and sponsored by a medical technology company that 
makes insulin needles) on the management of injection sites, LH can be detected 






Frid et al. 2010a). However, this approach is focussed on detecting defined nodules 
rather than the wider tissue disruption that can occur with LH (Seyoum & Abdulkadir 
1996). More recently, the use of ultrasound has been used to detect LH and has been 
shown to have higher diagnostic sensitivity both in terms of the frequency and the 
extent of the LH detected (Ghazaleh et al. 2018). Consequently, the prevalence of LH 
has been reported as being significantly higher (56%) when compared to clinical 
examination (Volkova et al. 2015). However, it is possible that this disparity reflects 
the fact that ultrasound is more sensitive in detecting LH at a sub-clinical level, as 
there is no currently recognised threshold for clinically significant LH. Clinical 
significance should reflect the point at which the LH’s impact on glucose levels lead to 
extend hyperglycaemia and increased frequency of hypoglycaemia. Hence, while both 
clinical and ultrasound based studies suggest that LH is a common problem (Gupta et 
al. 2018, Kapeluto et al. 2018, Gentile et al. 2016a, Volkova et al. 2015), it is yet to be 
established at what level the LH becomes problematic in terms of glucose 
management and glycaemic control. Therefore, studies are needed to: (1) classify LH, 
identifying clinically relevant grades or levels where glycaemia becomes disrupted; 
and (2) identify and test strategies to prevent, minimise or manage the LH. 
 
In terms of the clinical effect of LH, injections into the LH regions can attenuate insulin 
absorption and activity (Famulla et al. 2016, Johansson et al. 2005, Young et al. 1984, 
Thow et al. 1990). The adipose tissue in LH-affected tissue can become more fibrous, 
resulting in reduced blood vessels and flow around and through the tissue, leading to 
the decreased absorption of insulin and an altered insulin action curve (Heinemann 
2010, Young et al. 1984). This effect has recently been investigated in glucose 
clamping studies to quantify the levels of insulin action and glucose response when 
insulin exposure is mediated by LH. Famulla et al. (2016) used a glucose clamp to 
maintain blood glucose concentration for 24 hours in the study participants, followed 
by regular insulin injections into the LH or normal tissue. Insulin absorption and action 
were found to be substantially diminished and showed increased response variability 
when the insulin was injected directly into LH areas in both studies (Famulla et al. 






and evaluated using a mixed meal tolerance test, the study showed a net reduction in 
the impact of insulin on glucose when injected into an LH region of 20-25%. Slower 
absorption and decreased insulin action were identified when the insulin was injected 
into LH tissue rather than normal adipose tissue, with considerably greater post-meal 
glycaemic excursions (Hovelmann et al. 2015). It was strongly suggested by this study 
that insulin was not effectively absorbed when injected into LH tissue, leading to erratic 
glucose control with both high to low glucose variations. It should be noted, however, 
that such studies are conducted in very controlled conditions. So while they may show 
the effect of LH on insulin action in these conditions the extent to which this translates 
to the ‘real world’ context where multiple extraneous factors (injection behaviours, 
insulin requirement, carbohydrate estimation, exercise/activity and stress levels) 
influence glucose levels and insulin action is unknown. Nevertheless, these 
unpredictable blood glucose responses to insulin, may be very frustrating for people 
with diabetes, potentially undermining their self-confidence in optimally adjust their 
insulin therapy and increasing the risk of hypoglycaemia if they overcompensate with 
insulin doses or inject in areas not affected by LH (Vora & Heise 2013). The net impact 
of LH on patient behaviours may lead them to alter their self-management behaviours 
in a way that increases their overall glucose exposure to avoid hypoglycaemic events 
(Gradel et al. 2018, Gonder-Frederick et al.1997).  
 
Hence, it is very likely that LH may contribute to glucose variability in people with 
T1DM. While there are multiple interpretations of the term ‘glucose variability’, it can 
be generally understood as a deviation of blood glucose from a mean or ideal value 
over time (hours and days) - a phenomenon that has also be described as ‘glucose 
fluctuation’ (Vora & Heise 2013). Glucose variability (GV) is also observed as day-to-
day differences in glucose values obtained at set time points, or in the 24-hour blood 
glucose profile, and such variability goes under the term ‘predictability’ (Vora & Heise 
2013). In people with diabetes using insulin therapy, the term ‘within-subject variability’ 
usually describes differences in the blood glucose response from one injection to 
another in the same individual (Vora & Heise 2013). This variability contributes to GV 






the extent and rate of absorption, distribution and clearance of insulin and 2) a 
pharmacodynamic component, determined by insulin’s metabolic effects (Heinemann 
2002). Since the variability in insulin pharmacokinetics - which is commonly 
understood as variability in exposure between injections or ‘within-subject variability’ - 
for most insulin preparations is largely determined by the absorption profile of insulin, 
an understanding of the factors influencing insulin absorption is necessary in terms of 
improving glycaemic control and the long-term prognosis in people with diabetes. 
 
Some studies have explored the correlation of GV and LH severity (Strollo et al. 2016, 
Blanco et al. 2013, Ibarra & Gallego 1998). However, the methods used to determine 
this association in these studies were varied and none identified the clinical relevance 
of the observations made (A full review and critique of these studies presented in the 
next chapter). Therefore, more data are needed to confirm the effects of LH on 
variations in glucose levels and to establish a system with which to classify the level 
and significance types of LH. 
 
Factors with insulin use other than the anabolic effect of the insulin have also been 
postulated as contributing to develop LH development, many of which relate to patient 
level behaviours. These risk factors include the reuse of needles, failure to rotate the 
insulin injection sites and the utilisation of incorrect injection techniques (Grassi et al. 
2014, Blanco et al. 2013, De Coninck et al. 2010, Vardar & Kizilci, 2007). In addition, 
the prevalence of LH has been associated with patient characteristics including low 
education levels, the duration of insulin use, younger age, and low socio-economic 
status (Al Hayek et al. 2016, Al Ajlouni et al. 2015, Ji & Lou 2014, Blanco et al. 2013, 
Hajheydari et al. 2011, De Coninck et al. 2010, Vardar & Kizilci 2007, Ibarra & Gallego 
1998, Hauner et al. 1996). If LH is going to be prevented in the future it will be important 
to gain a greater understanding of these patient level factors in addition to establishing 
the clinical impact of LH. However, the focus of this study is to consider the clinical 







1.4 Summary  
People with T1DM are exposed to high levels of subcutaneous insulin, potentially 
leading to the development of LH lesions. LH can significantly impair the rate of insulin 
absorption, thereby increasing variability in glucose levels and the risk of 
hypoglycaemia. The factors responsible for the development of LH are multifaceted 
and are related to individual patient behaviours, preferences and injection technique. 
It has also been established that clinical examination may not be adequately sensitive 
to detecting LH reliably, whereas ultrasound techniques while more sensitive may lack 
clinical specificity. In the absence of an objective model for determining when LH is 
clinically significant in respect of GV, it is difficult to determine what is the optimal 
method for screening LH. Without a clear clinical definition of LH thresholds and 
hazard it is likely that LH will remain an under recognised and under-managed 
problem. Consequently, it is important to develop a valid grading scale for LH, 
validated against measures of GV, which could then be used to determine the true 
extent of LH in diabetes populations, and according to which more robust strategies 
could be developed to prevent, screen and manage LH. This study will undertake 
some important preliminary work to help fulfil these objectives by exploring the 
relationship between different ultrasound detected LH profiles, glucose regulation 
(time in range), GV, glycaemic control and the incidence of severe hypoglycaemia in 
participants with T1DM.  
 
1.5 Organisation of the thesis  
The thesis is organised into five chapters, as follows: 
• Chapter 1: Introduction; 
• Chapter 2. Literature Review (incorporating a systematic review of glycaemic 
control and glucose variability in the context of LH); 
• Chapter 3. The study methodology, including sample selection, standard 
operating procedures and the processes used for data analysis; 
• Chapter 4. Study findings; 






Chapter 2. Background 
This chapter presents the current theoretical and empirical knowledge relevant to this 
study, together with an overview of current practices for the management of LH in 
relation to people with diabetes treated with insulin. The chapter also presents a 
systematic review of current evidence in relation to the impact of LH on glycaemic 
control and variability. The chapter is organised as follows: 
 
• Aetiology, pathophysiology of LH; 
• Factors contributing to the development of LH; 
• Current clinical guidance, policy and practice associated with LH; 
• Current methods for the assessment and characterisation of LH; 




LH is a form of lipodystrophy which is characterised by the accumulation of extra 
subcutaneous fat and protein. Lipodystrophy also encompasses lipoatrophy which is 
a loss of subcutaneous fat (Handelsman et al. 2013, Reeves et al. 1980). While 
lipodystrophies are associated with a number of different conditions (Monajemi et al.  
2007, Mandal et al. 2006), they are most commonly observed in diabetes in the context 
of subcutaneous insulin administration. The relationship between lipodystrophy and 
diabetes is long-standing, with reports of the lipodystrophic effects of insulin going 
back to the 1930s, where it was observed that frequent injections of insulin into the 
same area of skin may lead to changes in subcutaneous tissue, sometimes presenting 
as a swelling (LH) or as a dissipation of tissue observed as dips and hollows in the 
subcutaneous tissue at the site of injection (lipoatrophy), (Richardson & Kerr 2003, 
Rowe & Garrison 1932, Eeg-Olofsson 1930). The incidence of lipoatrophy has 
diminished over recent years as this was largely caused by an autoimmune response 
to the now rarely used, animal insulins (Hussein et al. 2007, Richardson & Kerr 2003), 
and hence following the introduction of human and analogue insulins lipodystrophy in 






While the data on the pathology of LH are limited, it is generally accepted that LH 
involves hypertrophy and hyperplasia of adipocytes in area of the subcutaneous tissue 
with frequent insulin exposure (Vardar & Kizilci 2007, Hauner et al. 1996). The 
pathophysiology of LH results from the consequence of the localised anabolic effect 
of insulin on adipocyte growth (Singha et al. 2016, McNally et al. 1988). The 
physiological mechanisms that drive the tissue synthesis behind LH are quite complex. 
In normal physiological conditions adipocyte growth is in part mediated by insulin 
growth factor in particularly insulin growth factor 1 (IGF1) (Boucher et al. 2016). As 
IGF1 and insulin are molecularly very similar, insulin can bind on to the insulin growth 
receptor on the adipocyte thereby stimulating cell growth. Hence, it is almost inevitable 
that tissues that are over exposed to insulin will become hypertrophic. Indeed, 
histologic examination of LH tissues show an increase in the adipocyte size, with 
insulin exposed cells being nearly double the volume of non-exposed cells (Fujikura 
et al. 2005).  
 
It has also been hypothesised that a mild inflammatory process may contribute to the 
development of LH lesions. It has been suggested that the introduction of material into 
the body during the injection process can cause an inflammatory reaction that may 
increase the density of the effected tissue (Anderson et al. 2008, Anderson & Shive 
1997). Insulin antibodies have also been associated with LH in children and 
adolescents with T1DM (Raile et al. 2001), although their direct pathogenic role in this 
condition has not yet been established. Indeed, there is no evidence that insulin 
antibodies are promote the growth of adipocytes (Vardar & Kizilci 2007, Hambridge 
2007, Hauner et al. 1996).  
 
The phenotypical characteristics of LH are heterogeneous, and LH can be complex in 
presentation. LH areas usually present either as a nodule, formed of hypertrophic  
adipocytes, or as fibrocollagenous scar tissue within the dermis (Wallymahmed et al. 
2004) and can vary in size from relatively small and undetectable lesions to lesions 






they can occasionally present as a soft lesion which maybe more difficult to detect in 
standard physical examination (Gentile et al. 2016a). A more detailed characterisation 
of LH can be gained from ultrasound scans. The scanning of the injected 
subcutaneous tissues can show nodular areas of concentrated dense tissue, as well 
as more general areas of increased echogenicity suggesting some increased density 
to the subcutaneous tissue presenting as diffuse areas of disrupted tissue. The 
nodules and diffuse areas often present together (Kapeluto et al. 2018, Bertuzzi et al. 
2017, Mulnier et al. 2017, Perciun & Mihu 2014). Kapeluto et al. (2018) defined this 
change further as the nodules not having a capsule or vascularity, which differentiates 
the US signature of LH from haematomas or fluid filled cysts, which do have capsules 
(Kapeluto et al. 2018). In some cases, LH nodules contain hypoechogenic areas which 
may be fluid (oedema) or areas of necrosis (Bertuzzi et al. 2017, Perciun 2010). 
Thickening of the dermal layer and loss of a clear delineation between the 
subcutaneous and dermal layer at an injection site has been identified as a potential 
inflammatory response to repeated injections of insulin (Bertuzzi et al. 2017, Perciun 
2010). Fluid examination from nodules has sown high insulin content within the intra-
nodular fluid (Gentile et al. 2018). 
 
There are very few histological studies of LH. Fujikura et al (2005), presented a case-
study with a detailed histological investigation of an extensive LH area which was 
surgically excised. The tissue was analysed using Hematoxilin-cosin tissue staining 
and electron microscope examination. The analysis showed significant hypertrophy of 
the adipocytes in the insulin exposed area, the cells were double the size of those 
observed in the unexposed tissue. They also observed some evidence of hyperplasia, 
with infiltration of adipocytes into the dermal tissue and an increase number of smaller 
less mature adipocytes being observed in the LH affected area amongst the enlarged 
adipocytes. As an explanation for the latter observation, they point to studies showing 
that adipocyte hyperplasia is known to occur in obesity, when adipocytes volume is 
doubled; and the fact that insulin is known to mediate the proliferation of 
preadipocytes. In another case-study, a tissue sample of a large LH lesion was taken 






hypovascular collagen with fibroblasts, suggestive of tissue damage. They also 
reported small areas of necrosis. Overall, these limited data concur with the 
assumption that LH is largely mediated by the anabolic effect of insulin leading to 
adipocyte hypertrophy and hyperplasia, alongside some general inflammatory 
changes which may be related to intensive tissue invasion and possibly trauma.  
 
2.2 Factors associated with the development of LH 
 
The risks for developing problematic LH are multifactorial and accumulative. Patient 
behaviours and insulin delivery systems have all been considered as risk factors, the 
most commonly cited risk factors in the literature are: lack of site rotation; needle 
reuse; a high or low body mass Index (BMI); frequency of injections; incorrect injection 
technique; a low level of general education; longer duration of diabetes and longer 
duration of insulin use; female gender; younger age; needle length; and low socio-
economic status (Sürücü & Arslan 2018, Al Hayek et al. 2016, Al Ajlouni et al. 2015, 
Ayad et al. 2014, Ji & Lou 2014, Blanco et al. 2013, Hajheydari et al. 2011, De Coninck 
et al. 2010, Vardar & Kizilci 2007, Ibarra & Gallego 1998, Hauner et al. 1996, Seyoum 
& Abdulkadir 1996). A lack of site rotation was consistently reported to be the most 
significant risk factor in these studies, although it was also the most frequently studied. 
The evidence for each of the factors that have been implicated in LH development are 
outlined below. 
 
2.2.1 Insulin injection behaviours 
Failure to rotate insulin injection sites effectively or size of rotation area for injections 
has been identified as a strong contributing factor to the development of LH. Despite 
extensive education and training on self-management, injection technique and insulin 
administration, in general people treated with insulin still do not rotate between 
injections sites (De Coninck et al. 2010). A survey of insulin site rotation in 201 people 
with T1DM, found that 22% of respondents used only one site, with the most common 
reason for not changing the site being a fear of pain (Patton et al. 2010). LH occurs 
because people with diabetes tend to inject into the same site repeatedly. LH 






hands reach most naturally. In Gentile et al.’s (2016b) study of 60 people with diabetes 
using insulin and having LH lesions, participants’ injection techniques were assessed 
using a questionnaire and 37% (n=22) of the participants report that injecting into LH 
affected areas is less painful, reinforcing their preference for the LH site. 
 
Needle reuse is another commonly reported factor influencing the development of LH. 
The use of the same needle more than once can cause damage to the tip of the needle 
and lead to a loss of needle lubrication, making the injection more traumatic to the 
injection area and with the subsequent tissue damage potentially accelerating the 
development of LH (Waddingham 2008, Vardar & Kızılcı 2007, Teft 2002). Blanco et 
al. (2013) assessed the frequency of LH in 430 people with diabetes using insulin-
injecting (the study included both T1DM and T2DM) and found that more than 56% 
(n=240) of the participants reused needles at least once. Another cross-sectional 
study of 174 people with T1DM (52%, n=91 with LH and 48%, n=83 without LH) 
showed that infrequent needle changing was associated with a near eight-fold 
increase risk of developing LH (Adjusted OR= 7.47, p= 0.001) (Al Hayek et al. 2016).  
 
2.2.2 Body mass Index  
While studies have identified BMI as a factor related to LH, the evidence is 
contradictory. A cross sectional study of people with diabetes treated with insulin (223 
people with T1DM and 56 people with T2DM) found that people with higher BMI were 
less likely to have LH (estimated OR= 0.82, p< 0.01) (Hauner et al. 1996). The authors 
argue that people with higher BMI have a larger surface area to inject into, potentially 
reducing the concentration of insulin exposure (Hauner et al. 1996). While Al Ajlouni 
et al. (2015) in a study of 1090 people with T2DM diabetes treated with insulin, found 
that LH was significantly higher among those with high BMI (between 35 and 39.9 
kg/m2) (p= 0.034). This finding may be related to the fact that increased BMI is 
associated with insulin resistance and hence the potential for higher insulin dosages, 
thereby increasing subcutaneous insulin exposure. However, when BMI was modelled 
alongside other factors in a multivariate logistic regression it was not significantly 






the studies reporting a lower incidence of LH in obese people may be that the LH is 
harder to detect in people who are overweight. Overall, evidence around the 
relationship between BMI and LH is weak, as the studies follow different methods and 
were conducted in different samples so the conclusions that can be drawn are 
equivocal. Most importantly, it is very difficult to extrapolate from either of these studies 
to the T1DM population as the insulin exposures and phenotype of T1DM and T2DM 
are very distinct. 
 
2.2.3 Diabetes duration 
The duration of diabetes is also suggested to have a link with the presence of LH 
(Wallymahmed et al. 2004). In a study by Al Ajlouni et al. (2015) of 1090 people with 
T2DM diabetes treated with insulin, LH was identified in 71% of people with a duration 
of 10 or more years, compared to (29%) in those <10years duration. Another study of 
65 people with T1DM diabetes with LH showed that duration of diabetes was 
associated with a one-fold increase risk of developing LH (OR =1.16, 95% CI 1.05-
1.32, p< 0.01) (Omar et al. 2011). None of these studies were prospective, so while 
length of insulin use would seem to be logically related to the development of LH, 
neither study provides insights into the length of exposure and the presentation of LH.  
 
Therefore, from the current evidence available it would seem that the most important 















2.3 Effect of LH on insulin absorption 
 
Insulin absorption has been shown to be attenuated in LH affected sites compared to 
other sites without LH in the same individual (Gradel et al. 2018). In the case of 
advanced LH, the subcutaneous tissue is reported to be fibrous. The rate of insulin 
absorption—which depends on diffusion of insulin molecules across the endothelial 
barrier into the blood stream—may be reduced due to the lack of blood vessels in the 
area (Heinemann 2010). It has been shown that metabolic control in people with 
diabetes with LH is improved when they are instructed to apply the insulin into other 
sites, indicating that insulin absorption may be impaired when they repeatedly use 
sites with LH (Blanco et al. 2013). A recent crossover study of 13 people with T1DM, 
using a euglycemic glucose clamp with deliberate injections into LH showed significant 
blunting of insulin absorption profiles and markedly increased variability when 
compared to injections into adjacent normal tissue (Famulla et al. 2016). People with 
diabetes and LH have been reported to have higher average insulin requirements as 
well as higher rates of unexplained hypoglycaemia and GV (Blanco et al. 2013). 
Despite these data, the full extent to which LH impacts on insulin absorption and 
subsequent glucose regulation has not been studied clinically. It is important,  
therefore, to consider whether LH is associated with increased risk of adverse clinical 
outcomes by impeding insulin adsorption thereby potentially generating fluctuations in 
glucose levels. Hence, further studies are required to consider the clinical significance 
of LH and its impact on glucose regulation. 
 
2.4 Assessing and Managing LH in Clinical Practice  
 
Increasing awareness of the importance of LH in diabetes care has led to the 
development of several international guidelines for managing injection areas and for 
detecting LH (Frid et al. 2016a, FIT 2016). The two main international 
guidelines/recommendations for the assessment of LH are those from the American 
Association of Diabetes Educators (AADE) (Siminerio et al. 2011) and the Forum for 
Injection Technique (FIT 2011). These guidelines recommend that LH must be 
assessed annually, and that site rotation of injection sites be emphasised at each 






their injection sites and should aim to use open-ended questions to elicit as much 
information about injecting behaviours as possible as these practices can be quite 
complex (Teft 2002). The assessment should also include a physical examination and 
palpation of the injections sites to look for any signs of problems or signs of LH 
(Pledger et al. 2012). The clinician is advised to palpate the tissue using their fingers 
in the areas that the individual identifies as their injection sites (Siminerio et al. 2011, 
FIT 2011). Any nodules that are visible and/or palpable should be marked and 
recorded so that recovery can be monitored and compared at future appointments 
(FIT 2011). The current FIT guidelines recommend that the clinician uses an 
examination lamp and lubricating jelly to improve the sensitivity of the palpation 
technique (FIT 2016). One recent multi-centred UK study examining the 
implementation of one of FIT guidelines (n=75 participants, 55 with T2DM and 20 with 
T1DM) reported that two thirds of those assessed demonstrated improved injecting 
behaviours (increased site rotation and LH avoidance), they also reported: reductions 
in the palpated size of nodules; decreased insulin doses (a mean of 5.6 units) and 
metabolic improvement (a mean reduction of 4.4 mmol/mol [0.4%] in HbA1c) (Smith 
et al. 2017). However, much of the data collected in this studies was based on self-
report, assessmnet fidelity was not reported and there were was no control group. 
 
Furthermore, the extent to which these guidelines are implemented in routine clinical 
care is unknown, nor is it known how frequently or rigorously LH is assessed in general 
(Gentile et al. 2016a). A limitation of the guidelines is that they are not based on 
empirical evidence, or supported by  a validated screening method for the detection of 
clinically important problematic LH; instead they rely on clinical examination by health 
professionals, which will be variable and may underestimate or fail to detect significant 
LH. A recent observational study considering how lesion features (size, location and 
shape) influence the ability of trained and non-trained health professionals to identify 
LH, based on physical examination of typical injection sites, found that the trained 
health professionals were unable to identify some lesion types particularly the flat 
small type and arm-localised LH lesions (Gentile et al. 2016a). Furthermore, an 






with diabetes has shown that smaller areas or less dense LH areas may be missed 
with the palpation method (Volkova et al. 2013). Therefore, more specific screening 
techniques are required to ensure that most clinically relevant LH is detected.  
 
2.5 LH prevalence by screening methods  
 
2.5.1 Physical Examination  
LH prevalence based on physical assessment suggest that LH is common in people 
with T1DM, although there is some variation between studies in the levels of 
prevalence, which ranged from 30 to 64% (Table 1).  
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This variability may be explained by a number of factors, most notably the lack of a 
standardised and validated (in terms of accuracy) method for detecting the LH. These 
studies used a range of procedures including visual inspections and palpation of 
injection sites. Furthermore, the studies lacked details as to the level of training the 
examiners received and were there were multiple examiners inter-rater assessment 
reliability was not reported. Only one study followed a published protocol and detailed 
that the examiners were trained (Grassi et al. 2014), However, in this study they did 
not differentiate participants with T1DM and T2DM, so it is difficult to relate the 
prevalence specifically to those with T1DM. Indeed, only two studies were exclusive 
to T1DM with one study giving a separate prevalence for the T1DM participants 
(Hauner et al. 1996). While most of the studies reported duration of insulin use and 
insulin doses; none of the studies adjusted for duration and volume (daily insulin dose) 
of insulin exposure, which may be a relevant factor in considering the prevalence of 
LH. It may also be that pathogenesis of LH is different in T1DM and T2DM; while the 
former may have longer duration of insulin exposure, the latter are generally more 
obese and insulin resistant which means there insulin doses can be quite large 
compared to those with T1DM. Therefore, without a more objective screening method 
it is difficult to form a true estimate of the incidence of LH. Hence, in the next section 
consideration is given to studies using ultrasound to identify and characterise LH 
reveal.   
 
2.5.2 Ultrasound Detection of LH 
Ultrasound (US) provides the opportunity to look in more depth at the extent to which 
LH is present in insulin exposed areas as well as providing a more detailed insight on 
the characteristics of LH affected areas. US can provide a much more detailed 
perspective on the nature of LH compared to palpation in respect of the size and depth 
of tissue changes observed following repeated insulin exposure (Bertuzzi et al. 2017, 
Perciun & Mihu 2014, Blanco et al. 2013, Volkova et al. 2013, Perciun et al. 2012, 







A study of 215 people with diabetes (type not specified) treated with insulin (Volkova 
et al. 2013) reported that US scanning detected 56% more LH lesions than with 
palpation alone. Bertuzzi et al.’s (2017) study identified overall equivalence in the 
detection of LH using US and palpation, although they found that US was able to 
detect more sites in the arm and gluteus regions than palpation. This study also 
reported high precision in the US-assessed LH region in relation to the size and 
distribution of the affected areas (Bertuzzi et al. 2017). The LH extensions were noted 
to be 5cm2 bigger with US (~35 ± 10 cm2) compared to those recorded by palpation 
and inspection (~30 ± 15 cm2). 
This suggests that US may be a more sensitive method for detecting LH compared to 
palpation. However, no standard protocol for using US to detect LH has yet been 
established. Furthermore, it could be that using US as a method lacks specificity in 
relation to detecting clinically important LH, as some levels of LH may be non-
problematic, and it is likely that all people using insulin will develop LH to some level. 
This lack of clinical specificity as a problem in the management of LH in general, as 
with most screening-based diagnostic it is important to have some means of estimating 
the clinical risks to patients so that these can be graded in respect of the size and 
distribution of the problem. In the context of diabetes this might best be considered in 
respect of glycaemic control and GV as they may confer hazard for short- and long-














2.6 Grading of LH 
 
Attempts have been made to develop grading systems for LH. Based on physical 
examination, Kordonouri et al. (2002) offered a scale with four grades: Grade 0 = no 
changes; Grade 1 = visible hypertrophy of fat tissue but palpably normal consistency; 
Grade 2 = massive thickening of fat tissue with higher consistency; and Grade 3 = 
lipoatrophy. Conwell et al. (2008) used a slightly different scale also with four grades: 
Grade 0 = absent; Grade 1 = mild; Grade 2 = moderate; and Grade 3 = severe. 
However, neither of these studies actually provided any measure of size to qualify LH 
as mild, moderate or severe. Nor did they report data on the clinical validity of these 
grading systems in relation to GV, poor glycaemic control of the presence of 
problematic hypoglycaemia. A study by Hauner et al. (1996) used a ruler to scale the 
size and the height of the LH above the skin; the researcher also classified LH as 
‘discrete’ when tissue swellings did not exceed a size of 3 cm in diameter and of 0.5 
cm in height. However, again the relationship between the degree/different sizes of 
LH and changes in glycaemic control was not studied. This has led to the assumption 
that larger palpable nodules cause more glucose fluctuation than smaller lesions, and 
if the nodules cannot be seen or felt, then they are not causing a problem. The latter 
element of this assumption may lead to an underestimation of the impact of LH on 
glucose regulation.  
 
Four studies attempted to classify LH into types or grades using US. Perciun (2010) 
included five levels for LH grading: 1) nearly-normal, 2) diffuse echogenicity (fibrous 
tissue) with no well-defined delineation between dermis and subcutis, 3) focal areas 
within this tissue (nodules within diffuse areas), 4) focal areas with hypoechogenic 
halos within the nodules, a thickened dermal layer and loss of delineation between the 
dermis and subcutis layers, 5) Nodules with a hypoechogenic necrotic or liquid-filled 
areas and thickened dermis (Perciun 2010). Mulnier et al. (2017) further identified a 
four-level grading scale of LH based on: the presence of diffuse areas; nodule size 
and nodule number; and inflammatory changes. Bertuzzi et al. (2017) characterised 
LH on the basis of hyperechogenic regions with prevailing fibrosis, hypoechogenic 






granular assessment of LH, reporting whether the nodules were capsulated or had 
evident vascularity to provide  five levels of classification: 1) well circumscribed either 
by hyperechoic foci with defined borders or a nodular shape with a hypoechoic halo, 
2) heterogeneous in echotexture compared with surrounding tissue, 3) associated with 
distortion of surrounding connective tissue with 4) absence of vascularity and 5) 
absence of capsule (Kapeluto et al. 2018) . 
 
US has additional advantages over palpation as it can better assign the nature and 
severity of LH in much more detail compared to palpation enabling greater granularity 
in grading the LH (size, distribution and density); thereby giving clinicians the 
opportunity to give more detailed advice to patients. Therefore, further studies are 
needed to determine an optimal grading systems and measurement method to 
determine LH. Such studies need to formulate and validate these systems and 
methods in relation to the GV.   
 
2.7 Prevention and management of LH 
 
Primary prevention refers to prevention of a condition prior to its occurrence and 
secondary prevention relates to minimising the effect of a problem once 
identified/diagnosed. In terms of primary prevention of LH the emphasis in current 
guidelines has been on optimal injection technique, including site rotation and 
avoidance of needle reuse (FIT 2016, Kalra et al. 2016). However, the effectiveness 
of the injection site rotation protocol advocated in the current guidelines has not been 
extensively studied (Ibarra & Gallego 1998), with the exception of one study of insulin-
treated people with diabetes which suggested that this method may have some 
protective value against LH (Blanco et al. 2013). Of the 430 participants who took part 
in the study, 64% (n= 277) had LH; only 2% (n=6) of them had used the rotation 
technique correctly and 92% (264) were not using rotation or the technique correctly 
(Blanco et al. 2013). The low rate of LH in the group using the correct technique may 
be related to the fact that these participants were more recently diagnosed and may 






with diabetes suggests that primary prevention is currently ineffective. Therefore, 
optimal strategies for site rotation and their impact on LH development are yet to be 
identified. Furthermore, any method of site rotation is dependent on the willingness of 
the patient to observe the rotation protocol and there may be many reasons why 
patients may find following the rotation difficult. Including remembering to change sites 
or that for social and psychological reasons patients may develop a preference for 
certain sites.  
 
Another factor that can impact on patient behaviours in managing their injection sites 
is the health education received from health care professionals. In a systematic 
litreature review by Frid et al. (2010b), of studies that asked people with diabetes about 
the information and training they had received on insulin injection techniques, most of 
the studies reported that people with diabetes could not identify having received any 
education on insulin injection technique or site management. This was also the case 
even when people with diabetes had attended education sessions that included site 
rotation training; this implies that either people with diabetes do not retain the 
information provided at education sessions or they chose not to follow the suggested 
advice (Pledger et al. 2012). It may be that current advice is too complicated or not 
practicable for people with diabetes to follow in the course of their daily life routines 
(Pledger et al. 2012); or that there is a lack of awareness within the community of 
health professionals and insulin-treated people with diabetes on the prevalence and 
significance of LH. 
 
Once LH develops, the management is to change the injection sites and avoid the 
affected areas in the hope that regression will occur. Recommendations as to the 
length of time that insulin injection into LH tissue should be avoided varies between 
studies (Hauner et al. 1996, Wallymahmed et al. 2004). The FIT guidelines 
recommend not injecting into sites close to LH site and that some areas may need to 
be rested for more than one year (FIT 2016), although they provide no objective data 






included 53 children with T1DM, after a six months period of avoiding the LH areas, 
the clinical examination diagnosed the remission of some hypertrophies and nodular 
aspects. Also, the US technique identified more residual images and certified which 
types of echostructures had recovered or not. The US showed reduced echogenicity 
when the sites had been rested, suggesting dissipation of the LH, but not in all cases 
and particularly not in those showing greater fibrosis of the fat tissue (echogenicity), 
or in those with possible necrosis at baseline scan. However, as the study was 
conducted in children who are still growing and developing and may have different 
rates for  repairing tissue damage, these observations may not be common to adults 
with diabetes. 
 
If avoidance of affected areas or any of the other therapeutic options fail (such as 
switch from multiple daily injections to CSII), some clinical groups have reported on 
the use of more invasive techniques such surgical extraction or liposuction (Barak et 
al. 1996, Samdal et al. 1993). However, while such procedures may result in good 
cosmetic outcomes (Hardy et al. 1993, Samdal et al. 1993) their impact on the capacity 
of the remaining tissue in insulin dispersal and glucose regulation is unknown 
(Richardson & Kerr 2003). 
 
In the next section a detailed systematic review of the literature addressing the impact 













2.8 Systematic review of the impact of LH on glycaemic control and variability 
A systematic review of the empirical literature examining the association between LH 
and GV and/or glycaemic control in insulin-treated people with diabetes was 
undertaken to inform the conduct of the study. The review was designed to fulfil the 
following objectives: 
 
• to identify and retrieve all primary studies examining the relationship between 
LH and GV and/or control;  
• to critically appraise the identified studies to determine their quality; 
• to consider the methods used to determine LH and measure GV; 
• to extract data on the relationship between detected LH and GV and glycated 
haemoglobin (HbA1c); 
• to synthesise the collective evidence from the identified studies to estimate 
the observed association between LH and GV and HbA1c. 
 
2.8.1. Review method 
This section details the methods used to perform the systematic review, consideration 
is given to study identification; study inclusion criteria; data extraction; critical 
appraisal; and data synthesis. The Preferred Reporting Items for Systematic Reviews 
and Meta-analysis (PRISMA) statement was followed for the conduct and reporting of 











2.8.1.1 Study Identification 
Appropriate studies were identified primarily through a protocol-based search of 
electronic databases, supplemented by citation searching, secondary references, key 
author searching and hand-searches of relevant journals to enhance the sensitivity of 
the search. Given that the review aimed to identify observational studies examining 
the association between LH and GV and HbA1c with potentially a high level of 
heterogeneity in respect of study types, a protocol was developed with high sensitivity, 
comprised of two facets: population (terms and synonyms for diabetes and LH) and 
outcome (terms and synonyms for HbA1c or GV). Following consultation with a library 
information specialist scoping searches of electronic bibliographic databases 
representing nursing, medicine and social sciences were conducted to refine the 
search. Each search was adapted to reflect the indexing and search guidelines for 
each database. These scoping searches and key articles were used to refine the 
selection of keywords and index terms for the protocol. The scoping searches 
suggested that the inclusion of the outcome filter (HbA1c and GV) was too specific 
excluding potentially relevant studies, hence the final protocol focused exclusively on 
diabetes and LH terms. Furthermore, the scoping review identified that many studies 
include both participants with T1DM and T2DM, and in many cases these were not 
differentiated in the studies. However, because the likely mechanism and impact on GV 
is common, in term of how it may impede the absorption and action of insulin, it is likely 
that there will be some commonality between the effects of GV and insulin in both (people 
with TIDM and T2DM). Therefore, it was deemed to be appropriate for the overall review 
to consider both types. However, it is acknowledged that the differences between T1DM 
and T2DM might bring some confounding elements in the association between LH and 
HbA1c and GV. Therefore, consideration will be given in sub-analysis to determine 
whether or not there was any distinction in variability reported in articles that were 
exclusively on T1DM. The full search terms used are described in Appendix (1). 
 
To facilitate the search process, the thesaurus of terms was checked to identify 
additional relevant terms. Index terms were focused or exploded according to 






when appropriate to create a more concise search. Limitation by database filters such 
as “humans” was also employed. The syntax of the search terms was then customised 
for each specific database. The selected databases were searched individually, and 
the citations from each database were electronically exported to Endnote version 9.0, 
checked for duplicate references, and then combined into a single EndNote reference 
library. Duplicate references were identified using EndNote automated duplicates 
finder and by manual sorting, then recorded and removed prior to screening. 
 
LH is studied in multiple research and clinical contexts; hence a wide range of 
bibliographic databases were chosen; MEDLINE (Medical literature on-line) which 
contain medical literature, published in medical, nursing and health journals (Polit & 
Beck 2013, Bruce et al. 2008); EMBASE (Excerpta Medica dataBASE) containing 
biomedical articles (Polit & Beck 2013, Bruce et al. 2008); CINAHL (Cumulative Index 
to Nursing and Allied Health Literature) containing studies from other relevant 
disciplines including nursing (Grove et al. 2012); and WoS (Web of Science database) 
includes conference abstracts (Chadegani et al. 2013). The databases were searched 
from inception until 18th March 2019. Table (2) presents an example of the search 
strategy for EMBASE database. Detailed search strategies for each database are 

















Table 2: An example of the Searching Strategy for EMBASE database 




exp diabetes mellitus/ 
exp insulin dependent diabetes 
mellitus/ 





Free text Diabetes Mellitus.mp.  
Diabetes mellitus type 1.mp. Insulin 





Type 1 diabetes.mp.  
Type 1 diabetic.mp. T1D.mp. 
T1DM.mp. 
DM type 1.mp. 
IDDM.mp. 
Juvenile diabetes.mp. 
Diabetes mellitus type 2.mp. Type 2 
diabetes.mp. 
Type 2 diabetic.mp. T2D.mp. 
T2DM.mp. 





























Fat hypertrophy.mp.  
Fat lump.mp. 
Fatty lump.mp. 











The citations yielded from this search were screened for eligibility. The titles of the 
citations were read and excluded if they clearly did not meet the research criteria. 
Subsequently the abstract for the remaining citations were reviewed, including 
citations where it was not possible to determine from the title whether they met the 
search criteria. When duplicate conference abstracts were presented, the most recent 
was chosen. Pertinent abstracts were selected from the review and full text articles 
retrieved and read to determine whether they met the inclusion criteria. Full texts were 
also retrieved to check for relevance in the case of citations where the eligibility was 
ambiguous from the abstract alone. Authors were contacted when the abstract was 
deemed to meet the inclusion criteria, but the full text was not available. The cited 
references of the relevant articles identified were then screened to search for any 
unidentified studies (Greenhalgh & Peacock 2005). The citation was scrutinised, and 
full text articles read. The reference list of the First Injection Technique (FIT) guideline 
(FIT 2015, FIT 2016) was searched to check for potentially eligible articles not 
retrieved by the computer search. The following conferences abstract websites were 
searched for unpublished studies: American Diabetes Association (ADA); Diabetes 
UK; European Association for the Study of Diabetes (EADS); and Advanced 
Technologies & Treatment for Diabetes (ATTD). The final decision to include studies 
was based on the explicit inclusion criteria, differences were resolved with discussion 
by the research supervisors.  
2.8.1.2 The Inclusion criteria were: 
• Participants with T1DM as per study criteria or people with diabetes treated with 
insulin therapy (including both T1DM and T2DM) 
• Studied the relationship between LH and HbA1c and/or GV in insulin-treated 
people with and without LH 
• Studies where the population comprised both adult and paediatric with diabetes 
were included if separated data were provided for the adult participants  
• Observational studies using quantitative methods (cross-sectional or cohort 
studies), experimental studies were included if they provided a baseline 






2.8.1.3 Studies and reports were excluded as follows: 
• Case studies, clinical audits, non-systematic literature reviews, guidelines, 
editorials and opinion pieces 
• Studies in which the study population comprised only T2DM or paediatrics, or 
gestational diabetes or people with human immunodeficiency virus (HIV) 
• Participants receiving insulin via a CSII (insulin pump). 
 
The search was not limited by language, in order to maximise identification of relevant 
literature; however, only articles published in the English Language were included. 
The Publication date was not a limiting criterion to enhance the sensitivity of the search 
strategy. The results of this search and the selection criteria are summarised in the 






































2.8.1.4 Data extraction  
Studies meeting the inclusion criteria were obtained and reviewed for inclusion. Data 
were extracted using spreadsheet (Excel), based on the review objectives (Appendix 
(2). Items were developed, and the data extraction sheet was piloted and refined on 
three studies (Blanco et al. 2013, Ibarra & Gallego 1998, Hauner et al. 1996). The 
extraction sheet covered the following topics:  
 
• study characteristics (first author’s last name, year of publication and 
location); 
• Study objectives and study design; 
• participant characteristics (age, gender, diabetes type, duration of diabetes, 
duration of insulin use, injection sites); 
•  method of detection, definition, grading and classification of LH; 
•  the examiner who undertook detection and the procedure that followed to 
detect the LH; 
• HbA1c and GV; 
• prevalence of LH.  
 
2.8.1.5 Quality Assessment  
To establish the methodological quality of the selected articles and their strengths and 
limitations, each article was critically appraised to determine the overall quality of the 
research. As anticipated in the research inclusion criteria, most of these studies were 
either cross-sectional or cohort observational studies. Therefore, the relevant studies 
were assessed using the Quality Assessment Tool for Observational Cohort and 
Cross-Sectional Studies devised by the National Institutes of Health (NIH 2014). This 
tool measures 14 different criteria included; study design, selection of participants, 
validity and reliability of study instrument (LH detection methods)/, and statistical 
analysis. Each items of the tool were evaluated as “yes,” “no,” “not applicable,” “cannot 
determine,” or “not reported.” This was then used to guide the overall rating for the 






their fulfilment for each item in the appraisal tool and the checklist of the identified tool 
is presented in Appendix (3). All quality assessments were performed by a single 
assessor. 
 
2.8.1.6 Data synthesis 
The purpose of data synthesis is to present a valid interpretation of the collective 
bodies within the work of the studies included in the review. Three different methods 
of data synthesis were used: tabulative summary, narrative synthesis and meta-
analysis. The narrative synthesis was used to summarise findings collectively in 
respect of observations that did not aggregate to form a consistent data presentation, 
but which offered interpretation to a common point. In this review, the extracted data 
from studies were grouped according to study characteristics and then tabulated to 
summarise in a standardised way the study participants, methods and findings. In 
seven studies that reported HbA1c values for those with and without LH, a statistical 
meta-analysis was undertaken using the RStudio version 1.1.456 software (RStudio 
2015). The meta-analyses were performed using a random effects model to combine 
the results of individual studies allowing for study heterogeneity. Forest plots showing 
the point estimate and confidence intervals for each study were created. The 
heterogeneity was quantified by the inconsistency test I2, which quantifies the 
percentage of total variation across studies that is due to heterogeneity rather than 
chance (Higgins et al. 2003), where 0%, 25%, 50% and 75% indicate, respectively, 












2.8.2 Review Findings 
2.8.2.1 Search outcomes 
 
The electronic search identified 9043 studies published from 1950 to 18th March 2019, 
6499 of which did not meet the inclusion criteria at title screening and there were 1683 
duplicates. After reviewing the abstracts, 42 studies were selected for further 
evaluation, the full text was obtained, read and screened against the eligibility criteria 
and nine studies were deemed eligible to be part of the review. Studies that did not 
meet the eligibility criteria were excluded and the reason for excluded is detailed in the 
PRISMA flow chart (Figure 1).  
 
The characteristics of the studies, the sample, the detection method of LH and GV 
/glycaemic control data are presented in Table 3 and 4. All studies were observational; 
most of the studies utilised a prospective approach except one which used a 
retrospective approach. Seven studies presented data on HbA1c in participants with 
and without LH (Deeb et al. 2019, Pozzuoli et al. 2018, Ji et al. 2017, Strollo et al. 
2016, Hajheydari et al. 2011, Hauner et al. 1996, McNally et al. 1988) and three 
studies presented data on GV in participants with and without LH (Strollo et al. 2016, 
Blanco et al. 2013, Ibarra & Gallego 1998). 
 
2.8.2.2 Quality assessment 
 
The NIH quality assessment tool for observational cohort and cross-sectional studies 
was used to assess the quality of included studies (NIH 2014). A study scored a point 
when it fulfilled a criterion with the scores displayed in Appendix 3.1, a maximum score 
of 14 is possible. Five studies had an overall rating of good (score 9 to 12) and four 
studies were rated fair (score 7 to 8). In general, studies lacked sample size 
justification and level of follow-up, three studies (Hajheydari et al. 2011, Ibarra & 
Gallego 1998, McNally et al. 1988) did not provide information about the reliability and 
validity of the examination criteria or the procedure of LH detection. Despite the overall 







2.8.2.3 Study and participant characteristics 
 
Six of the included studies were conducted in Europe (United Kingdom, Germany, Italy 
and Spain) and three further studies were carried out in Asia (China, United Arab 
Emirates and Iran). Three of the included studies were older than ten years (Ibarra & 
Gallego 1998, Hauner et al.1996, McNally et al.1988). 
 
A total of 2565 participants treated with insulin were included in the review, out of these 
48% (n=1239) participants had LH. The participants had a mean age of 47.56 years 
(± 23) and include 46% (n=1140) male and 54% (n=1353) female participants, and 
one study did not report the gender. In the studies identifying type of diabetes 32% 
(n=713) were T1DM and 68% (n=1506) were T2DM. One study (Deeb et al. 2019) 
included exclusively people with T1DM. Four studies reported duration of diabetes and 
this ranged from 3 months - 41 years (Strollo et al. 2016, Blanco et al. 2013, Hajheydari 
et al. 2011, Ibarra & Gallego 1998). 
 
2.8.2.4 Prevalence, detection method and anatomical distribution of LH  
 
In studies using visual inspection and digital palpation to detect LH the reported 
prevalence ranged from 14.5% to 77.1%. Four of the most recent studies (Deeb et al. 
2019, Pozzuoli et al. 2018, Ji et al. 2017, Strollo et al. 2016) described the detection 
method procedure of LH, further three studies (Deeb et al. 2019, Pozzuoli et al. 2018, 
Strollo et al. 2016) followed a standardised approach “the pinch manoeuvre” as 
described by Gentile et al. (2016) and one study took into consideration the body 
positions of participants when they evaluated the injection sites and examination 
environment (Ji et al. 2017). None of the studies reported any grading method of LH, 
apart from one study, which classified LH as “discrete” when tissue swellings did not 
exceed a size of 3 cm in diameter (Hauner et al. 1996). Eight studies examined the 
anatomical distribution of LH sites, with the abdomen, thighs and arms being the most 
frequently identified, with the gluteal area being the least commonly used (Deeb et al. 
2019, Pozzuoli et al. 2018, Ji et al. 2017, Blanco et al. 2013, Hajheydari et al. 2011, 






2.8.2.5 Measurement of GV in the included studies 
 
In the studies that reported GV, in participants with and without LH, the GV was crudely 
assessed using methods based on self-monitoring of blood glucose. The GV 
definitions varied between the studies: both Strollo et al. (2016) and Blanco et al. 
(2013) defined GV as ‘fluctuations of blood glucose values from between < 3.3 mmol/L 
(60 mg/dL) to > 13.9 mmol/L (250 mg/dL) on at least three occasions per week in an 
unpredictable manner, for at least six months (Blanco et al. 2013 p. 446 – 447). While 
Ibarra & Gallego (1998) study defined GV as ‘irregular or unstable when more than 
two glycaemic fluctuations per week were unexplained’ (Ibarra & Gallego 1998 p. 9). 
Clearly, both methods were not well characterised and with a high risk of measurement 
error and inconsistency. 
  
2.8.2.6 Association between LH and GV 
 
Strollo et al. (2016) study demonstrated that participants with LH 70.1% (n=255) had 
at least a fourfold increased risk of developing GV compared with those who have not 
had LH 29.9% (n=109), (OR=4.43 (95%CI 3.11-6.33), p< 0.001. While the Blanco et 
al. (2013) study, found that participants with LH 93% (n=136) had nearly a fourteen-
fold increased risk of developing GV compared to those without LH 7% (n=10), 
(OR=13.79 (95 % CI 6.97 to 27.31), p < 0.001. In the Ibarra & Gallego (1998) study of 
128 participants, of which 43% (n=55) had glycaemic profile fluctuations, the study 
showed that participants with LH 75% (n=41) had nearly a fivefold increased risk of 
developing GV compared with those who have not had LH 25% (n=14), (OR=4.71 (95 
% CI 2.18 to 10.15), p< 0.001. (Table 3: presents the reported relationships identified 











2.8.2.7 Association between LH and glycaemic control 
 
Seven studies reported observation on the association between LH and glycaemic 
control. All but one study reported that participants with LH had higher HbA1c levels   
compared to those without LH (see Table 4), which reports the HbA1c levels observed 
in those with and without LH. It is important to note that there were some differences 
in the characteristics of the comparison or reference samples without LH in the studies 







Table 3: Reviewed studies examining the association between LH and GV 
References 
location 
Study design  Population characteristics Assessment and 
prevalence of LH 
%(n) 
GV 
% (n) with and without LH  
(OR (95%CI) 
n (T1DM) n 
with GV 
Gender 
 % (n) 








387 (81) 364 M45.5(176),  
F 54.5(211) 




LH present: 70.1 (255)                                                                                                    
LH absent: 29.9 (109)                                                
OR = 4.43 (3.11-6.33)                                           
p< 0.0001 
Blanco et 
al. (2013)  
 Spain 
Cross-sectional 430(177) 146 M 51.4 (221),  
F 47 (202)     
49(±22.8) Visual inspection 
& ultrasound was 




LH present: 93 (136)                                                                   
LH absent:   7  (10)                                                                                                           
OR = 13.79 (6.97 - 27.31)                                                                                





Cross-sectional  150 (113) 55 M 38 (57),  
F 62 (93)    
36.9 (±17.9) Visual inspection 
& palpation 
 
52 (78)   
 
LH present: 75 (41)                                                                    
LH absent:  25 (14)                                                                                                             
OR = 4.71 (2.18 - 10.15)                                                  
p = 0.0001 










 Table 4: Reviewed studies examining the relationship between LH and glycaemic control 
References  
location 




HbA1c with and without LH  
 
 
(mean±SD) mmol/L [%] 





Deeb et al. 
(2019)   
United Arab 
Emirates 
Cross-sectional 65 NS 54.65 ±16 Visual inspection & palpation 
Examiner: trained team 
 
32.3 (21) 
LH present:  
69 ±9.1 [8.5 ±0.83] 
LH absent:   
54 ±9.8 [7.1 ±0.9] 
p= 0.001 
Pozzuoli et al. 
(2018) 
Italy 
Cross-sectional 352 (36) M 43.2 (152), 
F 56.8 (200) 






61 ±15.3 [7.7 ±1.4]  
LH absent:   
61 ±14.2 [7.7 ±1.3]                                                            
p=0.83 
Ji et al.  
(2017)     
China 
Cross-sectional 401 (27) M 49.9 (200),  
F  50.1 (201) 
59.6 ±11.5 Visual inspection & palpation 
Examiner: Trained study staff                                             
 
53.1 (213) 
LH present:  
66 ±19.7 [8.2 ±1.8]                                                                        
LH absent:  
61 ±16.4 [7.7 ±1.5]                                                               












HbA1c with and without LH  
 
 
(mean±SD) mmol/L [%] 





Strollo et al. 





387 (81) M 45.5 (176), 
F  54.5 (211)     
61 ±16 Visual inspection & palpation  
Examiner: medical staff                      
 
77.1 (298) 
LH present:  
67 ±13.1 [8.3 ±1.2]                                                                                                   
LH absent:   
58 ±12.0 [7.5 ±1.1]                                                
p< 0.001 
Hajheydari et 
al. (2011)  
Iran   
Cross-sectional 220 (56) 
 
M 27.3 (60),  
F 72.7 (160) 
49 ±17.9 Visual inspection & palpation                                                                                   
Examiner: one specialist 




80 ±24.0 [9.5 ±2.2]                                                                           
LH absent:  
72 ±20.8 [8.7 ±1.9]                               
p= 0.03 
Hauner et al. 
(1996) 
Germany 
Cross-sectional 279 (223) M 44 (123),  
F 56 (156) 
41.4 ±13.3 Visual inspection & palpation                                                                                
Examiner: Trained physician                                                       
 
32.3 (90) 
LH present:  
74 ±19.7 [8.9 ±1.8]                                                                                                   
LH absent:   
73 ±18.6 [8.8 ±1.7]                                                               
p=0.68                                            
McNally et al. 
(1988)   
United 
Kingdom 
Cross-sectional 281 (NS) M 54 (151),  
F 46 (130)   
45.5 ±19.75* Visual inspection & palpation                                                                                  
Examiner: two researchers                    
27.1 (76) 
LH present:  
81 ±28.4 [9.6 ±2.6]                                                                                                     
LH absent:   
77 ±26.2 [9.2 ±2.4]                                                                   
p=0.24 
LH, Lipohypertrophy; n, Number; M, Male; F, Female; NS, Not Stated; SD, Standard deviation; * Estimate SD from range 
62 
 
Table 5: Characteristics of participants with and without LH 
References                                 (n (%); or mean ±SD and /or range) 
LH present No LH  
Hajheydari  
et al. 2011   
Gender:  
M 17 (28.3), F 18 (11.2) 
Education Level:  
Elementary/Secondary school 
level: 31 (86) 
University level:  
4 (11.4)  
Gender:  
M 43 (71.7), F 142 (88.8) 
Education Level: 
Elementary/Secondary school 
level: 172 (93) 
University level:  
13 (7) 
McNally  
et al.1988    
Mean age: 
 40 (11-82) 
Gender:  
M 40 (52.6), F 36 (47.4) 
Mean duration of insulin use: 
14.3 (±9.8) 
Injection site/LH aware:  
43 (56.6) 
Mean age:  
46.3 (7-86) 
Gender:  
M 111 (55), F 90 (45) 
Mean duration of insulin use: 
9.4 (±9.7) 
Injection site/LH aware: 
117 (58.2) 
Hauner  
et al.1996        
Total Daily Insulin (Units): 
49 (±16)  
Total Daily Insulin (Units): 
45 (±15) 
Strollo et al. 
2016           
Mean age:  
61 (±10) 
Gender:  
M 100 (34), 211 (66) 
Duration of insulin use: 
 17 (±9) 
Mean age:  
63 (±12) 
Gender: 
M 87 (98), F 2 (2) 
Duration of insulin use:  
20 (±8) 
Pozzuoli et al. 
2018    
Mean age: 
 68.2 (±12.6) 
Duration of insulin use: 
11.6 (±9.6) 
Total Daily Insulin (Units): 
48.8 (±25.9) 
Mean age:  
67.3 (±11.9) 
Duration of insulin use: 
7.2 (±7.3) 
Total Daily Insulin (Units): 
37.8 (±21.4) 
 
A meta-analysis was performed to assess the overall difference observed in the 
collected studies in HbA1c values for those with and without LH. Participants with LH 
had clinically significantly higher HbA1c values than participants without LH. The 
estimated difference for the studies was 6.1 (95% CI 2.1 -10.2) mmol/mol [0.56 (95% 
CI 0.19-0.93) %], which represents a clinically important difference in respect of the 
risk of diabetes complications. A high heterogeneity among studies was observed (I2 








Figure 2: Forest plot mean difference (95% confidence interval) in HbA1c for 
participants with LH versus participants without LH. 
 
A sub-analysis excluding studies that included animal insulin was also undertaken. 
Excluding these studies increased the estimated difference in HbA1c levels between 
the LH and non-LH participants to 7.4 mmol/mol [0.68%] (see Figure 3).  
 
 
Figure 3: Forest plot showing mean differences (95% confidence interval) in HbA1c 
for participants with LH versus participants without LH in studies using human insulin 








2.8.3 Review Discussion 
This systematic review and meta-analysis identified nine studies, evaluating the 
association between LH and GV and glycaemic control in insulin-treated people with 
diabetes. The majority of these studies reported findings relating to glycaemic control 
and only three were related to GV. The glycaemic control studies suggest that 
participants with LH had higher glycaemic levels compared to those without LH. The 
limited data available on the association between GV and LH was inconclusive and 
limited by the methods used to assess the GV. 
 
The prevalence of LH varied across studies by some margin. This in part maybe 
explained by the variation in the methods used for detecting LH. While most of the 
studies reported that they used visual inspection and palpation, they did not specify 
any quality assurance or fidelity protocols. As result of the inconsistency the 
estimations of LH prevalence may be either under or over estimated.  
 
The association between glycaemic control and LH is difficult to interpret from these 
studies. While the LH may have been a contributing factor, it could also be inferred 
that people who are prone to develop LH due to limited insulin site management may 
have deficits in other areas of their diabetes self-management (such as glucose 
monitoring and carbohydrate adjustments). Ji et al. (2017) reported that in a study of 
401 adult participants injecting insulin, correct site rotation was more common in 
participants without LH (92.3%) compared to those with LH (67.6%), p < 0.0001. The 
same observation was seen in the study of Pozzuoli et al. (2017), the participants with 
LH were less likely to rotate the site of injection (45.7 vs. 59.7%; p = 0.028). Therefore, 
it is not possible to identify from these studies the extent to which the LH contributed 








The data do suggest, however, that people with diabetes using insulin need regular 
reviews of their insulin injecting behaviours and some guidance on avoiding LH, 
although there is no current best evidence on site-rotation models. In one survey with 
>1,000 participants performed in Europe, less than 50% of the participants reported 
that they were taught about LH (Strauss et al. 2002), and there were no details on the 
quality or validity of the advice provided. The study of Smith et al. (2017) which 
reported some improvements in glycaemic control with the introduction of LH 
assessment and standardised injection education suggests that some LH intervention 
may lead to improved control.  
 
The relationship observed in these studies is not explanatory; it is associative. 
Therefore, we do not know whether the relationship is causative. It is known, for 
example, that psychological problems can mediate self-management performance in 
people with diabetes, psychological distress has been associated with higher 
glycaemic levels (Snoek et al. 2015). Therefore, it may be that people with diabetes 
who have problems such as depression or are less attentive to their diabetes self-
management may be less diligent in relation to their injection behaviours. Perhaps 
psychological factors may be important in relation to the development of LH. It could 
also be that having LH may contribute to diabetes distress by making glucose 
management more unpredictable and frustrating, hence further studies are required 
to consider the association of psychological factors on LH. In addition, as highlighted 
in Section 2.2 (factors associated with the development of LH) injection technique, the 
number of injections performed, the reuse of injection needles, the size of the injection 
area usually used, and other related factors all seem to contribute to the development 
of LH (Ji et al. 2017, Blanco et al. 2013). This again would suggest that people with 
diabetes need more support in increasing their awareness of LH and how to avoid it. 
 
However, before any recommendations can be made on how to improve the 







unknowns in respect of LH and its impact on metabolic control and glucose regulation 
that need further consideration. A significant area of weakness in the current 
knowledge base is the lack of consistency in how LH detected and characterised. It is 
also not clear from the previous studies on LH at what point they become clinically 
problematic in terms of diabetes control. Consideration below is given to the limitation 
of the review and what its findings relay for the conduct of this study and future 
research in general.   
 
2.8.3.1 Strengths and Limitation of the review  
 
1. Limited source material for the review- Multiple electronic databases and other 
search strategies were applied in order to decrease the chance of missing relevant 
articles. Additionally, the reference lists for each study were checked and turned to 
citation tracking to identify many relevant articles. However, despite using these 
methods only nine studies were included, although it is likely that this was a fairly 
complete capture of the studies that have consider LH and GV and/or glycaemic 
control.  
 
2. Heterogeneity and lack of clarity on LH detection methods and GV assessment- 
While the included studies reporting using similar detection methods for LH (visual 
inspection and palpation), there was no clear definition of the protocol observed. 
Neither did the studies give details of the characteristics of the LH observed. The GV 
methods were also very weakly defined, in the Strollo et al. (2016) and Blanco et al. 
(2013) studies, GV was defined as ‘fluctuations of blood glucose values from between 
< 3.3 mmol/L (60 mg/dL) to > 13.9 mmol/L (250 mg/dL) on at least three occasion per 
week in an unpredictable manner. While Ibarra & Gallego (1998) study defined GV as 
‘irregular or unstable when more than two glycaemic fluctuations per week were 
unexplained’ (Ibarra & Gallego 1998 p. 9). The clinically specificity of these definition 







not able to offer any meaningful interpretation of the relationship between GV and LH. 
Looking forward to future more vigorous methods for the assessment of self-monitored 
blood glucose results to standardised criteria are required. The optimal method for 
assessing GV is continuous glucose monitoring (CGM). CGM measures interstitial 
fluid every 5-10 seconds and an average glucose value is calculated every five 
minutes, although there is some variability between CGM systems (Funtanilla et al. 
2019, Secretariat 2011). This gives a more complete picture  of daily glucose 
fluctuations by providing a continuous trend of the glucose level. In tandem with 
individual level data inputs (food intake, insulin use and activity) it is possible to 
consider how these different glucose affecting events impact on the glucose level. In 
the context of studying LH this would allow for these factors to be assessed when 
considering the impact of LH on the GV and to estimate the impact of injected insulin 
on the glucose level. 
 
Following these limitations, we recommend that future LH studies need much more 
robust methods for assessing GV, that also allow for the assessment of some of the 
main extraneous factors that can influence glucose levels. There should also be 
standard reporting of LH (including grading system) and optimally this should be 
undertaken using US. For observational studies, it is also necessary to minimise 
potential information or classification biases by using appropriate participant selection 
methods adjusting for differences in the comparison groups (age, gender, duration of 
diabetes). Prospective studies are also needed, involving enough participants to 
consider the effect rather than the association between LH and GV. Before and after 
studies with participants changing injection sites to estimate the impact of LH affected 
areas on GV should be considered, prior to larger trials where participants with a 
standardised levels of LH can be randomised to usual injection areas versus injecting 
into areas not affected by LH to consider differences in GV and insulin requirement. 
Although a big challenge to overcome is how to change individual behaviours in the 
intervention groups and how to avoid behaviour change in the control groups once 







These factors were, as far as was feasible, consider and adopted within the study 




This chapter has set out the empirical data available regarding LH, highlighting the 
prevalence of LH and detailing some of the risk factors associated with it. The review 
has also identified that there may be some associations between LH and GV and LH 
and glycaemic control, although these observations are limited by the paucity of 
methods used in the studies. Particular attention has been drawn to the lack of 
standardised procedures to detect LH and to define GV. Hence, this study will 
undertake some preliminary work to explore the association between LH and GV; and 
develop a process for assessing and characterising LH in a more robust way. The 
following chapter sets out the aim and objectives for this study and the adopted study 



















Chapter 3: Methods 
This chapter details the method and instruments used in the conduct of the study. The 
chapter discusses the design adopted by the study and outlines the rationale for the 
adopted measures and the model for the analysis. Consideration is given to the 
following: 
 
• Study aim and objectives 
• Study approach and theoretical perspectives 
• Study design and hypotheses 
• Study setting, population and sample 
• Study measures 
• Data collection and management 
• Data analysis 
• Process evaluation  
• Validity and Reliability  


















3.1 Aim and objectives 
The study aims and objectives for the study were developed in response to the issues 
identified in the previous chapter. The primary aim of the study was to explore the 
association between ultrasonographically characterised LH lesions with time in range 
(TIR 4 to 10 mmol/L) and glucose variability (GV) in people with T1DM. The secondary 
aim was to identify a process for assessing and characterising the LH. The study 
objectives were to: 
 
1. Characterise (location, morphology and distribution) different presentations of 
LH tissue in participants with T1DM using ultrasound. 
2. Investigate the effect of observed LH presentations on GV; glycaemic control; 
and/or incident severe hypoglycaemia. 
3. Study the relationship between LH and participant insulin-injecting 
behaviours, and type of insulin. 
4. Compare physical clinical assessment of LH (palpation) to ultrasound 
detected LH. 
5. Consider participants’ experiences of changing their injection sites.  
6. Assess: study procedures; recruitment, retention and completion rates; and 
adverse events.   
 
3.2 Study approach and theoretical perspectives 
 
In the previous chapter the underpinning clinical issues were identified, together with 
a review of current knowledge on the study topic. This review revealed that there is 
currently a lack of standardised methods for assessing and characterising LH, and the 
clinical impact of LH on glucose levels and variability is poorly understood. Clearly, 
these are important considerations for an intervention to minimise the impact of LH on 
glucose management in people with T1DM. Hence, what is required is a study that 
can begin to identify optimal methods for characterising LH and assessing its impact 







as a preliminary study to consider how LH can be characterised and to explore its 
potential impact on glucose regulation and GV, to inform the development of a future 
intervention. In this section, consideration is given to different methodological 
strategies for undertaking such a study and the rationale for the study approach. 
 
The first step in identifying a study approach should be to consider the level of theory 
to be addressed. Dickoff and James’ (1968) classic taxonomy of theory progression in 
clinical inquiry provides a useful point of reference in determining the level of theory 
for the study. Their taxonomy identifies four levels of theory development: 
 
1. Factor isolation—at this level the focus is on identifying a phenomenon or an activity 
that has clinical relevance. This level in relation to LH, has to some extent been 
addressed in previous studies, as we know that LH is a clinical problem with some 
data to show that it has a clinical impact on glucose regulation. However, what is not 
known is how the problem might be best addressed. It is also evident that more 
understanding of the nature of LH is required, particularly in how it should be 
characterised and assessed. 
 
2. Factor relating—at this level the focus is on building a theoretical context for the 
original observation considering what activities or strategies might be useful in 
addressing the problem. In the context of this study this would be related to 
determining whether LH impacts on glucose levels, as this has only partially been 
addressed in previous studies. It would also be important to consider other factors 
such that may be important for a future intervention, such as how do people with 
diabetes find changing their injecting behaviours.  
 
3. Situation relating—at this level the focus is on identifying factors that might inform  







the context of this study that would be to test the impact of an intervention (avoiding 
LH areas) to estimate its impact on glucose levels.  
 
4. Situation producing—at this level the focus is on assessing the probability that an 
intervention has a predictable impact on a specific outcome (questions of 
effectiveness). This level would be typically addressed by a larger study, usually a 
clinical trial, with the adequate statistical power to establish with confidence whether 
changing an injection site to avoid LH (following an explicit reproducible process) 
would improve glucose levels and GV.  
 
Considering this taxonomy, it would seem that the level of theory desired from this 
study is largely Level 2., although there is also some primary knowledge required in 
respect of characterising LH. The characterisation of LH is important as the size and 
distribution of the LH might influence the effect the LH has on an individual’s glucose 
levels. It is also clear from the literature review that there are potentially multiple 
components and behaviours involved in assessing and managing LH, which 
introduces a degree of complexity. Addressing this complexity will be kept to nay future 
intervention. Therefore, as the ultimate purpose of this study would be to inform a 
future intervention to help reduce the impact of LH on people with diabetes, it is useful 
to consider the study with reference to the Medical Research Council’s (MRC) complex 
evaluation framework. The MRC have defined complex research as follows: “the 
greater the difficulty in defining precisely what exactly are the ‘active ingredients’ of an 
intervention and how they relate to each other, the greater the likelihood that you are 
dealing with a complex intervention” (Campbell et al. 2000). The MRC complex 
evaluation framework is similar to the taxonomy of Dickoff & James (1968), as it follows 
a process for developing theory and translating it into an intervention. At its inception  
the framework was comprised of four clinical phases (following a pre-clinical theory-







• Phase I- the modelling phase, in which potential mechanisms of action are 
explicated and intervention components are modelled in relation to the 
outcomes of interest.  
• Phase II- exploratory studies, these studies focus on the acceptability, feasibility 
and efficacy of an intervention.  
• Phase III- requires a definitive randomised controlled trial designed to assess 
the complexity of the intervention.  
• Phase IV- long-term follow-up and replication studies. 
 
The MRC complex evaluation framework has subsequently been updated into a more 
iterative process that involves: defining and understanding the clinical problem; 
conceptualising the problem using established theory to identify the argument for the 
relationship between the intervention and the problem; collecting diverse evidence to 
enable more expansive assessments of confounding variables; and optimising the 
intervention and outcomes selected to ensure a valid assessment of the intervention 
(Campbell et al. 2007). The proposed LH study will require some modelling in respect 
of the characteristics of the observed LH and the relationship with GV, but it will 
primarily sit within the exploratory phase, by exploring the impact of avoiding LH areas 
on GV. In keeping with the modified version of the MRC guidelines for evaluating 
complex interventions, the study will also consider: the relationship between the 
problem and the intervention (LH and GV); collecting different data sources that may 
be relevant to the impact of LH and avoiding LH affected areas (insulin type and 
injecting behaviours); and in estimating the potential outcomes that could be useful in 
studying the impact of LH on glucose regulation.  
 
In the exploratory phase of the MRC framework, the principle approach is to undertake  
feasibility or pilot studies prior to the main study, to refine/consider: data collection 
processes, outcome selection; and potential intervention components. Distinguishing 







consensus meeting has produced guidance on how to distinguish the two (Eldridge et 
al. 2016). The guidance states that: “A feasibility study asks whether something can 
be done, should we proceed with it, and if so, how. A pilot study asks the same 
questions but also has a specific design feature: in a pilot study a future study, or part 
of a future study, is conducted on a smaller scale.” (Eldridge et al. 2016). These 
guidelines specify that pilot studies should be viewed as a type of feasibility study, 
which tests out a basic assumption (such as the change that would form part of an 
intervention) to inform a future study- pilot studies can be either randomised or non-
randomised. As one objective of this study is to test the assumption that GV will be 
reduced if insulin is injected into an area not affected by LH, then this element would 
be considered a pilot-study. The study also aims to address some additional feasibility 
questions such as: identifying an approach for characterising and assessing the LH, 
and practical issues in relation to a future study such as recruitment and retention.  
 
In relation to developing insights from feasibility studies that will inform the conduct of 
a future study, particularly in respect of areas of complex intervention, a process 
evaluation should be conducted. The current MRC guidance on process evaluations 
recommends that process evaluations should begin with feasibility studies (Moore et 
al. 2015). Process evaluations study the setting, the implementation, and the 
mechanisms of an intervention to support the interpretation of the findings (Oakley et 
al. 2006). In the MRC process evaluation framework there are three areas: context 
(the impact of contextual factors on the intervention); implementation (fidelity, dose, 
reach and adaptation); and mechanisms of impact (considering participant 
experiences, mediating factors and unexpected occurrences). In the context of this 
study, it is important therefore, to assess some of these processes, to inform the 
development of an intervention to reduce the impact of LH; and to provide information 
on how to conduct a future study assessing such an intervention. As this study will 
assess the impact of changing injection behaviours on GV, it will be important to 







assessing adherence. In terms of a future study it will also be important to estimate 
recruitment and retention (reach). There is also a need to consider the fidelity of the 
LH assessment procedures and to decide whether it is necessary to adapt the study 
in anyway.    
 
A recent international consensus project, classified feasibility and pilot studies as 
exploratory studies (Hallingberg et al. 2018). The study group behind this project, 
defined the purpose of exploratory as to decide whether and how to proceed with full-
scale evaluations. In terms of this study the how part relates to the need to understand 
some of the issues that need to be considered in any future research: methods for 
assessing LH and characterising it; procedures for the conduct of the study such as 
supporting people with diabetes in changing injection behaviours; and how to optimise 
study recruitment and retention. In relation to should,  the key consideration is to 
establish whether avoiding LH affected areas will be beneficial in terms of glucose 
regulation and estimating that potential benefit (effect).  
 
Therefore, this study follows an exploratory research approach to examine some 
preliminary parameters that would be important in considering the intervention 
components and design for a future study to assess whether supporting people with 
diabetes in avoiding areas affected by LH would improve their glucose management. 
The approach is grounded in current MRC guidance for complex evaluations for 
assessing feasibility questions and process evaluation. Hence, the study objectives 
and methods have been designed to incorporate questions of feasibility and process 








Table 6: Methodological approach to study objectives 
Objective Exploratory 
Approach 
MRC Framework  
level 
Dickoff & James 
level 
1. Characterise LH Feasibility Modelling I 
2. LH effect GV Pilot Exploratory II 
3. Injecting behaviours Feasibility Modelling I 
4. US vs. DP assessment LH Pilot Exploratory NA 
5. Participants experiences Feasibility PE NA 
6. Procedures/recruitment Feasibility PE NA 
DP, Digital palpation; PE, Process Evaluation; NA, Not applicable; Vs., Versus 
 
3.3 Study Design  
The study was designed to address the identified objectives for the study and following 
the study approached identified in the previous section. Following from the previous 
section there were a number of different objectives and approaches to integrate within 
the design. An experimental model was required to estimate whether there was an 
effect of LH on GV; and more descriptive data were required in respect of 
characterising the LH and for the process evaluation. Hence, the study followed an 
integrated design, with experimental study focussing on the impact of  LH on GV (the 
GV study) and a parallel LH characterisation study, with an embedded process 
evaluation. This section presents the details of that integrated design.   
 
3.3.1 The GV study 
This element of the study was designed to estimate the effect of LH on GV, by 
considering the difference observed when participants injected insulin in areas 
unaffected by LH. While there have been previous studies (as outlined in the previous 







are conducted in extremely controlled conditions. Therefore, in this study the intention 
was to consider the effect in a clinical context as would occur if LH avoidance were to 
be tested in larger clinical study. Studying the effect in a “real world” rather than lab-
based context does bring with it a number of challenges, particularly given the multiple 
factors that might mediate the effect of interest: injection behaviours and adherence; 
variations in underlying insulin requirements; and the multiple factors that can impact 
on GV (daily food and activity variations). As an exploratory study, it was important to 
try and capture these parameters in the data, to try and develop an understanding as 
to how they might be considered in a future study.  
 
The exposure (independent variable) of interest in the design was the administration 
of insulin into areas without LH, in people with diabetes who had been identified as 
having significant areas of LH affected tissue. Designing a study to test the effect of 
this exposure introduced some important challenges, these included: maintaining 
internal validity in the exposure condition; and the challenge of addressing the relativity 
of GV. The former relates to the need to compensate for the potential hazard in respect 
of increasing the insulin effect when injecting in non-LH areas. This demanded that 
the research incorporated a period of insulin adjustment in a way that would minimise 
any effect GV while also protecting participant safety. In relation to the latter, the issue 
was the multitudinous factors that can contribute to GV (diet, exercise, correction 
factors). These factors can vary between people and within people based on their day-
to-day activities and decision making. One solution to this problem could have been a 
randomised controlled trial design (RCT). However, while an RCT may have reduced 
some of the individual person variability, it would not overcome the issue of reducing 
and managing insulin doses in the transition from LH to LH free injection sites. It would 
also not be feasible to recruit sufficient participants to adjust fully for the patient-level 
GV factors. Hence, the study was designed using the participants as their own 








The case-crossover design is an extension of the crossover design to observational 
studies. It was introduced in 1991 as a new technique to examine the effects of 
exposure outcomes with rapid sensitivity (Maclure 1991), such as the interaction 
between insulin and glucose. In a case-crossover design each participant contributes 
their own control and on-treatment conditions. In this study this reflects a comparison 
of: recorded glucose levels while the participants injected in their usual way - with no 
site changes; to recorded glucose levels after a five-week washout period injecting 
exclusively into areas not affected by LH. The case-crossover design is based on 
subject-matched sampling (Maclure 1991), in this study the presence of LH and GV 
(defined by the standard deviation of their recent self-monitored blood glucose 
readings). Therefore, GV study is based on the case-crossover design. 
 
The case-crossover element of the study has been designed to examine the 
relationship between ultrasonographically characterised LH lesions and GV in people 
with T1DM. GV will be measured in two conditions: Condition 1- will be normal injecting 
practice (which will include injecting into LH areas) and Condition 2- injecting 
exclusively in areas not affected by LH. The participants will be screened (including 
clinical and ultrasound examination for LH) and then monitored using blind continuous 
glucose monitor (CGM) for one week to measure GV in Condition 1. Following this 
baseline observation period, it will be necessary for an insulin adjustment phase as a 
safety measure to avoid the potential for hypoglycaemia when participants inject 
insulin into areas not affected by LH, as the amount and speed of the delivered insulin 
may be affected. Importantly, no changes will be made to the participants type of 
insulin or frequency of injections (details of the insulin adjustment phase are provided 
in the study procedures). Then participants will move to Condition 2, where undergo 
repeat monitoring with blind CGM for another week while continuing to inject 








3.3.2 LH Characterisation study 
The objective of this study was to generate knowledge in relation to characteristics of 
LH. This is important as there are currently no standardised or validated systems for 
assessing or grading LH and developing models for this would be useful for future 
studies. It would also be useful to estimate the level of LH observed in participants in 
the GV study to consider this as a mediating factor. Another consideration for this 
study, was to consider the method for determining LH. As outlined in Chapter 2. The 
current clinical model for assessing LH is through visualisation and digital palpation. 
This approach, however, is difficult to standardise and shows much lower sensitivity 
compared to ultrasonic methods of assessment. Hence, this part of the study was also 
designed to compare current best-practice for clinical examination of LH with 
ultrasound detected LH. 
 
The LH characterisation study was designed as a pragmatic observational study built 
out of the GV study. It was anticipated that a proportion of people with LH who were 
eligible for the GV study may decline participation. These people were invited to 
participate in LH characterisation study, where they would have their LH assessed 
with digital palpation and ultrasound. They were also given advice on avoiding their 
LH affected sites and invited to return so we could assess their experiences of 
changing sites. This observational study was also used to compare digital palpation 
examination of LH using a current gold-standard approach to ultrasound detected LH.  
 
Hence, the study overall study design comprised; a case-crossover study to assess 
impact on GV (the GV study); and an observational study for characterise LH regions 
in a larger sample of people and to compare digital palpation with ultrasound for LH 
detection (the LH characterisation study). Figure 4 shows the recruitment flow for the 
















3.3.3 Process Evaluation  
The process evaluation was used to consider the feasibility objectives of the study. As 
an exploratory study, it is important to identify factors that could help optimise study 
procedures for a future study. The process evaluation was used multiple data 
collections points to: monitor adherence with study procedures; assess recruitment 
and retention; and collect data on participants’ experiences of the study.   
 
3.4 GV study measures 
The MRC framework for complex evaluation studies, recommends that in exploratory 
stage feasibility studies the aim is to optimise outcome selection, for a future study 
(Eldridge et al. 2016, Moore et al. 2015). This requires testing or modelling outcomes 
to identify this which may be most sensitive to the intervention mechanism (in this case 
changing injection sites to LH free areas of tissue). The outcomes of interest for the 
GV study were, time in range, indices of GV and insulin requirements. Time in range 
and GV were measured in two conditions (before and after injection site change) for 
each participant using a blinded CGM device [The Medtronic iPro2 CGM System]: 
Condition 1 - participants injected in their usual way (with no changes to their injection 
sites, insulin dose or behaviour); and Condition 2 - a second week of glucose recording 
after a five-week washout period were they were advised to inject exclusively into 
areas not affected by LH. The other study measures were also assessed following 
each condition. The selection of measures used for the study are detailed below.  
 
3.4.1 CGM measures  
The CGM sensors generate a large volume of glucose data, the variability of which 
can be assessed in multiple ways. The primary variability measure for this study was 
the proportion of time spend in range based on a target glucose range of 4-10 mmol/L 
(Danne et al. 2017). While time in range is not a measure of GV, it is an important 







the uncertainty of the impact of LH on glucose regulation, time in range was identified 
as potentially the most sensitive indicator for the impact of changing injection sites on 
overall glucose exposure, it would also provide insights into the amount of 
hypoglycaemia experienced by participants following the change of sites. A minimum 
threshold for improvement of an increase of ³10% for time in range was set as a 
reasonable clinical threshold to indicate a transferable benefit in reducing risk of 
complications, a change of 10% in people who spend <40% of time in range reduces 
the risk of microvascular complication by 30% with benefits increasing when the 
proportion is lower as there is an inverse correlation between time in range and 
complications (Beck et al. 2019). To further consider the impact of changing sites 
consideration was also given to time spend below range (4 mmol/L) and time above 
range (10 mmol/L), as this also is clinically important when assessing insulin action 
and sensitivity when the injection sites were changed in Condition 2 (Danne et al. 
2017). 
 
In addition to time in range it was particularly important in assessing the impact of LH 
on glucose regulation to measure GV. As identified in the literature chapter previous 
studies that have assessed the relationship between LH and GV have used crude 
methods for this assessment, such as the standard deviation of self-monitored glucose 
readings. As the data from the limited clamp-study suggested that LH was associated 
with altered insulin activity curves and glucose responses (Famulla et al. 2016), 
assessing the impact of GV would help test this assumption in a real-world clinical 
context. Hence, a number of GV measures were assessed, with each measure 
contributing slightly different information on the glucose profiles generated by the CGM 
data (assessing the volume and magnitude of glucose excursions). These measures 
included:  
 
• Standard Deviation (SD) of mean glucose - The SD is a widely used 







shows how much variation or dispersion there is from the average (Hill et al. 
2011). 
 
• Coefficient of Variation (CV) - The CV (which is the SD divided by the mean) 
has the advantage of being a metric relative to the mean, which makes it more 
descriptive of hypoglycaemic excursions than the SD alone (Rodbard 2012). 
Stable glucose levels are defined as a CV <36%, and unstable glucose levels 
are defined as CV ≥36% (Monnier et al. 2017). 
 
• Mean Amplitude of Glucose Excursions (MAGE) - The MAGE is a measure of 
within-day GV to assess the degree of glucose excursions (Service et al. 1970). 
The MAGE is calculated as the mean height of excursions >1 SD from the 
mean.  
 
• Mean Absolute Glucose (MAG) calculates the sum of the differences between 
successive glucose values divided by the total time measured in hours 
(Hermanides et al. 2010). 
 
• Means of the Daily Differences (MODD) - The MODD is a measure of the blood 
glucose changes resulting from day-to-day variation and is calculated on the 
absolute difference between paired CGM values obtained during two 
successive days (Molnar et al. 1972). 
 
• Continuous Overlapping Net Glycaemic Action (CONGA) - CONGA assesses 
GV within a predetermined time window (McDonnell et al. 2005), it represents 
the SD of all valid differences between a current observation and an 
observation (n) hours earlier. The longer the time interval the wider the window 
of variation considered, generally 1, 2 or 4 hour intervals are used (Rawlings et 
al. 2011). In this study the 4 hour interval was used to provide and a more 







3.4.2 Glycaemic control 
Glycaemic control was assessed using a measure of glycated haemoglobin (HbA1c) 
and 1,5-Anhydroglucitol (1,5-AG). While HbA1c was primarily collected as a reference 
value in defining the characteristics of the participants, and it was also measured again 
following the Condition 2 exposure as an outcome, to ascertain whether there had 
been any change in glucose exposure. However, HbA1c is not an optimal measure for 
assessing short-term changes in glucose exposure as it can take 2-3 months before it 
fully reflects the glucose levels (Parrinello & Slevin 2014).1,5-AG is a relatively novel 
marker for glycaemic control, measuring activation of glucose channelling into the 
polyol-pathway (Yamanouchi & Akanuma 1994). It has the advantage of being more 
sensitive to glucose exposures in the short term (Parrinello & Selvin 2014, Dungan 
2008). 1,5-AG is highly responses to changes in glucose levels, when the glucose 
level rises it inhibits reabsorption of 1,5-AG in the renal tubule leading to a drop in 
plasma level of 1,5-AG- these changes are detectable within a 24hr period and when 
assessed over 14 days it provides a short-term estimate of glucose exposure (McGill 
et al. 2004, Buse et al. 2003). Therefore, given the short period of observation adopted 
in the study and the need to estimate overall glucose exposure, 1,5-AG maybe a more 
sensitive marker of intra-cellular glucose exposure compared to HbA1c. While it is 
acknowledged that this study would not be able to provide a definitive estimate of its 
sensitivity to glucose changes in respect of avoiding LH affected areas, it would be 
possible to estimate whether it would be useful to include it as a marker in future 













3.4.3 Additional outcomes 
As injecting insulin to regulate glucose levels is a complex behaviour which can be 
demanding for people living with T1DM, consideration was given to other outcomes 
reflecting the participants: psychological orientation to diabetes; satisfaction with 
insulin; and their general quality of life. To capture the effect of changing injection sites 
on these areas, the following measures were used: 
 
• The Insulin-Treatment-Satisfaction-Questionnaire (ITSQ) - ITSQ consist of 22 
items with five subscales assessing treatment satisfaction for persons with 
diabetes on insulin over the past month, the subscales are: Inconvenience of 
Regimen (IR-5 items), Lifestyle Flexibility (LF-3 items), Glycaemic Control (GC-
3 items), Hypoglycaemic Control (HC-5 items) and Insulin Delivery Device (DD-
6 items). All items are scored on a seven-point Likert scale, which ranged from 
"not at all" to "extremely satisfied". The 22-item ITSQ provides an overall score 
and for each subscale, the sum score is divided by the number of items and the 
higher score indicates higher treatment satisfaction (Anderson et al. 2004).  
 
• Diabetes distress was measured using the 17-item Diabetes Distress Scale 
(DDS-17) - The DDS measures diabetes-related emotional distress across four 
subscales: regimen distress, emotional burden, physician-related distress, and 
diabetes-related interpersonal distress (Polonsky et al. 2005). The scale has 
been widely used and validated with good internal reliability (α > 0.87) and 
shows a discriminant association with measures of diabetes disease 
management and depression (Polonksy et al. 2005). Items are scored on a on 
a 6-point Likert scale with each item scored from 1 (no distress) to 6 (serious 
distress) concerning distress experienced over the last month (Appendix 7). A 
mean item score of ≥3 (which indicates moderate distress) is used to distinguish 









• Health-related quality of life was assessed using the EQ-5D-5L (Herdman et al. 
2011). The EQ-5D-5L is a generic instrument for describing and valuing health. 
It is based on a descriptive system that defines health in terms of five 
dimensions including: Mobility, Self-Care, Usual Activities, Pain/Discomfort and 
Anxiety/Depression and an EQ-Visual Analog Scale (EQ-VAS) (Herdman et al. 
2011). Each dimension is represented by one question, which all have five 
response options, where 1 is having no problems and 5 is being unable to do 
the activity or experiencing extreme pain or anxiety/depression. The EQ-5D-5L 
index score, is calculated from the five questions, scores can range from −0.28 
(a state worse than death) to 1.000 (best possible health state) (Devlin et al. 
2018). The EQ-VAS, which measure the overall health on that day, ranges from 
0 to 100 indicating worst to best possible health. 
 
3.4.4 Demographic and clinical characteristics  
 
Additional data were collected to characterise the participants, these data included 
demographic and biometric characteristics, as well as clinical parameters such as 
insulin type and doses. Demographic and biometric data include age; gender; 
ethnicity; education level/degree, duration of diabetes; diabetes complications; current 
medicines; past medical history; weight and body mass index (BMI), (BMI = weight 
(Kg)/height (m)2).  
 
In terms of clinical data an assessment of hypoglycaemia and insulin requirements/use 
was undertaken. Awareness and frequency of hypoglycaemia was measured using  
the Gold score, which asks the participants to rate whether they are aware that they 
are experiencing hypoglycaemia on a 7-point Likert scale, with 1 representing ‘always 
aware’ and 7 representing ‘never aware’, and a score of ≥4 implies impaired 
awareness of hypoglycaemia (Gold et al. 1994). Participants also indicated any severe 
hypoglycaemic episodes in the previous year. These data were important in relation 







participant may have been at increased risk of hypoglycaemia, if the insulin’s action 
was potentiated.  
 
A range of data on the type, doses and methods of administration used were collected, 
these included: type of insulin, total daily dose (proportion of basal and bolus insulin); 
and needle length. To consider whether the participant may be taking more or less 
insulin than might be anticipated, a physiological total insulin requirement was 
estimated based on this formula - 0.6units per KG of body weight (Rubin et al. 2011). 
While insulin requirements vary between individuals depending on the amount of 
residual endogenous insulin supply and factors related to insulin resistance, it provides 
a reasonable estimate for considering dose requirements in T1DM.  
 
3.4.5 Feasibility measures 
In order to consider feasibility aspects of the study (reach and fidelity), data were 
collected on the conduct of the study. These data included study recruitment, retention 
and attendance rates. The researcher kept a record of the total number of people who 
were screened for eligibility, the number of people who were eligible to participate, the 
total number who were approached to participate and total number of those who 
agreed to participate during the recruitment period. The total number of participants 
who completed the GV and LH elements of the study, and the total number of 
participants with missing data was also recorded.  
 
The participants fidelity with study requirements were recorded at Condition 2 to 
establish if they had maintained avoidance of LH affected areas and followed the 
insulin advice they had been given. These data were collected through a diary that 
participants maintained through the CGM monitoring periods in Conditions 1 and 2 
(see appendix 10).  Further data were collected via the exit interviews, which assessed 








3.5 Study setting 
The study was conducted in the diabetes’ clinics of two large teaching hospitals (Guy's 
and St Thomas' NHS Foundation Trust (GSTFT) in London, UK). These clinics provide 
care to approximate 2000 people with Type 1 diabetes, with around 100 people 
attending every day. People attending these services are managed by a multi-
disciplinary team of diabetes professionals. These diabetes services also provide 
structured education programmes for people with T1DM. The US scanning and 
physical palpation (digital palpation) took place in the diabetes clinic at St Thomas’ 
Hospital site, with access to bed space which provided privacy for confidentiality. 
 
3.6 Study participants (sampling and recruitment)  
This section outlines how the participants in the study were identified and recruited.  
 
3.6.1 Eligibility criteria  
Adults with T1DM were recruited to the study using the following eligibility criteria, 
which were agreed following the discussion with healthcare professionals and people 
living with T1DM: 
 
• Diagnosed T1DM and using insulin for >3 years. 
• Taking multiple daily injections ≥4 per-day. 
• Performing self-monitoring blood glucose testing an average of ≥4 tests per 
day or taking 3 tests per-day and willing to increase to 4 tests per day for the 
duration of the study. 
• GV with a SD≥3.5 mmol/L of mean glucose readings in the past 4 weeks. 
• Stable diabetes medication regimen (using the same insulin type and delivery 
method) six months before study entry. 









3.6.2 Exclusion Criteria 
• Age <20 years 
• T2DM or Gestational diabetes mellitus (GDM) 
• Have a condition or receiving therapies, other than insulin, associated with 
lipodystrophies such as amyloidosis. 
• Have another medical condition or take medicines that may influence blood 
glucose control (including currently active cancer; uncontrolled endocrine 
disorder; eating disorders; coeliac disease; and cystic fibrosis) 
• Any recent acute intercurrent illness impacting on blood glucose readings. 
• Have a serious medical or mental health condition that could limit adherence 
to required study tasks. 
• Using other injectable treatments in diabetes such as growth hormone or 
glucagon-like peptide-1. 
• Using continuous subcutaneous insulin infusion (CSII). 
• Not undertaking blood glucose tests ≥4 tests per day. 
• Unable to give consent. 
• Unable to speak English, as providing language support was beyond the 
scope of the recourses for the study. 
 
3.6.3 Study withdrawal criteria were as follows:  
Consenting participants who met the inclusion criteria were withdrawn from the study 
following baseline data collection, if: 
 
• They no longer met the inclusion criteria.  
• Their physician changed the insulin type or method of delivery. 
• Participant was unwell or was unable to comply with the study protocol (e.g. 
an adverse reaction to CGM sensor adhesive).  








3.6.4 Sample size  
The target was to recruit 34 participants to detect a 10% difference in the time spent 
in range between Conditions 1 and 2. This estimation was based on a power 
calculation (using G-power) for analysis of covariance (ANCOVA) with an estimated 
effect size of 1.3, with power at 95% and alpha @5%, with a 25% inflation to allow for 
dropouts and/or CGM sensor failure. The effect estimate was based on a previous 
crossover study (n=47) with CGM and percentage time in range (4-10 mmol/L) where 
a 10% (95%CI 8-11.2) increase in time in range (an absolute change) was observed 
(Van Beers et al. 2016).  
 
3.6.5 Expected recruitment rate  
To plan the study a recruitment was estimated, to ensure there was enough time to 
complete the recruitment within the time available. This identified that a recruitment 
rate of one to two potential participants a week minimum was needed over a four-
month period to recruit the target of 34 participants to the study. This was assessed 
as feasible given the high volume of people with diabetes attending the clinical sites 
and feedback from the public involvement (PPI) group. However, despite best efforts, 
the two months recruitment review suggested that this target would not be achieved, 
hence the study recruitment period was extended by a further two months. 
Unfortunately, recruitment remained low and at the end of this period (seven months 
from the start), therefore, a decision was made to close recruitment prior to achieving 
the required sample.  
 
3.6.6 Procedures to maximise retention 
Improving the retention rates of participants who are required to undertake multiple 
hospital visits is a challenge. A number of strategies that have been linked to increased 
study retention were utilised (Turner 2013):  
• Advanced appointment scheduling,  







• Scheduled visit phone call or SMS text reminders,  
• Flexible appointment scheduling, 
• £50 gift voucher was available for each participant that completed the study. 
 
3.7 Preliminary work and Ultrasound training  
As the study involved using US as a tool to detect LH, two researchers had undertaken 
six 2-hour long training sessions with Mrs.Susan Halson-Brown a senior sonographer 
and US trainer. Mrs. Halson-Brown is an international expert in US and a Senior 
Lecturer and Program Director for Specialist Ultrasound Practice at King’s College 
London (KCL). She provided training to the researchers involved in data collection, 
with an individualised condensed version of the full training course offered by KCL 
“Specialist Ultrasound Practice”. The training included how to use the US machine, 
how to identify different forms of LH, and how to take measurements of skin depth and 
nodule dimensions. One researcher undertook further practice for four days assessing 
the LH conditions for 11 volunteers to achieve a consistent level of competence, the 
volunteers had signed the training and education consent form. In addition to training 
the researcher and assessing their competence, Mrs. Halson-Brown also reviewed the 
scans undertaken to assess the LH measurements made on the images for accuracy. 
During this preliminary work, a standard operator procedure (SOP) for using US to 
detect and measure LH was developed by the researcher in order to enhance the 
reliability of measurement and ensure inter-examiner consistency (see appendix 
13.1). The SOP was approved by Mrs. Halson-Brown. The SOP detailed  the 
equipment required for scanning, the scanning procedure (anatomical sites to be 
reviewed) and the technique for using the US equipment. The Sonosite X-Porte US 
machine with a high-frequency linear probe (6-13 MHz) was used to collect all data for 
the study. The Sonosite X-Porte incorporates proprietary beam-forming technology: 
XDI (Extreme Definition Imaging). This signal analysis algorithm shapes X-Porte's US 
beam to pinpoint precision resulting in very precise images in superficial regions, such 







from the skin surface to muscle fascia was measured at the all identified injection sites 
as well as the area around the injection sites. The skin measures included: the dermis 
layer, and subcutaneous tissue (SC). LH tissues where identified as areas of hyper-
echogenicity which indicates greater tissue density. Any other abnormal changes to 
the tissue were also identified and labelled on the images and later interpreted with 
Mrs. Halson-Brown. In addition to areas potentially affected by LH (i.e. where insulin 
exposure occurred), a reference scan of normal tissue from an area not generally 
exposed to insulin, was undertaken for comparative purposes.    
 
3.8 Patient and public involvement  
It is increasingly recognised that public and patient involvement (PPI) can enhance the 
quality and relevance of health and social science research (Staley 2009), including 
PPI can provide valuable input in the health research during all phases of the study 
(Brett et al. 2014) Therefore, during the formative stage of the study, two people living 
with T1DM were involved in developing and reviewing  the study design. The PPI 
members were identified from the local clinical diabetes service by one of the PhD 
supervisors who worked in the clinical service. Their input was very helpful in 
determining the data collection processes that were employed to help ensure they 
would be more acceptable to potential participants. The two PPI group members gave 
their feedback on the draft questionnaires for the study, following which modifications 
were made to the content and format of the questionnaires. While these two PPI group 
members made a very important contribution to the study, a larger reference group 
should have used and given the recruitment issues mentioned above this would be an 
important consideration for any future study. Unfortunately, it was not feasible for this 











3.9 Project personnel  
Five people were involved in the conduct of the project; the chief investigator, 
ultrasonographer, two researchers (diabetes specialist nurse and PhD student) and a 
research assistant. All held honorary contracts with Guy's and St Thomas' NHS 
Foundation. A research assistant was employed for a one-year period to assist with 
data collection in the clinical setting and to conduct some of the exit interview at the 





























3.10 Data collection tools and study documents  
Standard operating procedures (SOPs) and data collection tools were designed and 
refined by the researcher with the support of experts in US and the study supervisors. 
Validated tools were used as previously indicated to assess the impact of injection site 
changes on insulin satisfaction and diabetes distress, using the: Insulin Treatment 
Satisfaction Questionnaire (ITSQ: Anderson et al. 2004); and the Diabetes Distress 
Scale (DDS: Polonsky et al. 2005). The EuroQol EQ-5D-5L was used to assess health-
related quality of life (Herdman et al. 2011) (see section 3.4.3 Additional outcomes on 
page 85 and 86). The demographic and clinical questions were researcher-developed. 
Following refinement by the study team, the tools were sent to the PPI representatives 
for feedback and amended.  
Participant information sheets and consent forms were designed specifically for the 
research project; refined by the researcher, supervisory team, PPI and the Health 
Research Authority approval process. Table 7 details the appendices for research 
tools, participant information sheets and consent forms.  




Participant Information Sheet: GV Appendix 5.1 & 5.2 
Participant Information Sheet: LH Appendix 5.3 
Consent forms Appendix 6 
Participant questionnaire Appendix 8 
Clinical Data Forms: Digital Palpation & Ultrasound Examination Appendix 9.1 & 9.2 
Continuous Glucose Monitor Diary Appendix 10 
Injection Site and Dose Calculation Form Appendix 11 
Participants’ interviews guide Appendix 12 
SOP 1 Physical examination and ultrasound scan technique Appendix 13.1 
SOP 2 Insertion Technique for the Ipro2 Continuous Glucose Monitor Appendix 13.2 
SOP 3 Identification of lipohypertrophy free injection sites and safety 








3.11 Data collection process 
3.11.1 Study Process and Field Activities 
After receiving the ethical approval from the Health Research Authority (HRA) on 
behalf of the NHS in England, pre-testing was undertaken to model participants 
recruitment. The aim of the pre-testing was to understand the organisation of diabetes 
outpatient clinics in the targeted hospitals to determine the appropriate method for 
approaching potential participants. Initial observations were conducted to familiarise 
the researcher with the outpatient diabetes clinic setting within GSTFT. These included 
outpatient diabetes clinics working environment, patients' appointment system, 
consultations, referral process, and all activities relating to the operation of diabetes 
clinic. The observations enabled the patient journey within the clinic to be mapped, 
identifying opportunities for screening and recruiting potential participants.   
 
3.11.2 Recruitment process 
Recruitment to the study took place from end of September 2017 once the local 
confirmation of capability and capacity permission was issued by the research site. 
Potentially eligible participants attending out-patients' diabetes clinics were 
approached and given some information about the study, either in the waiting room or 
directly after they had finished their appointment. They had the opportunity to discuss 
the study with the researcher and consider participation, they were given at least 48 
hours to consider their decision with family, friends and their clinical care team. A 
member of the research team would then contact them by telephone, text message or 
email and answer any additional questions, verify their understanding of what was 
involved and confirm their interest in study participation. A first appointment was 
arranged to gain written consent, and participants were informed that their 
demographic and clinical data would be collected through a review of their medical 
records and questionnaires. CGM insertion was facilitated for those who agreed to 
take part, either on the same day or arranged for the following Friday or time 







Clinicians were also briefed about the study and referred people with T1DM who they 
felt could benefit from the study for consideration. Clinicians were given a study 
identification card, including the eligibility criteria for both studies to identify potential 
participants (see Appendix 4). The number of eligible participants not recruited was 
recorded. 
 
3.11.3 Study procedures  
Data collection from consenting participants, who met the inclusion criteria, were 
organised over a series of visits to the clinical research facility at St Thomas’ Hospital, 
as detailed below. 
 
3.11.3.1 Section A. The study process for the GV study participants. 
Visit 1 - Consenting participants were required to bring their blood glucose meters to 
clinic at each visit and the researcher used Diasend™ software to download glucose 
values into the study database. At the beginning of visit 1 participants completed a 
structured questionnaire comprising questions on: socio-demographic characteristics; 
insulin use (insulin type, doses and needle length), insulin to carb ratios; diabetes 
education received; carbohydrate counting; diabetes complications; and incidents of 
severe hypoglycaemia. They also completed the DDS, ITSQ, EQ5D_5L 
questionnaires and the Gold score, and anthropometric assessment (weight/BMI) was 
conducted by the researcher. The questionnaires were self-completed and checked 
for completeness by a researcher during the visit (Appendix 7 schedule of 
procedures). Participants were also allocated a unique study identification number and 
their General Practitioners (GP) were notified by letter of their participation.  
 
Participants were fitted with CGM device (Medtronic Ipro2) by trained member of the 
research team. The iPro2 device calculates and stores glucose readings every five 
minutes (Medtronic MiniMed 2016). This type of sensor is “blinded” to the participant 







which may have influenced the participant to adjust their insulin doses according to 
the CGM reading. The sensor was placed in the anterior abdominal wall according to 
manufacturer’s Instructions and following the procedure detailed in SOP2 (Appendix 
13.2).  
 
During that week, participants were asked to continue measuring their blood glucose 
levels using their meter for a minimum of four times a day, and were given a diary to 
record details of their daily activities: all insulin injections (including dose), food and 
carbohydrate estimates per meal, physical activity, and hypoglycaemia (symptomatic 
or severe). Further, they were asked to indicate on a body map where they gave their 
insulin injection (Appendix 10). At the end of visit 1 participants were advised not to 
change their self-care habits and to maintain their normal injection behaviours, no 
changes in diet and exercise habits were required and they were not told the intention 
of the study was to identify LH.  
 
Visit 2 - One week after the CGM insertion, participants returned to have their CGM 
and blood glucose monitoring data downloaded and return their completed diary. The 
sensor was removed and plugged into a docking station to upload the readings into a 
computer that contains dedicated software, called Carelink iPro Software. The 
calibration data (at least two capillary blood glucose values per day) was entered and 
the results reviewed with the participants. CGM data were considered valid if at least 
four days of recording were obtained. Participants were then informed about the study 
purpose in relation to LH and re-consented. Consenting participants then had a digital 
palpation examination for LH following the standard operating procedure (SOP) (see 
Appendix 13.1 SOP1), which was documented anatomically. Digital palpation is the 
current clinical best-practice method for assessing injections sites and the protocol in 
the SOP1 followed the latest clinical guidelines and tested method for assessing LH 
(FITTER 2016, Frid et al. 2016a, Gentile et al. 2016a). The digital palpation was 







palpation was conducted blind to the US and vice versa and participants were advised 
not to discuss each examination with the researcher. 
 
The US examination of the injection sites was carried out with reference to the 
previously described SOP (SOP1 Appendix 13.1). The US investigation was carried 
out by an expert ultrasonographer/or an US trained diabetes educator. A high 
frequency linear probe set at between 6 and 13 megahertz (MHz) was used for the 
scanning. The SOP1 specified probe placement and recording of ‘normal’ non-injected 
tissue and tissue in injection sites at anatomic positions. Measurements were included 
skin thickness (epidermis and dermis) and subcutaneous tissue depth. In all injected 
areas images were recorded for signs of changes including morphology (nodular or 
diffuse) of LH. Following this assessment, it was revealed to the participants whether 
they had clinically significant LH. 
 
During the US scan the participants had an opportunity to see where their LH areas 
were, and what possible new area (LH free areas) they can use for their future insulin 
injection. After the scanning, the participants were advised to avoid injecting insulin 
into LH identified areas and were advised on adjusting their insulin dose following the 
change from the LH areas. This advice did not change their insulin model (mode of 
injecting) but did reduce doses to physiologic requirement (1unit per 0.6Kg body 
weight) to avoid risk of hypoglycaemia. While this is a population level estimate, it is 
an established clinical method for calculating an initiating dose of insulin and in the 
case of the study provided a reasonable margin of safety in reducing potential hazard 
of severe hypoglycaemia. This calculation gave the total daily insulin dose which was 
then divided by two to give the basal dose. If the participant had a carbohydrate to 
insulin ratio > 1 unit: 10 grams of carb they were advised to reduce back to that level 
(see SOP3 Appendix 13.3). At the end of this visit, the participants had venous blood 








Washout Phase-Insulin Stabilisation- Following any reductions in insulin doses, the 
participants had a washout or insulin stabilisation phase, where they were advised to 
follow their normal practice for dose intensification based on their blood glucose 
readings to compensate for any deficit or excess in the dose. During this period 
participants had ongoing monitoring from a diabetes specialist nurse to reduce any 
risk of hypoglycaemia (see SOP3 Appendix 13.3). The insulin stabilisation phase had 
been purely designed as a participant safety measure. Participants without LH left the 
study at this point with clinical advice from a diabetes specialist nurse on reducing their 
insulin variability. 
 
Visit 3- In this visit the participants returned after five weeks and were fitted with the 
second blind CGM sensor. The diary was also provided for them to complete, detailing: 
all insulin injections (including dose and sites); and food and carbohydrate estimates 
per meal for the next six days. It was emphasised that during this CGM phase they 
must only inject in their LH free areas. 
 
Visit 4- One week after visit 3 the participants returned to have their CGM sensors 
removed. At this visit, participants were given a clinical consultation involving a review 
of both CGM readings and given supportive advice on how to best manage their insulin 
injections going forward. The participants also completed the study questionnaires 
again and repeated blood test (HbA1c and 1,5-anhydroglucitol). At the end of this visit, 
a short exit interview was conducted to consider the participants’ experiences of 
injecting into LH free sites, and an appropriate clinical follow-up by the diabetes team 
was arranged for the participants if needed.  
 
Exit interview procedure 
Short structured interviews were held following completion of the study. The topics 
focused on experiences of changing the injection sites, as well as their views on any 







were interviewed face-to-face. The interviews were undertaken by one researcher and 
interview durations were variable, ranging from 20 to 40 minutes each. 
 
3.11.3.2 Section B. The study process for the LH characterisation participants. 
 
Participants, not eligible for or who declined the GV study were given the opportunity 
to participate in the LH characterisation study. This study progressed as follows: 
 
Visit 1 Consenting participants completed a face-to-face structured questionnaire 
comprising questions on: socio-demographic characteristics; insulin use (insulin type 
and doses, injection behaviours, delivery system (including needle length), insulin to 
carb ratios); diabetes education received; carbohydrate counting practice and 
competence; diabetes complications; and incidents of severe hypoglycaemia. They 
also completed the DDS, ITSQ, EQ5D_5L questionnaires and the Gold score and 
underwent anthropometric assessment (weight/BMI). Their injection sites were 
examined with digital palpation and with US as with the GV study. Unlike the GV study 
they did not have CGM or measurement of 1,5-anhydroglucitol, however, HbA1c was 
assessed. 
 
Visit 2 After six weeks’ participants returned, completed the study questionnaires 















3.12 Data management and entry procedures  
3.12.1 Data protection and storage  
Participants were informed, both verbally and through the Participant Information 
Sheet (Appendix 5), that the research team would access their medical records during 
the study, in order to collect clinical information about them. Participants provided 
written informed consent form to confirm their willingness for the research team to 
access their personal information. Each participant was assigned a unique study 
identifier, and this was used throughout the study. Personalised information with the 
unique study identifier were securely stored in restricted access, lockable containers 
at King’s College London (KCL). No personalised data were stored electronically; all 
data were anonymised stored on password protected university computers. In line with 
the university’s research framework, research records will be kept for a period of 10 
years on completion of the study, archived in line with KCL policy. Where possible, 
paperwork was scanned and stored electronically on a secure server. The researcher 
and the study supervisors met regularly to ensure high standards of data collection 
and analysis were maintained throughout. The study was later registered with KCL 
Data Protection Register to ensure compliance with the introduction of the General 
Data Protection Regulation (GDPR) (Regulation G.D.P 2016) which came into effect 
on the 25th May 2018.  
 
3.12.2 Data entry procedures  
The collected data (questionnaires and clinical data) were entered onto an encrypted 
database by the researchers. The blood test results were also entered onto the 
database from paper records or from Microsoft Excel datasheets provided by the 
laboratories used. The CGM data for Conditions 1 and 2 were downloaded by the 
researcher from the sensors, generating excel files. US images were categorised in 
terms of LH patterns and anatomical distributions for each participant and entered onto 
a Microsoft Excel and Microsoft Access data files then entered onto the main 







(SPSS) version 25.0 statistical software (IBM 2017) for analysis. The exit interview 
data were coded from the interview schedules and also entered into an excel spread 
sheet for analysis.  
 
3.13 Data analysis 
The data were analysed in three phases: 
3.13.1 Phase 1 Preparatory analysis 
The preparatory element involved: checking data for completeness and accuracy prior 
to entry into databases; Microsoft Access, Microsoft Excel and SPSS, undertaking any 
necessary data transformations or adjustments and exploring data distributions and to 
identify and investigate any outliers. 
 
The EasyGV version 10 software was used to calculated the Time in range (TIR), Time 
below range (TBR), Time above range (TAR), SD, MAGE, CONGA-4, MODD, and 
MAG. 
 
The LH assessment data from US and clinical exam in line with SOP1 (Appendix 13.1) 
were used to characterise the LH profiles. The LH patterns observed on the scans of 
each participant were described and characterised with reference to the presentation 
type (diffuse and/or nodular formation); location and distribution; and the width of the 
LH. These data were used to grade and map the LH regions. Grading was determined 
as follows: Grade 0 (no evident nodules or diffuse areas); Grade 1 (diffuse 
lipohypertrophy); Grade 2 (diffuse areas of the injected subcutaneous tissue 
containing clearly defined nodules with circumscribed margins sized 1-5.9mm); Grade 
3 (diffuse areas of the injected subcutaneous tissue, with clearly defined nodules of 
different sizes 6-7.9 mm); and Grade 4 (diffuse areas of the injected subcutaneous 







of the injected subcutaneous tissue, with clearly defined nodules >10mm). Descriptive 
data on the prevalence of these different types, grades and locations of LH was 
generated. The severity of LH nodules was calculated using the size and number of 
nodules, using the following formula: 
Severity= (max grade2 x nLH nodules)/100 
 
The ITSQ, DDS and QoL scores were calculated according to the developers’ 
instructions. The frequency of the bolus injection was counted from participants diary 
and CGM daily summary for Condition 1 and 2 and presented as percentage. 
 
3.13.2 Phase 2 Primary analysis 
The primary analysis tested the study hypothesis using nonparametric test (Wilcoxon's 
signed rank test) to assess the change in GV between Condition 1 and 2 including; 
time spent in target range, time spent below range and above range; the other GV 
measures. 
 
The change in glycaemic control, 1,5-Anhydroglucitol, study questionnaires and the 
total daily insulin (estimated insulin requirement, basal and quick acting insulin doses) 
was also assessed using the same test (Wilcoxon's signed rank test). 
 
A paired sample T-tests was utilised to assess the glycaemic control and total daily 
dose for all participants (GV study and LH characterisation study). The same test was 
utilised to assess the psychosocial measures (DDS, EQ5D_5L and the ITSQ). 
A descriptive analysis of the demographic and insulin treatment characteristics (GV 
and LH studies variables), presented as median (IQR) and mean (SD) respectively. 







To compare the procedure performed by palpation against the US to detect LH, these 
procedures where performed independently (blind), though they shared common 
anatomical map into which the identified LH areas were located. The total numbers of 
the identified nodules by both methods were calculated. The Cohen’s Kappa was used 
to measure the agreement between the two methods using US as reference standard 
(McHugh 2012). 
 
Figure 6: Flow chart of phase 2 data analysis 
 
3.13.3 Phase 3 Exploratory analysis 
As indicated in section 3.6.5 (Expected recruitment rate) the study did not complete 
full recruitment, potentially undermining the power of the study to be able to estimate 
the impact of site changes as hypothesised. To compensate for this limitation 
additional exploratory analyses were undertaken at the individual case level. This 







seemed to mediate the effects observed. Each participant was ranked by the level of 
impact seen on their time in range. This ranking enabled case to case comparisons 
and identified mediating factors that explain the observations made on GV. The 
studies provide an integrated analysis looking at the LH profiles of each case, a 
detailed analysis of glucose levels on the CGM considering how responsive the 
glucose levels were to quick acting insulin. Information from the questionnaires and 
exit interviews was also used to add explanation considering how adherent 
participants had been to observe their new injection areas.   
 
3.13.4 Missing data 
The researcher attempted to minimise missing data by checking different source 
information (electronic/paper) in the participants medical records to ensure data 
completeness as far as possible. For the questionnaire scales a minimum of 50% item 
completion was required before these were calculated. For the SPSS analysis missing 
were left blank and the “exclude cases analysis by analysis” function for missing data 
was used.  
Regarding the CGM missing data, periods without glucose values, in this study the 
data of participants who had a missing value >50 gap of readings ‘the defined Max 
Gap in EasyGV 10’ were excluded. In cases where the amount of missing values was  











3.14 Process evaluation data 
In this study the process evaluation assessed the implementation process and delivery 
of study intervention (included: insulin stabilisation and injection sites examination and 
recommendation regarding the avoidance of LH areas), fidelity with insulin adjustment 
and LH avoidance and reach/recruitment (Moore et al. 2015). 
The process evaluation used a mixed-method approach of data collection:  
• Quantitative data included: a report of the number and characteristics of eligible 
participants that decline participation in GV and LH characterisation studies; the 
body map in the CGM diary to monitor fidelity and compliance with injection site 
advice in the GV participants group.  
 
• The qualitative element involved brief semi-structured interviews with all 
participants at the end of the study. The interview was conducted face-to-face 
and explored with participants their experiences (positive and negative) with 
their respective injection site; LH knowledge and their motivation/intention to 
sustain their current injection behaviour.   
 
3.15 Validity and Reliability 
The validity of the study refers to the degree to which a concept is accurately measured 
in a study (Price et al. 2018). There are two main types of validity internal and external. 
Internal validity relates to how well the methods and measures used are in considering 
the research question; and external considers the extent to which the findings can be 
generalised (Gravetter & Forzano 2018). As the study was designed as an exploratory 
study the emphasis was on internal validity (Seale 2012). To enhance this validity, 
previously validated structured questionnaires were used to measure constructs of 
relevance to the study. A gold standard technique for digital palpation examination 
was used to assess the LH areas and this was blinded to the US to avoid bias, a 







The US examination followed a SOP to ensure consistent and valid measurements of 
the LH affected areas were conducted.  
 
The reliability refers to the consistency of the measurements (Price et al. 2018). There 
are several methods that can be used to test the reliability of measurements tools for 
example test-retest reliability and inter-rater reliability (Gravetter & Forzano 2018). 
Test-retest reliability requires that successive measurements be taken while the inter-
rater reliability refers to the extent to which two or more examiners agree (Lange 
2011). In this study, the US scan and digital palpation examination were performed by 
examiners with different level of experiences however to enhance the study outcome 
and measure a designed SOP was utilised by the examiners and verified by another 
researcher observing adherence to the SOP.  
 
3.16 Ethical Approvals Process and Research Governance 
3.16.1 Ethical approvals process  
Prior to accessing the participants and starting the fieldwork, ethical approval was 
obtained from the Health Research Authority (HRA), and no additional ethical issues 
were raised by the ethics committee. Ethics was obtained after submitting the full 
research protocol through the integrated Research Application System (IRAS), along 
with the participant information sheets, participant consent forms, and appropriate 
study documents. This application was also considered and approved by the Research 
and Development (R&D) at GSTFT. King’s College London acted as sponsor for this 
study. The HRA ethical approval to conduct the study was granted on the 02/08/2017, 
and permission to conduct data collection in GSTFT was sought from the R&D on the 
15/09/2017. Confirmation of this is included in Appendix 14. The data collection 








3.16.2 Research Governance  
The researcher followed the recommendations of the ‘Good Clinical Practice’ training 
undertaken and throughout the study complied with University and NHS Trust 
research guidelines. Appropriate sponsorship, ethics and R&D approval was in place 
prior to any data collection. The study is registered at ClinicalTrials.gov, number 
NCT03669770. 
 
3.16.3 Ethical issues in the conduct of the study 
The principle risk for participation in the study related to hypoglycaemia when injecting 
in LH free areas. Participants may have inflated their insulin doses to compensate for 
poor absorption and without adjustment this could cause hypoglycaemia when 
injecting in LH free sites. To mitigate against this risk, participants were asked to 
reduce their insulin levels as stipulated in study procedure section (3.11.3.1 Study 
process A Visit 2 on page 99 ). Prior to data collection, all the potential clinical hazards 
associated with this study were discussed with clinical colleagues not directly involved 
in the study and in meeting with diabetes team at GSTFT. This resulted in the 
engagement of health professional, and further support for conducting the study. In 
addition to that, most of the study visits took place on Fridays ensuring adequate safety 
monitoring over five consecutive days. Participants had 24-hour access to an on-call 
diabetes consultant and had written instructions in reducing insulin doses. 
The study had also the following safety monitoring procedures: an incident log for 
every participant to record any adverse events; an incident log for all clinical research 
areas to monitor adherence to study protocol and SOP and for recording any incidents 
that may occur in the conduct of the study; and weekly team meetings to consider any 








3.17 Contribution of the researcher to the study 
The researcher reviewed the outpatient diabetes clinic lists for potential participants 
and approached participants at their routine clinic appointment to invite them to take 
part in the study. The researcher administered the questionnaires, performed 25% of 
digital palpation examination, downloaded all CGM and SBGM data, was responsible 
for the transportation of US machine and organising shipping of the blood sample to 
the laboratory. The researcher undertook the double-entry of data (questionnaires, 
clinical examination forms, participants information sheets) onto Excel and SPSS 
databases. Consent forms and GP notification letters were printed and compiled by 
the researcher on a weekly basis. All statistical analyses were performed by the 
researcher under the direction of the main supervisor.  
 
3.18 Chapter summary 
This chapter provided a detailed explanation of the method used in this study. It 
demonstrated how the participants were recruited, and how the data were collected 
and analysed. Furthermore, the processes used to manage the data was outlined, and 
important ethical aspects considered and discussed. The next following chapters 







Chapter 4 Findings 
4.1 Introduction 
This chapter presents the findings of the study in three sections, detailing: the GV 
study analysis; the LH characterisation study data; and data on participant 
perspectives in relation to their injecting behaviours. The chapter is organised as 
follows: 
• GV study- findings 
Ø Sample characteristics 
Ø Distribution and morphology of the LH observed 
Ø Time in range and GV findings (baseline and follow-up) 
Ø Secondary outcome data – insulin satisfaction, diabetes distress and 
quality of life questionnaires 
• LH characterisation study- findings 
Ø Sample characteristics 
Ø Characterisation of LH in non-participants 
Ø Comparison of digital palpation and ultrasound in detecting LH. 


















Data were collected over a seven-month period, commencing in September 2017 and 
concluding in April 2018. A total of 226 people with T1DM were screened by the 
researcher to confirm eligibility, based on the study eligibility criteria. Ninety-five (42%) 
people with T1DM met the eligibility criteria, of whom 34 (36%) agreed to participate 
in the GV study, while 61 (64%) did not respond or declined to participate. The main 
reasons for declining participation were time investment and a lack of perceived 
benefit in participating. 
 
Of the 34 participants who entered the GV study, five did not attend their baseline 
assessment visit. Of the remaining 27 participants, 12 did not complete the study for 
the following reasons: inadequate baseline variability on CGM download 
(SD<3.5mmo/l) (n=3); insufficient CGM data (n=6); and being lost to follow-up (n=3) 
assessment. In respect of those who were excluded due to low GV, these people 
revealed that they had altered their insulin injecting behaviours or dose prior to their 
baseline assessment following advice from clinical staff, thereby making them 
unsuitable for inclusion. Hence, full data were available only for 15 participants, all of 
whom were included in the analysis. 
 
The participants who did not meet the GV study criteria because of inadequate blood 
glucose testing, but who had potential GV or LH, were offered the opportunity to take 
part in the LH characterisation study (58%, n=131). Of that group 47 (36%) agreed to 
participate in the LH characterisation study, and 84 (64%) did not respond or declined 
to participate. Details of these participants are presented in Section 4.8. An overview 
of participation in the GV and characterisation studies is presented in the flow chart 

















4.2 GV study Findings 
4.2.1 Participant characteristics 
The median age of the participants (n=15), was 32 (IQR, 25-60) years (range 20-71 
years), with a median duration of T1DM of 14 (IQR, 10-23) years. The majority of the 
participants were female (67%, n=10), of White ethnicity (87%, n=13) and had a 
degree or equivalent educational qualification (67%, n=10). English was the first 
language for 14 (93%) participants and for one it was a second language. All of the 
participants, with one exception, were right-handed. The median baseline HbA1c 
value of the participants was 65 (IQR, 55-70) mmol/mol [8.1 (IQR, 7.2-8.6) %]. The 
median body mass index (BMI) was 24.7 (IQR, 21.4-26.5) kg/m2. In addition to insulin 
injection, nearly half of the participants (47%, n=7) were taking other medication, 
including: cholesterol-lowering agents (n=4), Metformin (n=2), antihypertensive 
therapy (n=2), antidepressants (n=2), thyroxine (n=1), nonsteroidal anti-inflammatory 
drugs (n=1), and hormonal contraception (n=1). The level of comorbidity was low, with 
only two participants reporting other physical conditions; one participant reported 
hypothyroidism, breast cancer in remission, and brachial plexus syndrome. The other 
participant reported a history of depression. Only three participants reported diabetes 
complications, which included retinopathy (n=1), nephropathy (n=1) and a foot 
complication (n=1). 
 
The median age of the participants who did not complete (n=12) the study was 40 
(IQR, 30.3-49.5) years (range 22-65 years), with a median duration of T1DM of 22 
(IQR, 13.5-25.3) years and median baseline HbA1c value 64 (IQR, 56-70) mmol/mol 
[8 (IQR, 7.3-8.6) %]. Study withdrawal was more common in males (67%, n=8). A 
summary of the characteristics of the completed and non-completed participants is 







Table 8: Participant characteristics 




























             Male             









White           
Black            



























         10 (66.7) 
          4 (26.7) 






          1 (8.3) 
          4 (33.3) 
          4 (33.3) 
          3 (25) 

















          1 (6.7) 
              - 
          7 (46.7) 
          2 (13.3) 
          2 (13.3) 












HbA1c at baseline 
Median (IQR) mmol/mol 
Range mmol/mol 






















HbA1c categories   
 
42-52 mmol/mol [6.0-6.9 %] 
53-63 mmol/mol [7.0-7.9 %] 
64-74 mmol/mol [8.0-8.9 %] 
75-85 mmol/mol [9.0-9.9 %] 






         1 (6.7) 
         5 (33.3) 
         6 (40) 
         1 (6.7) 





              - 
          5 (41.7) 
          6 (50) 
              - 
          1 (8.3) 
Education level  
Secondary school level 









as first language 

























N, Number; SD, Standard deviation; BMI, Body mass index; %, Percentage; T1DM, 
















4.2.2 Insulin treatment characteristics  
Basal-bolus therapy was used by all participants, for bolus insulin: 60% (n=9) were 
taking insulin aspart; 33.3% (n=5) insulin lispro; and one participant used glulisine. 
Basal insulins were: glargine (40%, n=6); detemir (53.3%, n=8); and isophane insulin 
(n=1). The median total daily dose of insulin at baseline was 43 (IQR, 35.5-55) units. 
Prior to the study all the participants, except one who did not provide the data, reported 
testing their blood glucose four or more times per day. Two-thirds (67%, n=10) of the 
participants had attended a structured education programme incorporating dose 
adjustment and carbohydrate counting, while one participant observed carbohydrate 
counting without having attended a structured programme. The needle sizes used by 
the participants were as follows: 4-mm needles, 47% (n=7); 5-mm needles, 20% (n=3); 
6-mm needles, 27% (n=4); and 8-mm needles, 7% (n=1). A summary of the insulin 
treatment characteristics of the completed and non-completed participants is 



















Table 9: Insulin treatment characteristics 





Insulin requirement*   
 
Median (IQR) 
Baseline total insulin dose  
Baseline total basal Insulin  




       43.4 (36.3-49.3) 
       43.0 (35.5-55) 
       25.0 (18-31) 
       18.0 (14.5-20.5) 
 
 
     48.6 (43.8-54.2) 
     44.0 (33.5-68.5) 
     20.0 (18.5-34.5) 
     21.3 (13.9-36) 






              6 (40) 
              8 (53.3) 
                  - 
              1 (6.7) 
 
            3 (25) 
            8 (66.7) 
            1 (8.3) 
                - 



















             7 (46.7) 
             3 (20) 
             4 (26.7) 
             1 (6.7) 
 
            3 (25) 
            5 (41.7) 
            3 (25) 
            1 (8.3) 




















5 (4-5)  
 
Attended structured education n (%) 10 (67) 7 (58.3) 
Carbohydrate counting n (%) 11 (73) 8 (67) 
 










4.2.3 Hypoglycaemia awareness and frequency 
The participants’ awareness of hypoglycaemia is summarised in Table 10. In respect 
of the Gold score, 73% of participants (n=11) had normal awareness of hypoglycaemia 
(Gold score of 1-2), one participant had moderate awareness (scored 3), and 20% of 
participants (n=3) were noted to have impaired awareness (Gold score >4). Six 
participants had previously experienced a hypoglycaemic episode requiring third party 
assistance, with three participants experiencing such an episode in the previous 12 
months.  
Table 10: Awareness of hypoglycaemia 





Hypoglycaemia awareness (Gold score)  
             1-2 (Aware) 
             3 








           1 (8) 
 
Hypoglycaemia assistance  6 (40) 6 (50) 















           9 (75) 
           1 (8.3) 
           1 (8.3) 
             - 
             - 















4.2.4 Baseline glucose levels 
The standard deviations of the mean blood glucose levels, based on a download of 
one month’s data from participants blood glucose meters, indicated that both the 
participants and non-completers had elevated variability in their glucose levels (see 
Table 11). While these data do not adjust for variations in testing in respect of food 
intake, as the median number of tests per day was 5 (IQR, 4-5) and by considering 
the daily patterns for the glucose testing times, it would be reasonable to assume that 
the majority of the tests were pre-meals (in accordance with the standard 
recommendation for testing in structured education programmes). The table shows 
that the glucose standard deviation observed at the recruitment screening visit had 
reduced in some participants by the time of the CGM insertion visit. The time gap 
between participants being screened and having the CGM fitted varied from 0 to 49 
days (median=8 (IQR, 0-23)).  
 
Table 11: Median standard deviation of the mean blood glucose levels in the last 28 












Pre-recruitment Pre-CGM Pre-recruitment Pre-CGM 
4.9 (4.8-5.2) 4.8 (4.4-5.4) 5.4 (4.8-6.1) 5.4 (4.9-5.8) 







4.3 LH characterisation by ultrasound assessment 
All participants underwent US assessment of their injection sites following the baseline 
period (Condition 1). In this section the LH lesions observed are characterised, 
considering: grading; anatomical distribution; frequency; and severity. 
 
4.3.1 Grading 
US scanning identified heterogeneous areas of LH tissue at all injection sites in 
comparison to normal tissue seen in areas adjacent to injection sites that had not been 
used as an injection site. The affected subcutaneous tissue displayed areas of 
increased echogenicity or reflectivity in comparison to the normal tissue, suggestive 
of increased tissue density associated with hypertrophic fat tissue. This varied from 
diffuse patches to diffuse patches with reflective ‘nodules’ of differing sizes within 
them. The size of the nodules varied and in some instances they were very large. A 
few of these larger nodules had areas with reduced echogenicity within them, which 
may indicate low blood flow and necrotic tissue (across the whole study including 
those in the LH characterisation arm of the study), 42 areas of reduced echogenicity 
within nodules were identified in 30% (n=22) of the participants). These characteristics 
and the size of the nodules were used to grade the LH tissue into a grading scheme 
containing five grades: 1 = diffuse LH; 2 = nodules <6mm; 3 = nodules >6mm to <8mm; 
4 = >8mm to <10mm; and 5 = >10mm. The dermal layers also exhibited changes at 
the injection sites. The delineation between the dermal layer and the subcutaneous 
tissue is usually demarked by a clear margin between the tissues, in most of the LH 
affected areas this margin was less clearly defined or disrupted on US. The extent of 
the disruption to the margin varied between the areas affected by LH. In participants 
with  marked disruption to the dermal layer, the dermal layer was also observed to be 
thicker in comparison to adjacent areas not being used as an injection site. These 
changes are potentially suggestive of inflammation being present in the skin of some 
people who inject insulin. Examples of each LH grade (0-5), inflamed and disrupted 







Grade 0 - Normal tissue 
Areas not exposed to insulin without any evident LH were graded 0 (see Image 1). 
 
Image 1: Grade 0 - Normal tissue 
This image is of a right triceps area which was not exposed to insulin injections. The 
image shows a clearly defined dermis and dermal margin, without disruption at a 
thickness of 1.9mm. The subcutaneous tissue exhibits normal tissue with a depth of 














Grade 1 - Diffuse 
Insulin exposed areas, with diffuse changes to the subcutaneous tissue, were graded 
1 (see Image 2). 
 
 
Image 2: Grade 1 - Diffuse 
This image shows an abdominal injection site. The image reveals an area of increased 
reflectivity at around 9mm depth across the whole image. Nodules are starting to form 
within the site. The dermal layer is thickened (3mm) and disrupted. This participant 














Grade 2  
Diffuse areas of the injected subcutaneous tissue containing clearly defined nodules 
with sized 1–5.9mm (see Image 3). 
 
 
Image 3: Grade 2 
This image is from an anterior thigh injection site. The image shows one clear small 
nodule with a diameter of 5.1mm. The nodule is at a depth of 4mm (this participant 
was using 4mm needles). The dermal layer is normal in thickness, but with some 













Grade 3  




Image 4: Grade 3 
 This image is from the left triceps. The image shows a dermal thickness of 1.9mm 
and a clear margin between the dermis and subcutaneous layer. There is a nodule 
















Larger nodules >8mm to <10mm in size (see Image 5). 
 
 
Image 5: Grade 4 
This image shows lateral thigh tissue. There is loss of differentiation in the dermal 
margin, but not significant thickening. There is a large nodule with a width of 9mm and  




















Image 6: Grade 5 
This image is of an anterior thigh area. There is almost no delineation between the 
dermal margin and the subcutaneous tissue. The nodule is greater >10mm across and 
therefore was graded 5, and in this image there is also a diffuse area which is 27.6mm 
across. There is also a necrotic patch in the centre of the area, with a diameter of  













In contrast the below image (image 7) is of the same participants left anterior thigh as 




Image 7: Normal reference tissue 
Normal reference tissue in the left anterior thigh of the same participant as in image6. 
The dermal thickness is 2mm and delineation is seen between the dermal layer and 
subcutaneous tissue, unlike in image 6 where it is difficult to see any dermal 
differentiation at all and the thickness of the dermal layer is 3mm. The subcutaneous 













Additional features of LH were observed in some of the participants US images, 
illustrating some of the variability in the LH presentation. In US scans of two of the 
participants, small to medium size nodules (1.8mm to 6.5mm) were identified within 
the thigh and without evident diffuse tissue (Images 8). During the scanning one of 
these participants confirmed that this site was rested for the last eight years but had 
previously been used for ten years. One explanation for this could be that while the 
diffuse tissue has receded due to the cessation of insulin injections in this area, 
whereas the nodules are more enduring.  
 
Image 8: Previous injection sites show two nodules form the anterior thighs of two 















As previously indicated in Image 6, there were some hypoechogenic areas that may 
indicate the presence of necrotic tissue within the nodules. These areas were identified 
within five participants in six different injection sites (four in the thigh areas and one in 
each of the lower abdomen and the gluteal region) (see Image 9). 
 
 
Image 9: Hypoechogenic areas 
This image is of a participant’s left anterior thigh area; the image shows a dermal 
thickness of 2.1mm (A) with one large nodule at a depth of 4.8mm to the midpoint (B). 
This participant was using 6mm needles. The nodules were located within a diffuse 
area (C) of the injected subcutaneous tissue and had a width of 8.2mm (D). The right-










In some participants the dermal layer exhibited features suggestive of inflammation. 
In these areas the disruption to the interface between the epidermis and the underlying 
subcutaneous tissue was gross; this is indicative of inflammation in response to insulin 
and/or needle exposure. Image 10 shows a large diffuse area, with a width of 30.9mm, 




Image 10: Injection site inflammation 
This image is of a participant’s left flank hip area, the participant was using a 4mm 









4.3.2 Anatomical distribution and frequency 
 
LH nodules were detected in 14 of the participants, while one participant had no 
nodules but did have a large region of diffuse tissue. A total number of 160 nodules 
were observed, with the highest proportion being identified in the thigh (55%, n=88), 
followed by the abdomen (34.4%, n=55), triceps area (6.2%, n=10), and gluteal region 
(4.4%, n=7). The frequency of the LH nodules observed in the thigh area was greatest 
on the lateral aspect (59%, n=52) with the balance being observed on the anterior 
aspect of the thigh (41%, n=36). The proportion of nodules at the abdominal site was 
greatest in the lower abdomen (89%, n= 49), with very few being seen in the upper 
abdomen (11%, n=6) making this a good site for the LH-free tissue required for 
Condition 2. A body map of the anatomical distribution and frequency of the nodules 




Figure 8: This body map shows the frequency of nodules at each anatomical site by 





























Diffuse areas were noticed in most of the injection sites (n=55), while in four different 
injection sites the diffuse tissue was presented without nodules formation (see image 
2). The highest proportion of diffuse areas was seen in the thigh (53%, n=29), followed 
by the abdomen (31%, n=17), gluteal region (9%, n=5), and the triceps area (7%, n=4). 
 
A summary of the anatomical distribution and frequency of the nodules and diffuse 
areas observed is presented in Table 12. The table also describes the observations 
made of the non-completers, in which the incidence of LH nodules and diffuse areas 
was lower. 
 
Table 12: Anatomical distribution and frequency of the nodules and diffuse areas 
based on US scans 






Total observed (n) 
Median (IQR) number 







Anatomical sites Total Right Left Total Right Left 
Thigh 88 (55) 42 (48) 46 (52) 33 (25) 15 (45) 18 (55) 
Gluteal region 7 (4.4) 6 (86) 1 (14) 41 (32) 21 (51) 20 (49) 
Abdomen 55 (34.4) 27 (49) 28 (51) 50 (38) 26 (52) 24 (48) 






Total observed (n) 








Anatomical Sites Total Right Left Total Right Left 
Thigh 29 (53) 13 (45) 16 (55) 16 (31) 7 (44) 9 (56) 
Gluteal region 5 (9) 3(60) 2 (40) 12(24) 6 (50) 6 (50) 
Abdomen 17 (31) 8 (47) 9 (53) 18 (35) 9 (50) 9 (50) 









4.3.3 LH nodule size, grade and severity of LH 
The number of nodules identified was multiple in 14 of the participants, one participant 
presented with no nodules but had a large area of diffuse tissue. Of the participants 
with multiple nodules, two had less than five nodules, and 12 had more than five 
nodules. The size of nodules ranged between 1.8 and 14.8mm. In terms of average 
nodule size, the nodules in the thigh were greatest in size, followed by those in the 
abdomen; this distribution is the same when considering the maximum sized nodule 
in each area (see Table 13).  
 












                                            median (IQR) of all nodules and largest nodule                                            
Characteristic Participants 
(n=14) 
Anatomical sites All nodules (mm) Largest nodule (mm) 




5.5 (4.2-6.2) 8.1 (6.4-10.4) 
4.8 (2.7-6.5)   5.3 (4.4-6.5) 6.3 (4.3-8) 7.3 (5.2-8.2) 
5 (4.5-5.9) 5.5 (4.6-8.3) 6.8 (4.6-9.1) 7.6 (5.5-9.8) 




4.2 (3.8-5.3) 6.1 (5.1-7.1) 
2.8 5 3 7.1 
5 (4.5-5) 3.5 (3.4-5.8) 6.1 (5.3-6.4) 4.9 (4.4-7.1) 







The frequency of the LH grades observed for the largest nodules in each anatomical 
area is detailed in Table 14. Higher grade LH areas were clustered in the thigh area, 
followed by the lower abdomen.  
 














                                                                                                  n (%)                        
Area Total max graded 















13 - 3 (23) 1 (8) 6 (46) 3 (23) 
7 - 2 (28.6) 2 (28.6) 2 (28.6) 1 (14.2) 
10 -  - 4 (40) 4 (40) 2 (20) 






10 1 (10) 3 (30) 5 (50) - 1 (10) 
2 - 1(50) 1 (50) -  
8 1(12.5) 2(25) 4 (50) - 1 (12.5) 
Triceps 3 - 1 (33.3) 1 (33.3) 1 (33.3) - 








The severity scale (severity= ((max grade2 x nLH)/100), which reflects the size and 
number of nodules observed shows that 67% (n=10) of participants had scores of >1. 
Higher scores related to participants with multiple large nodules; one participant (ID 
GV-14) scored 0 as they had no LH nodules (Table 15). 
 
Table 15: Ranked LH Severity per participant 
Participants (n=15) 













GV-26 5 22 3.2-14.8 14.8 5 5.5 
GV-27 6 17 3.5-12.7 12.7 5 4.3 
GV-5 6 16 3.5-11.6 11.6 5 4 
GV-23 2 12 5.8-11.9 11.9 5 3 
GV-28 4 15 3.5-8.1 8.1 4 2.4 
GV-18 7 19 3-7.2 7.2 3 1.7 
GV-19 4 10 5-9.6 9.6 4 1.6 
GV-21 4 10 5-8.2 8.2 4 1.6 
GV-24 3 9 1.8-8.2 8.2 4 1.4 
GV-10 2 7 5.6-8 8 4 1.1 
GV-4 2 3 9-10.3 10.3 5 0.8 
GV-7 2 4 2.7-9.2 9.2 4 0.6 
GV-11 3 12 3.3-5.2 5.2 2 0.5 
GV-12 4 4 2.8-7.5 7.5 3 0.4 
GV-14 1 0 - - 1 0.0 
 
 
Collectively, these data show that most participants had a high exposure to LH tissue 
damage in a broad anatomical distribution across injection sites, predominantly in the 













4.3.4 LH severity and insulin antibodies 
 
Data were collected on insulin antibodies to consider any potential interplay between 
insulin antibodies and the observed LH. The antibodies included: insulin auto-
antibodies(IAA); islet antigen type 2 (IA2); and glutamic acid decarboxylase (GAD). 
The insulin auto- antibodies were replaced by zinc transporter 8 (ZnT8) antibodies 
during the study by the local laboratory. The antibody levels together with LH severity 
index are presented in table 16, for each participant  ranked by LH severity. To provide 
a summative assessment of the antibody levels, participants were graded as having 
high, medium or low antibody levels based on the strength of the antibodies detected 
(high= 1 or more highly elevated antibody; medium= 1 or more moderate antibody; 
and low minimal or no antibodies).  
 
Table 16: LH severity and insulin antibodies 
Participant LH 
severity 
IAA IA2 GAD ZnT8 Antibody 
grade 
GV-26 5.5 - 0.0 >2000 <1 3 
GV-27 4.3 - 72.4 2.3 668.5 3 
GV-5 4.0 3.4 0.8 9.4 - 1 
GV-23 3.0 - 0.0 461.4 <1 3 
GV-28 2.4 - 601.4 1401.1 6.9 3 
GV-18 1.7 - 78.9 17.5 3.1 2 
GV-19 1.6 - 111.4 0.5 <1 2 
GV-21 1.6 - 0.0 39.3 <1 2 
GV-24 1.4 - 39.5 57.9 <1 2 
GV-4 0.8 0.6 0.4 6.8 - 1 
GV-10 0.8 1.2 6.2 1.6 - 1 
GV-7 0.6 0.2 0.0 106.8 - 2 
GV-11 0.5 44.1 0.1 0.7 - 1 
GV-12 0.4 16.3 9.19 0.2 - 1 











It was evident from the data that there seemed to be some relationship between the 
level of antibodies and the severity of LH. There was a positive correlation 
(Sperarman’d Ranked Coefficient) of R2 0.6 between the grade of the antibody level 
and the LH severity index (p=0.02), (see Figure 9). While the limited number of 
observations mean that interpreting  the types of specific antibodies that seem most 
relevant is very limited, the GAD antibodies seemed to be the most commonly 
observed.  
 













4.4 Insulin injection behaviour 
4.4.1 Injection sites 
The most frequent areas for injections used by participants were the thighs, followed 
by the abdomen, and gluteal region, while triceps were seldomly utilised. Table 17 and 
18 presents percentages for specific injection areas or combination of areas, with the 
largest percentage of participants using a combination of abdomen/thigh/gluteal 
region sites. 
 
Table 17: Most to least frequently used injection areas (alone or combination) by 







                                                         n (%) 
Injection areas Participants (n=15) Cases 
Abdomen/thigh/Triceps 1 (6.7) GV-5 
Abdomen/thigh/gluteal 
region 
6 (40) GV-4, GV10, GV-12, GV-19, GV-21 
and GV-27 
Abdomen/thigh 3 (20) GV-23, GV-24 and GV-28 
Abdomen/thigh/ 
Triceps/gluteal region 
2 (13.3) GV-18 and GV-26 
Thigh/gluteal region 2 (13.3) GV-7 and GV-14 







Table 18: Injection sites used by participants and US-confirmed LH 
 
Case Participants (n=15) 
Abdomen Thigh Triceps Gluteal region US-confirmed LH 
C1 C2 C1 C2 C1 C2 C1 C2 
GV-4 Y(LL) Y (RL) Y - - - Y(R) Y(L) 3 nodules at right gluteal region and 1 diffuse at left lower abdomen 
GV-5 Y(L) Y(U) Y - Y - - - 7 nodules at lower abdomen, 4 nodules at thigh, and 5 nodules at 
triceps  
GV-7 - Y(L) Y - - - Y - 4 nodules at thigh 
GV-10 Y(L) Y(U+L) Y - - - Y - 7 nodules at thigh  
GV-11 Y(L) Y (U) - - - - - - 7 nodules at lower abdomen, one diffuse at right thigh and 5 
nodules at left thigh  
GV-12 Y(U+L) Y(U+L) Y - - - - - 1 nodule at upper abdomen, 2 nodules at thigh, and 1 nodule at 
gluteal region 
GV-14 - Y Y - - - Y - 1 diffuse at gluteal region 
GV-18 Y(L) Y(U) Y - Y - Y - 8 nodules at lower abdomen, 10 nodules and 1 diffuse at thigh a, 
and 1 nodule at triceps  
GV-19 Y(L) - Y   - - - Y - 5 nodules at upper abdomen, 5 nodules at thigh and 1 diffuse at 
right gluteal region 
GV-21 Y(L) Y(U) Y - - - Y - 10 nodules at thigh  
GV-23 Y(L) Y(U) Y - - - - - 9 nodules at lower abdomen and 3 nodules at thigh  
GV-24 Y(L) Y(U+L) Y - - - - - 9 nodules at thigh  
GV-26 Y(U+L) - Y Y Y - Y Y 7 nodules at lower abdomen, 11 nodules at thigh, and 4 nodules at 
triceps  
GV-27 Y(L) Y(U) Y  - - Y - 4 nodules at lower abdomen, 10 nodules at thigh, and 3 nodules at 
gluteal region  
GV-28 Y (L) Y(U) Y - - - - - 7 nodules at lower abdomen and 8 nodules at thigh  






4.4.2 Insulin doses and action 
To consider whether participants were taking higher insulin doses to compensate for 
the potential attenuating effect of their LH, their daily insulin requirement was 
estimated (0.6 units per kg body weight) and compared with their total daily insulin 
dose. The median daily insulin requirement calculated at baseline was 43.4 (IQR, 
36.3-49.3) units and the median total daily insulin dose used by participants was 43 
(IQR, 35.5-55) units. There were, however, variations between participants in the 
amount of insulin used compared with their estimated requirement as detailed in Table 
19. 
 Table 19: Participants’ total daily insulin doses and requirement 
 
Participant ID EIR 
(units) 
TDI at Condition 1 
(units) 
DIFF TDI (C1) - EIR 
(units) 
GV-5 35  75 +40  
GV-19 43  68 +25  
GV-27 33  46 +13  
GV-18 51  60 +9  
GV-14 43  49  +6  
GV-11 52  55 +3  
GV-26 40  39 -1  
GV-24 36  36  0  
GV-4 46  44 -2  
GV-7 47  43 -4  
GV-12 36  31 -5  
GV-23 49  42 -7  
GV-21 47  39  -8 
GV-28 35  27 -8  
GV-10 51  25  -26  








4.5 Change in Time in range and GV   
In this section the findings in respect of the changes observed in TIR and GV between 
Conditions 1 and 2 are reported. The primary outcome of TIR was assessed with the 
CGM data. The mean average time recorded by the CGM device was 5.7 (±0.7) days 
and 5.6 (±0.6) at Conditions 1 and 2 respectively.  
 
In relation to the primary outcome TIR (glucose range 4-10 mmol/L), there was a 
significant difference in the median values between Conditions 1 and 2 which were 
46.4% (IQR, 43.2-53.6) and 54.2% (IQR, 46.1-66.7) respectively (p=0.02)- this 
equates to a medium effect size of 0.6 (Cohen’s-d) based on the mean difference. Five 
participants achieved the primary outcome of a ³10% improvement in TIR. These 
observations are summarised along with the other GV indicators in Table 20. No 








Table 20: Change in Time in range and GV 
CGM Measure  
(Unit) 
C1 Median IQR C2 Median IQR Change C2-C1 Median P-value 
TIR   
(%) 
46.4 43.2-53.6 54.2 46.1-66.7 +7.8 0.02 
TBR 
(%) 
7.4 3.7-9.6 4.5 3.2-8.3 -2.9 0.5 
TAR  
(%) 
44.5 37.1-52.1 39.8 26.3-49.6 -4.7 0.1 
SD 
(mmol/L) 
4.2 3.7-4.7 4.2 3.5-4.7 0 0.3 
CV  
(%) 
43.2 38.5-47.5 44.2 40.5-48.2 +1 0.8 
CONGA-4  
(mmol/L) 
6.6 6.2-7.6 7 6.5-7.6 +0.4 0.9 
MODD  
(mmol/L) 
4.4 3.9-4.8 4.3 3.7-5.1 -0.1 0.7 
MAGE  
(mmol/L) 
9.2 8.9-10.6 9.6 7.7-10.5 +0.4 0.5 
MAG  
(mmol/L/hr) 
2.3 1.9-2.5 2.2 2.2-2.6 -0.1 0.4 
TIR, Time In Range; TBR, Time Below Range; TAR, Time Above Range; SD, Standard Deviation of blood glucose; CV, Coefficient of Variation; CONGA, 








It was observed that there were variations between individual participants in relation 
to the change in TIR, after altering their injecting sites between Conditions 1 and 2. A 
third of the participants showed an improvement in TIR, with the remainder showing 
little change or a slight reduction, although in one participant the reduction was more 
marked. Table 21 presents the LH characteristics for each participant ranked in 
respect of how much improvement was shown in respect of the time spent in range. 
Throughout this section this ranking is used, to consider the factors that may explain 
the individual differences in the impact of changing injection sites to avoid LH areas, 
in relation to GV between participants. The data in Table 21, show no clear pattern in 



























        Table 21: Cases ranked by improved TIR and LH characteristics 
Case Change TIR 
(%) 
Number of diffuse areas Number of nodules Range of the nodules width 
sizes 
(mm) 
Max Grade Severity 
GV-7 +24.7 2 4 2.7-9.2 4 0.6 
GV-28 +20.3 4 15 3.5-8.1 4 2.4 
GV-4 +20.2 2 3 9 -10.3 5 0.8 
GV-11 +11.9 3 12 3.3-5.2 2 0.5 
GV-21 +10 4 10 5-8.2 4 1.6 
GV-27 +7.7 6 17 3.5-12.7 5 4.3 
GV-5 +6.4 6 16 3.5-11.6 5 4 
GV-26 +3.6 5 22 3.2-14.8 5 5.5 
GV-12 +2.7 4 4 2.8-7.5 3 0.4 
GV-14 +1.2 1 0 - 1 0 
GV-23 +0.6 2 12 5.8-11.9 5 3 
GV-24 +0.04 3 9 1.8-8.2 4 1.4 
GV-10 -0.1 2 7 5.6-8 4 0.8 
GV-18 -3.7 7 19 3-7.2 3 1.7 







4.5.1 Insulin doses and action   
In this section the findings concerning changes that were observed in respect of insulin 
dose and action (number of effective injections) are reported, comparing Conditions 1 
and 2 with individual participant data ranked by changes in TIR (most to least 
improved).  
 
The data in Table 22 show the changes observed in TDI for each participant ranked, 
in relation to improvements in TIR. The data show that three participants (GV-4,GV-7, 
GV-28) improved TIR by ≥10% with no changes in their insulin doses, with two others 
(GV-5 and GV-11) improving with reduced insulin doses (≥ 20 Units of insulin). There 
were some patterns in the participants showing no improvement in TIR which may 
explain this observation. In two cases (GV-19 and GV-24) it was observed that they 
reduced their insulin (mainly quick acting) and then spent less time in hypoglycaemia 
(Time Below Range), with a corresponding increase in time spent in hyperglycaemia 
(Time Above Range). In the case of GV-23 the main change was an increase in period 
spent in the time below range. While this may be explained by the participant 
increasing their quick acting insulin by 4 units, it could also indicate that by injecting in 































Table 22: Insulin doses 
 
Case Participants (n=15) 


























































GV-7 -4 43 25 (58) 42 20 (48) 44 26 (59) +1 +1 0 67.9 +24.7 +3.1 -28.6 
GV-28 -8 27 15 (56) 27 15 (56) 29 15 (52) +2 0 2 56 +20.3 -4.3 -16.5 
GV-4 -2 44 30 (68) 38 24 (63) 45 32 (71) +1 +2 -1 78.3 +20.2 +0.2 -19.9 
GV-11 +3 55 30 (56) 49 24 (49) 35  24 (69) -20 -6 -14 68.8 +11.9 -15.3 +3.2 
GV-21 -8 39  18 (47) 39 18 (47) 34 18 (53) -5 0 -5 48.5 +10 -4.3 -5.7 
GV-27 +13 46 26 (57) 42 22 (52) 44 24 (55) -2 -2 2 54.2 +7.7 +5 -12.3 
GV-5 +40 75 38 (51) 45 20 (44) 50 20 (40) -25 -18 -7 44.1 +6.4 -15 +8.6 
GV-26 -1 39 24 (62) 35 20 (57) 41 24 (59) +2 0 +2 54.3 +3.6 -2.6 -1.9 
GV-12 -5 31 19 (62) 29 17 (59) 31 19 (61) 0 0 0 49.5 +2.7 +1.3 -4.7 
GV-14 +6 49  31 (64) 41 24 (59) 41 24 (59) -8 -7 -1 46.1 +1.2 +8.7 -9.3 
GV-23 -7 42 24 (57) 38 20 (53) 46 24 (52) +4 0 +4 54.2 +0.6 +5.3 -5.5 
GV-24 0 36 17 (48) 33.5 15 (45) 27 16 (59) -9 -1 -8 66.7 +0.04 -1.4 +1.2 
GV-10 -26 25 10 (41) 24.5 10 (41) 28 10 (36) +3 0 +3 46.6 -0.1 -0.3 +2.2 
GV-18 +9 60 40 (67) 56 36 (64) 60 36 (60) 0 -4 +4 40.5 -3.7 +0.3 +2.9 
GV-19 +25 68 34 (50) 60 30 (50) 62 40 (65) -6 +6 -12 34.5 -10.3 -5.7 +15.8 
TDI, Total daily insulin; C1, Condition 1; Ch, Change; TIR, Time in range; C2, Condition 2; TBR, Time below range; TAR, Time above range 







The number of bolus injections taken by participants at Condition 1 varied from 11 to 
26 injections per week (median=17 (IQR, 14-22)) and the percentage of effective 
injections ranged between 50 and 95% (see Table 23). Effective injections were 
considered to be those where the insulin effect was clearly evident (considering a peak 
effect at two hours from injection of a quick acting insulin on the glucose levels in the 
CGM trace). Non-effective injections relate to those where the insulin had a limited or 
poorly defined action; injections where the CGM signal was disrupted were not 
included as it was not possible to fully interpret the effect of the insulin, and doses of 
£1 unit were also excluded. The data show a significant improvement in the median  








Table 23: Effective bolus injections at Condition 1 and 2 
 
Participants (n=15) 






















GV-7 11 8 3 73 1 12 12 0 100 1 
GV-28 19 18 1 95 6  22 19 3 86 5 
GV-4 22 16 6 73 1 20 17 3 85 3 
GV-11 22 18 4 82 - 16 15 1 94 - 
GV-21 16 11 5 69 6 22 19 3 86 - 
GV-27 21 15 6 71 1 20 20 0 100 2 
GV-5 12 8 4 67 - 15 12 3 80 - 
GV-26 14 8 6 57 - 15 14 1 93 - 
GV-12 20 12 8 60 2 17 14 3 82 1 
GV-14 13 7 6 54 4 17 14 3 82 - 
GV-10 16 10 6 63 2 14 12 2 86 5 
GV-24 26 19 7 73 - 18 14 4 89 - 
GV-23 17 11 6 65 1 20 15 5 81 - 
GV-18 23 17 6 74 - 18 16 2 89 1 
GV-19 16 8 8 50 - 16 14 2 88 - 







4.6 Glycaemic control 
Glycaemic control was assessed using HbA1c and 1,5-Anhydroglucitol (1,5-AG). No 
difference was observed in HbA1c between Condition 1 (baseline) and Condition 2 
(follow-up visit) (median score: 65 (IQR, 55-70) mmol/mol [8.1 (IQR, 7.2-8.6) %] 
compared with 64 (IQR, 56-72) mmol/mol [8 (IQR, 7.3-8.7) %], respectively; p = 0.4). 
While seven participants did show some improvement in 1,5-AG, there was no change 
in the with median values between Conditions 1 and 2, being 8.7 (IQR,7.9-9.5) and 9 
(IQR,8.3-10.7) respectively (p = 0.40). Table 24 summarises the individual participant 
(ranked as previously detailed) level data; three participants showed clinically 
important change in HbA1c (GV-10, GV-14, GV27). GV-10 demonstrated an increase 
of 8 mmol/mol [0.8%] in HbA1c,  which may be related to potential under insulinisation 















Table 24: Glycated haemoglobin and 1,5-Anhydroglucitol 
   
 Case  Participants (n=15) 
HbA1c at C1 
mmol/mol (%) 




1,5-AG at C1 
µg/mL 




GV-7 64 (8.0) 66 (8.2) +2 (+0.2) 9.2 8.4 -0.8 
GV-28 100 (11.3) 100 (11.3) 0 7.7 7.3 -0.4 
GV-4 54 (7.1) 55 (7.2) +1 (+0.1) - 13 - 
GV-11 46 (6.4) 51 (6.8) +5 (+0.4) 9.2 8.6 -0.6 
GV-21 66 (8.2) 69 (8.5) +3 (+0.3) 8.5 11.4 +2.9 
GV-27 55 (7.2) 63 (7.9) +8 (+0.7)* 11.8 15.5 +3.7 
GV-5 103 (11.6) 102 (11.5) -1 (-0.1) 6.3 9.7 +3.4 
GV-26 63 (7.9) 64 (8.0) +1 (+0.1) 8.2 9 +0.8 
GV-12 67 (8.3) 65 (8.1) -2 (-0.2) 9.6 8.3 -1.3 
GV-14 65 (8.1) 60 (7.6) -5 (-0.5)* 13.1 6.7 -6.4 
GV-23 57 (7.4) 56 (7.3) -1 (-0.1) 8.8 8.6 -0.2 
GV-24 54 (7.1) 54 (7.1) 0 7.9 7.1 -0.8 
GV-10 69 (8.5) 78 (9.3) +9 (+0.8)* 6.4 9.5 +3.1 
GV-18 70 (8.6) 67 (8.3) -3 (-0.3) 9.5 10.7 +1.2 
GV-19 85 (9.9) - - 8.4 9.6 +1.2 
Reference Range for 1,5-AG: Normal= 10 – 31 µg/mL; 1,5-AG Abnormal=< 10 µg/Ml 
*Indicates clinically significant change 







4.7 Participant level measures (insulin satisfaction, diabetes distress, quality of 
life) 
This section reports the findings concerning the participant level measures, which 
included insulin treatment satisfaction, diabetes distress and quality of life.  
 
4.7.1 Treatment satisfaction using ITSQ 
There were no differences in the overall or sub-scale scores for the ITSQ treatment 
satisfaction scale between Conditions 1 and 2, as detailed in Table 25. While there 
were no statistical differences (this being attributable to insufficient power) the change 
in lifestyle flexibility score suggests that participants may have found their insulin 
routines less flexible as they changed their injections to unfamiliar sites.  
 
Table 25: Insulin treatment satisfaction 
 
Table 26 presents the ITSQ data for each of the ranked participants. In relation to the 
lifestyle flexibility scale, which includes questions concerning exercise and whether 
participants are confident that they can avoid hypoglycaemia. The responses suggest 
that changing injection sites impacted on the way participants experienced the effect 
of insulin, reducing their confidence in considering how much insulin to take. This 
response was seen both in those who had improved their TIR and in those who had 
not. Conversely, in relation to the hypoglycaemia control scale some participants 
showed increased satisfaction.  
                                           median (IQR) 
ITSQ items Condition 1 Condition 2 P-value 
Inconvenience of regimens 65.7 (45.7-74.3) 61.4 (54.3-74.3) 0.9 
Lifestyle flexibility 66.7 (47.6-76.2) 59.5 (55.9-67.9) 0.1 
Glycaemic control 47.6 (33.3-52.4) 47.6 (46.4-57.1) 0.3 
Hypo control 48.6 (28.6-60) 51.4 (33.6-62.9) 0.7 
Insulin delivery device satisfaction 64.3 (47.6-78.6) 64.3 (52.9-74.4) 0.8 







Table 26: Insulin treatment satisfaction data for each of the ranked participants 
                                              
Case Participants (n=15) 
ITSQ  IR LF HC GC DS 
C1 C2 Ch C1 C2 Ch C1 C2 Ch C1 C2 Ch C1 C2 Ch C1 C2 Ch 
GV-7 66.9 +3.3 74.3 -2.9 76.2 -4.8 68.6 +2.9 33.3 +23.8 71.4 +2.4 
GV-28 39.6 +6.5 42.9 +11.4 71.4 -9.5 22.9 +17.1 52.4 +4.8 28.6 +2.4 
GV-4 44.8 -6.5 45.7 -5.7 61.9 0 31.4 -5.7 47.6 0 45.2 -14.3 
GV-11 58.4 -2.6 65.7 -5.7 66.7 -9.5 54.3 -2.9 42.9 +4.8 59.5 0 
GV-21 55.2 -7.8 60 0 47.6 +19.1 57.1 -17.1 33.3 0 64.3 -23.8 
GV-27 48.7 +5.2 37.1 +17.1 52.4 0 25.7 +8.6 57.1 -14.3 71.5 +4.8 
GV-5 48.7 +11 65.7 -5.7 85.7 -28.6 14.3 +51.4 52.4 +4.8 42.9 +14.3 
GV-26 57.8 -2.6 74.3 0 38.1 -19.1 48.6 +14.3 23.8 0 78.6 -11.9 
GV-12 53.9 +12.3 37.1 +31.4 76.2 -9.5 45.7 +5.7 61.9 +9.5 59.5 +14.3 
GV-14 68.8 -3.9 77.1 -14.3 80.9 -4.8 60 0 38.1 +9.5 78.6 -4.8 
GV-23 64.9 -17.5 68.6 -20 66.7 -23.8 48.6 -17.1 61.9 -9.5 76.2 -16.7 
GV-24 68.2 +1.9 77.1 +5.7 57.1 0 62.9 0 47.6 0 80.9 +2.4 
GV-10 74.7 -2.6 85.7 -5.7 85.7 -14.3 60 +2.9 47.6 0 85.7 0 
GV-18 49.4 +5.2 65.7 +8.6 42.9 +14.3 40 -14.3 42.9 +9.5 50 +11.9 
GV-19 38.9 - 74.3 - 9.5 - 28.6 - 9.5 - 47.6 - 
ITSQ, Insulin treatment satisfaction; IR, Inconvenience of regimens; LF, Lifestyle flexibility; HC, Hypoglycaemia control; GC, Glycaemic 







No significant changes were observed in the DDS score between Conditions 1 and 2 
(p = 0.8) as summarised in Table 27. 
 
Table 27: Diabetes distress scale 
 
The majority of participants had moderate or severe distress, as shown in Table 28.  
 







                                                                                 median (IQR)  
DDS items Condition 1 Condition 2 P-value 
Emotional burden 2.2 (1.4-2.8) 2.1 (1.4-2.7) 0.7 
Physician-related distress 1.8 (1.5-2.3) 1.9 (1.5-2.6) 0.9 
Regimen-related distress 2.0 (1.6-2.8) 2.2 (1.6-2.9) 0.9 
Interpersonal distress       2.3 (1.7-3) 2.5 (1.3-3.4) 0.5 
Total score 2.1 (1.5-2.7) 2.1 (1.6-2.5) 0.8 
                                                                                               n (%) 




Little or no distress (<2.0) 5 (35.7) 4 (28.6) 
Moderate distress (2.0–2.9) 8 (57.1) 9 (64.3) 







In relation to the  EQ-5D-5L quality of life measure, a median visual analogue scale 
score of 70% (IQR, 65-80) was observed, ranging from 30% to 100% for the 
participants at Condition 1, with 40% (n=6) of the participants rating their health >80% 
on the EQ-VAS (100 = the best health you can imagine). The median index-based 
value was 0.88 (IQR,0.8-1.0), ranging from 0.5 to 1.0. After changing the injection sites 
(Condition 2), the median visual analogue scale score was increased to 80% (IQR, 
69.5-96.3), ranging from 60% to 100%, with 57% (n=8) of the participants rated their 
health >80%. The median (IQR) index-based value was 0.95 (0.9-1.0), ranging from 
0.7 to 1.0, with no difference between the median of the index value at Condition 1 























4.8 LH characterisation study 
In this section the data from the participants in the LH characterisation study are 
presented. The participants in this study were those who declined involvement in the 
GV study but were willing to have an US scan of their injection sites. These participants 
are defined as the LH group in the study. To enhance the scale of the analysis the 
baseline data from the GV participants, including those who did not complete the GV 
study, were included in the analysis (n=27), as the data in relation to the LH areas and 
characteristics were common. These participants are defined as the GV group. The 
analysis addressed the following areas: 
 
• The prevalence of LH (number, type, size and anatomical distribution); 
• A comparison of LH detection using US and via digital palpation. 
 
4.8.1 Sample characteristics of LH group 
Study participants (GV group and LH group) were similar in terms of age, duration of 
diabetes, ethnicity, education level, BMI and HbA1c. On average, participants were 
40.6 (±14.2) years old, with a mean duration of T1DM of 18.3 (±10.9) years. Most of 
the participants were of White ethnicity (82.4%, n=61) and had a degree or equivalent 
educational qualification (67.6%, n=51). The mean body mass index (BMI) was 25.5 
(±4.2) Kg/m
2
, and the mean baseline HbA1c value was 68 (14.5±) mmol/mol [8.4 
(±1.3) %]. English was the first language for 62 (83.7%) people and for 12 (16.2%) it 
was a second language. There were slightly more male participants 59.5% (n=44). 
One third of the participants (35.14%, n=26) reported diabetes complications, which 
included retinopathy (n=19), neuropathy (n=4), foot complications (n=4), nephropathy 
(n=2), and cardiovascular complications (n=1). A summary of the demographic 








Table 29: Demographic characteristics 
                                                                             (n (%); or mean ±SD and range) 
Characteristic Total  
(n=74) 
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White           
Black            












































































































                                                                             (n (%); or mean ±SD and range) 
Characteristic Total  
(n=74) 






Mean at baseline ±SD mmol/mol 
Range mmol/mol 
Mean at baseline ±SD % 
Range % 
 
  42-52 mmol/mol [6.0-6.9 %] 
53-63 mmol/mol [7.0-7.9 %] 
64-74 mmol/mol [8.0-8.9 %] 
75-85 mmol/mol [9.0-9.9 %] 





































Education level  
Secondary school level 
















              as first language  


































N, Number; SD, Standard deviation; BMI, Body mass index; %, Percentage; T1DM, Type 
















No differences were found between those who participated in the GV and LH 
characterisation study in respect of insulin types, total daily insulin at baseline and 
needle length. Basal-bolus therapy was used by all participants for bolus insulin; 
75.7% (n=56) were taking insulin aspart, and 20.3% (n=15) used insulin lispro. Basal 
insulins were glargine (36.5%, n=27), and detemir (58.1%, n=43). The mean total daily 
dose of insulin at baseline was 49.79 units (±18.13). The needle sizes used by the 
participants varied; 39% (n=29) used 4-mm needles, 32% (n=24) used 5-mm needles, 
23% (n=17) used 6-mm needles, and one reported using 8-mm needles. Three 
quarters of participants (n=54) reported testing their blood glucose four or more times 
per day. The majority of the participants (59%, n=44) had attended a structured 
education programme, including dose adjustment and carbohydrate counting, and 
78% (n=58) observed carbohydrate counting; out of 58 participants 18 (31%) had not 






















Table 30: Insulin treatment characteristics 







Insulin requirement*   
Mean ±SD 
Baseline total insulin dose  
Baseline total basal Insulin  
Baseline total bolus insulin  
 
 
       46.3 ±8.5 
       49.8 ±18.1 
       26.5 ±10.9 
       23.8 ±9.3 
 
    46.8 ±7.7 
    51.1 ±17.1 
    26.7 ±11.2 
    25.0 ±8.5 
 
   45.5 ±9.8 
   47.5 ±19.9 
   25.9 ±10.9 
   21.5 ±10.3 


































































































Attended structured education n (%) 44 (59) 27 (57) 17 (63) 
Carbohydrate counting n (%) 58 (78) 39 (83) 19 (70) 
 









4.8.2 Hypoglycaemia awareness and frequency 
The awareness of hypoglycaemia is summarised in Table 31. Seventy-three 
participants completed the Gold score question, and ten of them were noted to have 
impaired awareness (Gold score >4), and while 41% (n=31) of the participants had 
previously experienced a hypoglycaemic episode requiring third party assistance, with 
27%(n=20) experiencing such an episode in the past 12 months. 
 
Table 31: Awareness of hypoglycaemia 







Hypoglycaemia awareness (Gold score)  






      54 (73) 
      9 (12.2) 
     10 (13.5) 











Hypoglycaemia assistance  31 (41.9) 19 (40) 
 
12 (44.4) 
Frequency of severe hypoglycaemia during 





















































4.8.3 LH characteristics 
 
A total of 740 nodules were observed in the participants. The highest proportion was 
identified in the abdomen (43.2%, n= 320); followed by thigh (36.2%, n=271); gluteal 
region (17%, n=122); and triceps (3.6%, n=27) areas. Diffuse areas were noticed in 
most of the injection sites (n=304). A summary of the frequency of the nodules and 
diffuse areas observed is presented in Table 32 and Figure 12. 
 
Table 32: Anatomical distribution and frequency of the nodules and diffuse areas 
based on US scans 























Anatomical sites Total 
Thigh* 271 (36.2) 150 (33.3) 121 (41.7) 
Gluteal region 122 (17) 74 (16.4) 48 (16.6) 
Abdomen 320 (43.2) 215 (47.8) 105 (36.2) 























Anatomical sites Total 
Thigh 115 (37.8) 70 (35.4) 45 (42.5) 
Gluteal region 54 (17.8) 37 (18.7) 17 (16) 
Abdomen* 113 (37.2) 78 (39.4) 35 (33) 
Triceps 22 (7.2) 13 (6.5) 9 (8.5) 
*Thigh area includes right and left lateral and anterior thigh 









Figure 12: Number and frequency of the nodules 
  
The majority of the participants (n=71) had multiple nodules, with three participants 
presenting with one large diffuse area without nodules. Of the participants with multiple 
nodules, 15% (n=11) had less than five nodules, 43% (n=32) had between 5 and 10 
nodules, 23% (n=17) had between 11 and 15 nodules and 15% (n=11) had more than 
15 nodules. The size of the nodules ranged between 1.8 and 40mm. In terms of 
average nodule size, the nodules in the thigh were largest followed by those in 
abdomen, this distribution is the same when considering the maximum sized nodule 
in each area (see Table 33). Table 34 shows the LH nodule size based on US for the 











Table 33: LH nodule size based on US scans 
 
 
Table 34: LH nodule size based on US for the LH characterisation group 







                                            Mean ±SD of all nodules and largest nodule                                            
Characteristic Participants 
(n=71) 
Anatomical Sites All nodules (mm) Largest nodule (mm) 





5.9±2.6 6.6±3.4 7.3±2.8 8.2±3.7 
6.3±3.3 6.1±2.4 8.6±5.2 7.3±3.2 





5.8±2.8 6.1±1.0 6.6±3.5 8.8±1.4 
6.2±4.5 6.1±4.1 7.6±4.7 8.1±5.2 
Triceps 4.9±1.1 8.6±8.3 5.6±1.1 9.8±7.7 
                                            Mean ±SD of all nodules and largest nodule                                            
Characteristic LH group  
(n=45) 
Anatomical Sites All nodules (mm) Largest nodule (mm) 





6.9±2.8 8.6±4.9 8.1±2.9 10.7±4.5 
7.2±3.8 6.7±2.4 9.8±6.0 7.7±2.9 





6.5±2.7 6.0 7.6±3.3 9.9±0.5 
6.9±5.3 6.9±4.9 8.2±5.5 9.2±6.0 







The frequency of the LH grades observed for the largest nodules in each anatomical 
area is detailed in Table 35. Higher grade LH areas were found in the abdomen area, 
followed by the thigh. In the GV group the thigh was the area most affected by LH (see 
table 14 page 135).  
 
Table 35: Grading of largest LH nodules per anatomical area in 74 participants 
 
 
Table 36: Grading of largest LH nodules per anatomical area in LH group 
                                                           n (%)                        
Area Total max 














  Anterior thigh* 
  Lateral thigh* 
55 8 (14.5) 8 (14.5) 14 (25) 12 (22) 13 (24) 
31 5 (16) 6 (19) 8 (26) 8 (26) 4 (13) 
40 5 (12.5)  10 (25) 8 (20) 7 (17.5) 10 (25) 
Gluteal region 33 6 (18.2) 6 (18.2) 8 (24.2) 5 (15.2) 8 (24.2) 
Abdomen** 
  Upper abdomen 
  Lower abdomen 
58 5 (9) 13 (22) 20 (34) 9 (16) 11 (19) 
10 2 (20) 2 (20) 2 (20) 2 (20) 2 (20) 
55 4 (7) 14 (26) 20 (36) 7 (13) 10 (18) 
Triceps 11 5 (46) 2 (18) 2 (18) 1 (9) 1 (9) 
* Number inflation is observed when counting max grade in the anterior and lateral thigh 
independently.  
** Number deflation is observed when counting max grade in the upper and lower 
abdomen as one. 
                                                                     n (%)                        
Area Total max graded 















35 7 (20) 5 (14) 8 (23) 5 (14) 10 (29) 
17 4 (23) 3 (18) 2 (12)  5 (29) 3 (18) 
26 5 (19) 4 (15) 6 (23) 3 (12) 8 (31) 




39 4 (10) 8 (20) 10 (26) 7 (18) 10 (26) 
7 2 (29) 1 (14) 1 (14) 1 (14) 2 (29) 
38 3 (8) 10 (26) 10 (26) 6 (16) 9 (24) 
Triceps 6 4 (66) - 1 (17) - 1 (17) 
* Number inflation is observed when counting max grade in the anterior and lateral thigh 
independently.  
** Number deflation is observed when counting max grade in the upper and lower 







Table 37. details the severity index for LH, with the LH group having a higher mean 
index compared with the GV group. The severity distribution is shown in a histogram 
(Figure 13). The data show that while the majority of participants have a severity level 
<2.0, a significant proposition of participants with large multiple nodules score above 
4.0. 
 




Figure 13: Severity and frequency of the nodules 



















The scans identified 42 necrotic patches in nodules, this would suggest a crude 
prevalence for necrotic nodules of about 6%, and that around 30% of the participants 
had nodules with necrotic features on US scans (Table 38). 
 
Table 38: Anatomical distribution and frequency of necrotic patches 
 
Table 39 shows that the necrotic tissue was more common in higher grade (i.e. larger) 
LH nodules, with most being observed in the lower abdomen.  
 







Total necrotic patches observed (n=42) 
 




13 5 8 
7 2 5 
6 3 3 




18 7 11 
1 1 - 
17 6 11 
Triceps - - - 
Participants (n=22) 













1 - 1 2 3 
2 2 - 1 1 
Gluteal region - - 6 1 4 
Upper abdomen 
Lower abdomen 
- - - - 1 







4.8.4 Change in glycated haemoglobin (HbA1c) and TDI dose 
Follow-up data for HbA1c and TDI doses were available for 54 (73%) and 48 (64%) 
participants respectively (Table 40 and 41). No difference was observed in HbA1c 
between Condition 1 and Condition 2, with means of 67mmol/mol (8.3%) and 68 
mmol/mol (8.4)% (p = 0.09). 
  
Table 40: Change in glycated haemoglobin between Condition 1 and Condition 2 
 
 
There was a modest reduction in the mean total daily insulin dose of the participants 
who completed the follow-up (n=48) between Conditions 1 and 2, of 2.9±8.1 (P= 0.01); 
this is detailed in Table 41. 
 
Table 41: Total daily insulin between Condition 1 and Condition 2 
 
It was not possible to estimate GV or effectiveness of insulin response as these data 
were not collected, and while there were some data from blood glucose monitoring 
tests; many in the LH group tested <4 times per day. Hence, it was difficult to estimate 
any effects of identifying the LH areas and advising them to avoid them in this sample.  
Of the participants who were testing ³4 times per day (n=34) the mean change was 
not significant with a reduction in SD of -0.4 mmol/L. 




















C1 C2  C1  C2  C1 C2  
47.7±16.6 44.7±15.0.7 50.0± 17.7 47.2±16.1 44.8±14.9 41.6±13.4 







4.8.5 Education attendance and left/right handedness 
 
Previous attendance at a structured education programme was considered in relation 
to the prevalence of LH, comparing those who had and had not attended. No 
statistically significant difference was observed between those who had attended 
(n=42) and do those who have not attended (n=29) education in terms of the number 
of LH nodules observed, with means of 11.5 (±6.9) and 8.8 (±4.3) for those who had 
attended structured education and those who had not attended respectively (p=0.8).  
 
In terms of left/right handedness, 64 (86%) participants were right handed with  
distribution of the LH regions in these participants, being: skewed to the right in 32 
participants (50%); skewed to the left in 23 participants (36%); with remainder showing 
an even distribution (n=9, 14%). Of the six participants who were left-handed, four had 
more LH on the left side and two participants had more LH on the right side of their 
injection areas. One participant who was ambidextrous (using both the right and left 




















4.8.6 Digital palpation compared with ultrasound  
As all the participants had their LH assessed by digital palpation blind to the US scans, 
it was possible to compare how consistent palpation following a clinical protocol was 
compared with the US observations. A total of 528 areas where examined using both 
palpation and US. Table 42 identifies the number of agreements and disagreements 
between US and palpation.  
 






The data show that palpation had lower sensitivity in detecting LH compared with US. 
The number of areas in which LH was detected by US was double that of palpation. 
Overall concordance between palpation and US was 70.6%, with a Cohen’s kappa of 








Nodules US Palpation agree Palpation disagree 
Observed 147 149 







4.8.7 Insulin treatment satisfaction, diabetes distress and QoL 
In this section the data on insulin treatment satisfaction and diabetes distress are 
presented, comparing responses before and after participants were advised to change 
their injection sites to avoid the identified LH areas.  
 
No differences were observed in the total ITSQ scores or in any of the sub-scales 
between Conditions 1 and 2 (p = 0.5) (see Table 43). Likewise, no differences were 
observed in the DDS scores between Conditions 1 and 2 (p = 0.6) (see Table 44). 
 
In terms QoL at Condition 1 the mean (SD) visual analogue scale score of EQ5-5D-
5L was 71.5% (±17.8) and the mean (SD) index-based value was 0.9 (±0.2). In 
Condition 2 the mean (SD) visual analogue scale score was increased slightly to 














                                                                                                          Mean±SD 







C1 C2 P C1 C2 P C1 C2 P 
IR 58.8±17.2 59.2±16.5 0.8 58.1±17.3 58.8±17.5 0.7 61.0±17.2 58.7±15.2 0.5 
LF 61.7±16.3 60.9±15.8 0.7 62.5±14.9 63.7±15.5 0.6 60.4±18.7 56.3±15.4 0.2 
GC 42.7±12.9 46.9±11.8 0.6 40.9±11.8 45.9±11.4 0.8 45.2±14.2 48.3±12.4 0.4 
HC 43.7±18.9 44.9±20.4 0.5 43.8±18.8 44.9±22.0 0.5 43.6±19.5 44.9±17.9 0.7 
DS 39.5±17.4 39.4±17.3 0.9 58.1±18.5 58.4±18.2 0.9 64.3±3.1 64.2±15.6 0.9 
Total score 54.3±12.6 55.1±13.1 0.5 53.2±12.8 54.8±14.2 0.2 55.9±12.5 55.4±11.6 0.8 
ITSQ, Insulin treatment satisfaction; IR, Inconvenience of regimens; LF, Lifestyle flexibility; HC, Hypoglycaemia control; GC, Glycaemic 







Table 44: Diabetes distress 
 
Mean±SD 







C1 C2 P C1 C2 P C1 C2 P 
EB 2.3±1.1 2.3±1.0 0.9 2.4±1.2 2.4±1.2 0.6 2.2±0.7 2.3±0.8 0.5 
PD 2.1±1.0 2.2±0.9 0.2 2.2±1.2 2.2±1.1 0.7 1.9±0.7 2.1±0.8 0.2 
RD 2.4±1.0 2.3±0.9 0.9 2.5±1.2 2.4±1.1 0.6 2.2±0.8 2.3±0.8 0.5 
ID 2.4±1.0 2.4±1.2 0.5 2.4±1.3 2.4±1.2 0.9 2.3±0.8 2.4±1.1 0.3 
Total score 2.3±0.9 2.3±0.9 0.6 2.4±1.1 2.3±1.1 0.8 2.1±0.6 2.3±0.8 0.3 
DDS, Diabetes distress scale; EB, Emotional burden; PD, Physician-related distress; RD, Regimen-related distress; ID, Interpersonal 





4.9 Qualitative data on participant experiences  
Structured exit interview data (Appendix 12) were collected from 62 (84%) participants 
from both the GV and LH groups. The duration of the interviews ranged from 20 to 45 
minutes. The interviewers asked specific closed questions regarding injection 
behaviours, and participants were asked to comment on how they found changing 
their injection sites. The data on changing sites is presented in Tables 45, 46 and 47, 
indicating the responses to each of the questions with illustrative participant comments 
for each question. The responses suggested that participants had mixed views about 
changing sites, with the majority reporting no difficulty, although approximately one 
third of participants did find it challenging, and preferred their previous sites or found 
new sites painful. Hence, changing sites may be more challenging for some people 
with diabetes, and they may require additional support in observing site changes. 
However, the majority of respondents did feel that changing sites had positive impact 




























Question Response n (%) Comments 
Yes No No 
response 
Difficulty in 
changing sites  
18(29) 40 (65)    4 (6) • “Found it difficult to remember” 
• “Took a couple of days to 
remember” 
• “Easy to follow and change the 
site but it was harder to do it in 
public places” 
 
Desire to use 
the old injection 
sites 
 
23 (37) 27 (44)  12 (19) • “Injected once or twice in old site" 
• "Occasionally, just due to habit" 
• "Wanted to go back for 
convenience and to reduce 
stigma of people noticing me 
taking injections" 
• "Wanted to go back every single 
time, but didn't" 
 
Pain at the new 
injection sites 
22 (35.5) 33 (53.2)  7 (11.3) • "More tender in certain spots" 
• " found the old site - legs - more 
painful" 
• "No difference in pain, bruising in 
the first week but old site used to 
bleed more" 
• [New injection site] was painful 




33 (53) 18 (29) 11 (18) • "More stable" 
• "Just the same" 




35 (56.4) 12 (19.4) 15 (24.2) • "A measurable difference" 
• "With regard to using the old site it 
was "a bit of luck" whether the 
insulin worked; with new site feels 






Participants were also asked to give their views on different methods of managing 
injection sites to lower the risk of LH. They were asked to consider rotating anatomical 
sites (upper abdomen; lower abdomen; lateral thigh) every three months or seasonally 
to rest areas for longer. Participants did not consider either option as appealing (see 
Table 46) 
 
Table 46: Injection site rotation 
Question Response n (%) Comments 
Yes No No 
response 
Injecting into 
one site for 
three months 
55 (89) 4 (6) 3 (5) "It would be impracticable to rotate as 
would not be able to take the trousers 
down in public space. it would be good 
to inject early morning and evening in 
four sites (upper R/L thigh and R/L 
buttock) and rotating those every month 
and then rotate injections around four 
sites in abdomen (upper L&R, lower 




45 (73) 10 (16) 7 (11) • “Very pleased by using the 
seasons” 
• “It is too long to inject into just 
one site” 


















In terms of receiving advice on injection sites or whether they were reviewed (see 
Table 47), participants reported mixed experiences. While half reported having been 
given advice regarding injection sites, three-quarters had not been given clear 
instructions as to how to do this and less than half had their sites inspected in the last 
two years. These data suggest that the process of site management may be somewhat 
ad hoc, and does not seem to be a priority for clinicians.  
 
Table 47: Instruction and examination of injection site management 
Question Response, n (%) Comments 

















13 (21) • “Lots of information at the beginning of 
the diagnosis but nothing since” 
• “Told to not do it in the same place, 
keep moving around sites, but vague 
information." 














• "Was given forms but didn't read them 
so doesn't know" 
• "Just told to avoid going into the same 
area, all news to me when you guys 
approached me." 
• Remembers having his abdomen 
divided into quadrants when he was a 













• “Maybe 5 times in 20 years" 
• Asked "any complaints?" but not 
actually looked at or touched 
• "Examined in the last two years - only if 
issues" 
• “Only once in clinic prior to referral to 










4.10 Feasibility observations  
4.10.1 Injection sites procedure  
All participants in the GV and LH characterisation studies had their injection sites 
scanned and examined by US and digital palpation as per protocol (SOP). The 
duration of the examination session varied from 10 to 20 minutes, while the US scans 




From September 2017 to February 2018, a total of 226 people with T1DM were 
screened from diabetes out-patient clinics at GSTFT, of whom 95 (42%) met the 
eligibility criteria and 27 (28%) participated in the GV study. In LH characterisation 
study the recruitment rate was slightly higher; out of 131 who met the eligibility criteria, 
47 (36%) participated in the study (Figure 7 section 4.1.1). 
 
4.10.3 Retention rate 
The retention rate in the GV study was 89 %. Three out of 27 participants left the study 
(two did not complete the Condition 2 and one withdrew). In the LH characterisation 
group 81% (n=38) of the participants completed the study and 19% (n=9) of the 
participants did not complete Condition 2. 
 
4.10.4 CGM insertion  
CGM sensors were fitted to all participants (n=27) enrolled on the GV study in 
Conditions 1 and 2. Sensor failure or insufficient CGM data occurred in six 









4.10.5 Insulin dose stabilisation 
All participants in both the GV and LH characterisation arms of the study received 
insulin advice as per protocol after having US screening of their injection sites. 
Unfortunately, the compliance with the insulin advice was not recorded. However, in 
the exit interviews 19 (31%) of participants reported taking less insulin than before 
changing the injection sites, with two participants reporting taking more insulin than 
before, and 29 (47%) did not notice any change in their insulin dose. Twelve 
participants provided no data on their insulin doses. 
 
In the GV participants, TDI dose data were available from the participants’ CGM 
diaries, allowing a comparison between Conditions 1 and 2.  At follow-up (Condition 2 
last visit) 40%(n=6) of the participants reduced their insulin by >4 units, 53% (n=8) had 
not changed their dose and the one increased their doses by >4units. Some 
participants (20%, n=3) were not advised to reduce their dose as it was consistent with 
their estimated insulin requirement. 
 
4.10.6 Adverse events 
No severe hypoglycaemic events (those that would require third party assistance for 














4.11 Chapter summary 
This chapter has presented the study findings from the GV and LH characterisation 
studies. The findings from both analyses indicate that LH is a prevalent clinical effect 
of insulin exposure. The data also suggest that LH is heterogenous in its morphology, 
with diffuse areas and nodules being the most common observation. The size, number 
and distribution of LH areas observed in participants varied depending on their 
injecting habits. The US scan data highlight some novel observations associated with 
LH areas, including dermal disruption which is potentially indicative of inflammation, 
and areas that could be necrotic tissue. In terms of the impact of LH on insulin and 
glycaemic control the data showed a somewhat complex picture. In relation to TIR and 
GV, there was  a mixed picture, with approximately one third of participants exhibiting 
improvement in time spent in range (4-10mmol/L), while the remainder showed either 
no improvement, or in a few cases a decrease. The exit interviews reveal that many 
participants found changing injection sites to be challenging, but most also reported a 
beneficial impact of the change on their glucose levels and responsiveness to insulin. 
The interviews also suggest that injection site assessment and management advice is 
currently limited. The findings are discussed in more detail in the next chapter, with 



















Chapter 5. Discussion 
An exploratory case-crossover study was presented in this thesis, the study aimed to 
test the association between US characterised LH lesions and glucose levels (TIR and 
GV) in people with T1DM. The GV study included data from 27 participants, with 
completed follow-up data on 15 participants. Data were also presented from an 
observational study of 47 participants who had their injection sites examined in order 
to assess whether US scanning of injection sites could be used as a tool to detect, 
characterise and grade LH tissue.  
 
In this chapter, study findings are discussed in relation to the research aim and 
objectives with reference to the wider literature on the impact of LH on TIR and GV, 
the chapter is organised as follows: 
• LH characterisation and detection 
• Time in range and GV 
• Insulin doses and adjustments  
• Insulin injecting behaviours 
• The use of ultrasound in LH assessment 
• Process evaluation findings 
• Insulin antibodies and LH 
• Insulin satisfaction, diabetes distress and quality of life 
 
The chapter also addresses the study strengths and limitations; and Implications for 













5.1 LH characterisation and detection 
 
The study has provided some novel insights into the clinical features of LH in insulin 
exposed tissue as observed with US scan. The study has shown that LH is 
heterogeneous in nature  in terms of the characteristics and size of the affected tissue 
observed. The study has also revealed some previously un-noted features of LH 
related tissue damage. The scanned injection areas mostly revealed areas of 
increased echogenicity or reflectivity of the dermal tissue compared to sites not 
exposed to insulin injections. In some areas the delineation between the 
subcutaneous and dermal layer disappeared and increased in thickness, suggestive 
of inflammation that may be related to increased insulin exposure. This finding was 
congruent with those of Perciun (2010), who undertook US scans of 40 insulin treated 
participants and reported complex multilayer changes including possible inflammatory 
reactions at injection sites. Some evidence of inflammatory tissue damage was also 
reported in one of the studies examining the histology of LH samples, with increased 
fibroblasts being present (Wallymahmed et al. 2004). This finding is important as it 
extends the classic interpretation of LH as being nodular in form and suggests that 
tissue damage is more generalised than has been previously considered or as 
described in current LH guidelines (FIT 2016). While it is not possible to say whether 
these changes have the same effect on glucose levels when injecting insulin as LH 
nodules, what can be observed is that nodules rarely occur independently of wider 
tissue change. Indeed, the comparison between US and digital palpation assessment 
of LH observed in the study suggest that what is physically palpated and identified as 
LH is often shown under US to be predominantly diffuse (dense) tissue.  
 
In the study participants a wide range of LH presentations (ranging from single nodules 
to multiple nodules and diffuse areas) were observed. The anatomical distribution of 
the LH mirrored the injection site preferences and were concentrated in the thigh and 
lower-abdominal areas. These observations were again largely congruent with the 
previous US studies of LH (Kapeluto et al. 2018, Bertuzzi et al. 2017, Perciun et al. 
2014, Perciun 2010). Whether the number of presenting nodules or tissue changes 






the case (GV-4) that showed an improvement in TIR by 20% had only one large 
nodule. While the magnitude of effect observed in this case may be explained by the 
fact that the participant had multiple alternative injections areas without LH to use, it 
also illustrates the potential effect of one LH site on insulin absorption, which in this 
case  which varied by a third in the LH and non-LH conditions. 
 
Areas of reduced echogenicity were also observed in some nodules, suggesting no or 
low blood flow indicating the possibility of necrotic tissue, as has been reported in 
previous studies (Perciun 2010). Perciun (2010) observed hypoechoic irregular 
shaped lesions attributed to necrosis in 7.5% (n=3) of participants, although they also 
suggested they could be areas of haematoma. The data from this study, however,  
suggest that these areas of potential necrotic tissue in LH tissue could be more 
common, as they were observed in around a third of the participants in both the GV 
and LH characterisation participants. The likelihood, that these observations are areas 
of necrotic tissue, is supported by one of the two previous studies that have examined 
LH tissue, were necrotic tissue was found in the sampled tissue (Wallymahmed et al. 
2004). However, what is not known is whether this necrotic tissue plays a role in insulin 
absorption or glucose regulation or indeed whether they convey any other health 
hazards. Hence, the presence of necrosis and inflammation warrants further 
investigation to confirm the US based observations, via either tissue biopsy or 
screening for inflammatory markers and cytokines that are associated with necrotic 
adipocytes and may mediate insulin signalling (Stafeev et al. 2017). Another 
observation that may indicate evidence of inflammatory processes or potentially 
trauma related to needle insertion, was dermal disruption. These were seen as areas 
where the margin between the dermis and the underlying subcutaneous tissue is either 
ill-defined or in some cases absent. Perciun et al. (2010) also referred to this dermal 
disruption and identified as one of their subtypes of ‘subcutaneous lesions’, defining it 
as ‘diffusely inhomogeneous hyperechoic thickened subcutis with an poorly defined 







This study also confirms the high prevalence of LH in people with T1DM, with a total 
of 740 LH nodules observed in the sample. Therefore, given that most participants 
reported that they had never previously had a thorough clinical examination of the LH 
areas suggests that this problem is largely undetected. This observation is congruent 
with the survey undertaken by Frid et al. (2016b) of which reported that 38.9% 
(n=4864) of the participants had never been examined for LH. This variation suggests 
that diabetes health professionals are either unaware of the significance of LH or are 
unsure as to the appropriate methods for detecting it (Gentile et al. 2016a). While the 
palpation procedure adopted for this study was based on the latest clinical guidelines 
and tested method for assessing LH (FITTER 2016, Frid et al. 2016a, Gentile et al. 
2016a), the clinical examination was significantly inferior to US as suggested by 
previous studies (Kapeluto et al. 2018, Volkova et al. 2015). The agreement observed 
between the US and the clinical examination was moderate (κ=0.44) which is very 
similar to the findings of Kapeluto et al. (2018) study, who in a study of 103 participants 
(8% had T1DM) also reported moderate agreement (κ=0.50). Therefore, finding better 
ways for detecting LH are important, while raising awareness of LH and promoting 
assessment guidelines are important, first steps it is important to develop more robust 
data on the clinical impact of LH on glucose regulation to support more extensive 
consideration of LH in people with T1DM. This will require larger studies examining 
the multi-modal effects of LH on diabetes management and insulin action. Technology 
may also enhance and objective LH detection and assessment. Portable US 
technology is now being developed which has the same accuracy as larger scanning 
machines. Hence with training, member of the diabetes team may be able to undertake 
LH scanning with US either routinely or in cases where insulin absorption problems 
are suspected.  
 
An additional output from the study was the introduction of a novel LH grading model. 
While it was not possible to assess or validate the grading system against an external 
clinical metric such as GV, it was possible to apply the grading consistently in 
assessing the LH areas identified. The study also provided additional features to 






introduced a grading model that has more detailed features compared to some of the 
earlier grading systems based on visualisation or measurement alone (Conwell et al. 
2008, Kordonouri et al. 2002, Hauner et al. 1996). While the grading system shares 
some similarities with the US-based grading system of Perciun (2010) who identified 
five grades of LH, it is perhaps easier to interpret as it integrates the diffuse tissue with 
nodule size and the presence of necrotic tissue. It would now be important to possibly 
compare the two grading systems in terms of clinical application and to consider 
whether the grade indicates a risk for altered insulin action. Indeed, it may be the grade 
of the LH rather the number of LH areas that conveys that risk as evidence in the 
participant with one large grade nodule who significantly improved his TIR by avoiding 
that area.  
 
Another new metric introduced into the analysis was a LH severity index (severity= 
((max grade2 x nLH)/100), based on size and number of nodules. However, again  this 
index showed no pattern in respect of the GV findings suggesting that frequency of 
nodules may not be so important. Therefore, larger nodules which are used more 
frequently may be more important than smaller more distributed areas of LH. One 
association that was observed was between the level of severity and insulin 
antibodies, which may be an additional area to explore in respect of the value of the 
severity index (see discussion section 5.7).  
 
Putting the collective outputs from the characterisation finding of the study together, 
including the grading criteria it is possible to identify a hypothetical model of the 
pathological features of LH. While it is not possible from a cross-sectional 
observational study to speculate on the progression of LH, it is possible to illustrate 
the pattern of observations from single to multiple nodules and the presence of 
disrupted and necrotic tissue. This model is presented figuratively below (see Figure 
14) and integrates the observations made in this study with those reported in previous 
studies (such as hyperplasia). The model illustrates the grading and severity index 
used in the study and shows some of the other novel observations made in the study 






for future studies and provide a tool for clinically characterising LH in people with 
diabetes.  
 




Finally, there was one observation in the study that may relay something of the 
enduring nature of LH. In the US scanning of  one participant had a defined nodule in 
an area which had not been used for injecting insulin for eight years. The image 
showed a clearly identified nodule but with slightly less dense tissue than was 
observed in active areas (see Image 8 page 129). Hence, it is possible that the effect 
of LH may be enduring, although this could also be an anomaly as no other such 
observations were made. Therefore, whether LH lesions recover when insulin 
exposure and injections cease remains unknown. Conducting a study to consider 
recovery may be challenging, as it could require a prolonged period of observation to 
establish recovery. There would also be a number of factors to consider, such as: the 
size of the affected area and the duration of insulin exposure; and most importantly 
what would determine recovery, would that be the point at which insulin adsorption in 






5.2 Time in range and GV  
 
The findings of the case-crossover study have provided some important new insights 
into the relationship between LH and glucose regulation. While the effects observed 
in the TIR findings were varied, the data showed that in about a third of cases there 
was an improvement in TIR ≥10% in the observation period, suggesting some 
potential benefit in changing sites. The improvements observed in TIR seemed to 
occur independently from changes in insulin doses, with the participants who improved 
their TIR either reducing their insulin dose or maintaining it at the Condition 1 level. 
This is the first study to report such findings. While previous studies have shown the 
effects of LH on insulin absorption and glucose levels, these studies used insulin 
clamps and were conducted in highly controlled conditions (Famulla et al. 2016, 
Hovelmann et al. 2015). In this study the effects observed were in the real-world 
context and are ,therefore, important as they show that there may be potential clinical 
benefits in preventing and managing LH in people with T1DM.  
 
However, the study has also identified that the relationship between LH and insulin 
action and glucose regulation is quite complex in the clinical setting. In relation to the 
GV measures and glycaemic control no differences were observed in between 
Condition 1 and Condition 2. The GV measures showed no pattern of association with 
the changes seen in TIR, with the exception of two participants (GV-5 and GV-11) who 
showed the largest reductions in their glucose CV on CGM, at 13 and 14% which 
corresponded with a reduction in their time below range of 15%. While it is also 
important to recognise that the lack of impact observed on the GV measures could be 
related to the small sample size and potentially to the insulin transition process as 
discussed below, it may also be that studying GV in this context is too heavily 
confounded (see study limitations section 5.9).  
 
In terms of glycaemic control, no significant differences were observed in HbA1c or 
1,5-AG. While the HbA1c result was may be related to the short time interval between 
measures (6 weeks) and that the participants did not have very high HbA1c’s at 






responsive to short-term changes in glucose exposure and is particularly sensitive 
post-prandial glucose levels, might have shown more sensitivity to the changes in the 
glucose levels observed. However, again there was no consistent pattern of change 
in either HbA1c or 1,5-AG. The 1,5-AG test which is particularly sensitive to post-
prandial hyperglycaemia (Dungan et al. 2006), did not show a consistent response in 
the participants who had the largest reductions in time above range which is somewhat 
unexpected. Hence, the value of this measure in assessing glucose exposures in 
relation to studies of LH avoidance may need further consideration. 
 
Therefore, while the results show an indication of clinical benefit in relation to glucose 
regulation in avoiding LH effected areas, the data suggest that the association is likely 
to be heavily confounded by extraneous factors. There are multiple factors at play in 
glucose regulation (diet, activity, stress etc.) and these may well have had an impacted 
on the study findings particularly given the small sample of participants and the short 
period of glucose monitoring (see study limitations). A particularly important mediating 
factor in respect of the study may have been the process of adjusting insulin doses for 
Condition 2. The intention was to reset insulin levels to a baseline level based on the 
participant’s body weight (0.6 units per Kg) to reduce the risk of hypoglycaemia and 
then to stabilise doses following each participants usual approach to insulin dose 
adjustment based on blood glucose testing in a six week wash-out phase prior to a 
follow-up CGM. The aim was to do this without changing the participants insulin 
regimen, the type of insulin and how they estimated their insulin doses. The difficulty 
was that not all the participants observed this advice and maintained their current dose 
(see section 5.4). Furthermore, participants may have benefited from more support 
when they switched away from their LH areas as exemplified in one participant (GV-
14) with no change in TIR. This participant reduced their time above range by 9.3% 
but had a corresponding increase in time below range of 8.7% despite reducing the 
insulin dose by 8 units. This could indicate that the participant was receiving more 
active insulin doses following site changes. The learning point perhaps was that while 
the participant had a reduction of 8 units in the TDI from 49 units to 41 units, 7 of those 






have been more appropriate. Hence, had the post transition insulin reductions been 
better considered they would have improved their TIR significantly, Identifying, a 
model for transitioning insulin doses to avoid hypoglycaemia when transitioning away 
from LH affected areas should be an important consideration for future clinical studies.  
 
One additional observation that may indicate a beneficial effect of changing sites was 
observed in the increased number of bolus injections with evident effect on glucose 
levels. While there are many factors that could have mediated these observations in 
a small sample of participants the changes were generally consistent across the 
sample, suggesting some improvement in the action of quick acting insulin when 
moving to LH free sites.  
 
Therefore, despite its limitations, the GV study has provided some important insights 
into the relationship between GV and LH than has been provided by the previous 
studies (Strollo et al. 2016, Blanco et al. 2013, Ibarra & Gallego 1998). As outlined in 
chapter 2, these studies used very crude estimates of GV (using mainly the SD of self-
monitored blood glucose tests) and non-standardised methods for detecting LH. 
These studies were further limited by using non-matched controls comparing GV in 
people with and without LH which does not allow for any estimation of the association 
between LH and GV independent of a large number of confounding variables (age, 
duration of diabetes, gender, education, self-management behaviour etc.). In this 
case-cross-over study it would seem that the association between LH and GV is likely 
to be heterogenous in nature in people with T1DM. This would suggest the need for a 
more pragmatic approach, in which people with diabetes can (once their LH areas 
have been identified) be supported in trying new sites with more individualised in 











5.3 Insulin doses and adjustments  
 
The study has identified some important learnings for future studies in respect of 
insulin doses in the transition away from LH affected injection sites. In studying the 
impact of LH on GV in a clinical context (rather than using insulin clamping models) it 
is clear that there is a need to actively manage the insulin adjustment process when 
transitioning away from LH areas. In this study participants were reset to a 
physiological estimate based on 0.6 units per KG (with 50% being allocated to basal) 
to avoid hypoglycaemia, although not all observed this advice. Avoiding potential 
hypoglycaemia was deemed of high importance in the study, as the clinical 
supervisors for the project had previously observed this problem and the risk was also 
suggested in previous studies. The Blanco et al. (2013) study, for example, reported 
a strong association between LH and the incidence of frequent unexplained 
hypoglycaemia (39%, n=108) in those with LH compared to (6%, n=9) in those without 
LH, which they explained by exposure to insulin in areas with and without LH. An 
advantage of this approach was thought to be that would individualise reductions, 
whereas other studies have adopted a 20% overall reduction to TDI (Campinos et al. 
2017). 
 
The overall picture observed in the GV study in respect of changes in insulin doses   
was inclusive and inconsistent. Overall, considering participants in both GV and LH 
characterisation arms of the study, there was a modest reduction in insulin doses with 
a drop in TDI of around 3.0 units. This reduction corresponds with a 2.0 unit (95%CI 
1.4-2.5 units) drop in insulin reported in another multi-centre study of 346 participants 
assessing the impact of LH advice on injecting behaviours, although they include 
people with both T1DM and T2DM and did not specify the proportion of each (Grassi 
et al. 2014). In a similar intervention study (RCT) of LH education and changes to 
needle length with 123 participants (50% with T1DM), a drop in TDI of 5 units over six 
months was observed in the intervention group, although the controls also had a 
reduction of 3 units (Campinos et al. 2017). Hence, the average impact of LH 






However, when looking at patterns of changes in insulin dose and impact on TIR in 
the GV study the picture becomes more complex. The data showed that while some 
participants had quite significant reductions in insulin doses, with corresponding 
reductions in time above range or increased hypoglycaemia; others who did not 
change doses also showed a reduction in their time above range, suggesting some 
stability in their insulin requirements following transition away from LH areas. As 
highlighted in the previous section, one participant increased her time below range 
despite reducing her TDI dose. Therefore, it is important to identify more effective 
processes for managing insulin doses when avoiding LH areas, to compensate for this 
variability. In this study the process was perhaps too passive, as it followed the 
participants usual adjustment practices to stabilise the participants doses rather than 
more active support, this was done to avoid confounding. It may also be that the 
physiological estimate used in resting insulin levels for the wash-out phase was too 
conservative in some participants. In addition, it might be important to give greater 
attention to bolus insulin doses as there were seen to be more active when moving 
away from LH areas. Therefore, it may have been better to have been more active in 
supporting participants in assessing and reviewing insulin ratios as well as basal 
insulin doses in a more managed way; while acknowledging that this could conflate 
the impact of the LH on glucose regulation, as providing insulin adjustment support 
may do this independently to the avoidance of LH areas. Establishing how best to 
manage this transition is important clinically, as current LH guidelines only advise the 
need to reduce insulin when moving away from an LH area without specifying in detail 
how this should be achieved other than increasing blood glucose monitoring (FIT 
2016). One possible study design, that might compensate for the confounding effect 
of providing insulin advice, would be to: compare LH assessment/advice plus insulin 
support; with insulin support without LH advice to see if the former showed superiority 
over insulin advice in isolation, in people with identified LH (although blinding might be 
problematic in such a study as it would be necessary to screen both intervention and 
control subjects for LH). Despite these methodological challenges, identifying a 






or severe hypoglycaemia, while also optimising insulin doses in order that the benefits 
of avoiding LH tissue can be fully and safely assessed.  
 
5.4 Insulin injecting behaviours 
 
A key factor in understanding LH is the behavioural habits associated with insulin 
injecting. Most people with T1DM not using CSII, will need to inject insulin at least 4-
5 times daily. They will need to inject in the context of their lives fitting it around 
activities and their work. Given the somewhat limited range of easily accessible places 
for injecting insulin, it is highly likely that people with T1DM will have favourite injection 
sites. In addition, these habits will become habituated over a significant period of time 
and may be difficult to change. Previous studies have shown that many people with 
diabetes do not rotate between injections sites (Gentile et al. 2016b, De Coninck et al. 
2010, Patton et al. 2010) despite education of the importance of rotation. In the 
qualitative interviews of all the participants across the GV and LH characterisation 
arms of the study (n= 62), around a third of participants said that they found changing 
sites difficult. With remembering to use their new sites and problems in using them in 
public places, being the most common explanations. The majority of participants also 
said they had not been given detailed education on changing injection sites and only 
half had their sites checked in the last two years. The impression would seem to be 
that whatever advice people with diabetes are given on site rotation the advice 
provided does not translate into their behaviours in many. This suggests that people 
with diabetes are either not inclined or able to follow advice or the advice provided is 
not clearly received or reinforced by health professionals. It is likely, the psychological, 
cognitive and social processes play an important role in regulating injecting behaviours 
in people with diabetes contributing to the development of LH. To date, the data on 
these processes are limited and need further exploration to inform the education and 
support provided to people with T1DM. One study of people with and without LH 
(n=215 people with T1DM), they reported higher levels of depression and lower levels 
of treatment satisfaction, although there were no differences in motivation or diabetes 






support in attending to site rotation to avoid LH, a better understanding of the 
behavioural regulators in respect to injections is required.  
 
An anecdotal observation made during the conduct of the study was that participants  
valued seeing the LH areas on the US, suggesting that this visualisation may be useful 
in incentivising  behaviour change. Although, this did not make the adjustment to new 
injection areas, as detailed above, any easier for some participants. Future studies of 
LH should consider these behavioural factors and adopt more robust procedures to 
monitor compliance with injection site changes. This may involve the development of 
behavioural support systems such as prompts, reminders and to-up education by 
clinicians.   
 
There have been some studies that have considered combinations of needle length 
changes and supportive education that have shown some success in helping 
participants to adjust insulin behaviours (although most are sponsored by needle 
length manufactures). The Grassi et al. (2014) study, which involved palpation of LH 
and one-to-one education from a nurse, showed a 25% increase in the number of 
participants who rated injection technique as being very important with an increase 
from 40% (n=138) at baseline to 65% (n=224) three months post-intervention. They 
did not, however, assess or report on whether this translated into behaviour change. 
In the Campinos et al. (2017) study, which involved education from a nurse (avoid LH 
areas, leaving 1 cm between injections, resting sites for 2-4 weeks and injection grids), 
two-thirds of participants met their criteria of satisfactory injection behaviour (avoiding 
LH, switching to a 4mm needle, and changing needles after each injection) at the 6 
month follow-up. Again, they provided no data on fidelity to the advice as the outcome 
was based on patient self-report. In the study of Smith et al. (2017), 75 participants 
(20 with T1DM) were exposed to injection site training based on the FIT guidance and 
again change to 4mm needles (the study was sponsored by a needle manufacturer), 
showed some impact on LH indirectly with a 65% increase in site rotation in accord 
with the FIT guidelines based on self-report (3-6 month follow-up). An interesting 






palpation at follow-up with a reported reduction in the size of the LH of 14% and 8% 
in the abdomen and thigh areas respectively. This observation was not objectively 
verified, and it is not consistent with the findings of this study where evidence of 
historical LH was found for a number of years after they had rested an injection sites. 
Therefore, a potentially important question to consider is what happens to a 
hypertrophic nodule when insulin exposure ceases and whether there is resolution or 
recovery in the area in respect of insulin absorption.  
 
This study also undertook detailed mapping of the LH areas to consider the  
anatomical distribution of the lesions. The data from the whole study sample, showed 
the highest concentration was in the abdomen followed by the thigh, gluteal area and 
triceps. While the overall distribution was general to both the left and right side of the 
body, in right-handed participants the distribution of LH was skewed to the right side 
of the body by a margin of 14%. There were only six left-handed participants, four of 
whom had a bias of LH on the left-side. While it is not possible to unequivocally claim 
that hand dominance influences the distribution all LH lesions, it is likely that people 
who are right-handed tend to have a preference for injecting on their right side. If the 
distribution of insulin injections are important in LH development, then finding methods 
to help people with diabetes extend their sites more evenly (left/right and anatomically) 
may be useful. Although, the practicalities of such an intervention would need to be 
considered with people who have diabetes to ensure that such advise was feasible for 
them and easy to maintain.  
 
The findings of this study suggest that these behavioural factors are of major 
importance in the development of LH, and any intervention to prevent or minimise the 
clinical impact of LH should consider these carefully. Simply advising people with 
diabetes about the need to rotate may not be adequate. One potential way this could 
be addressed would be to engage people with diabetes and diabetes health 






overcoming psychological and social barriers; and to activate and reinforce behaviours 
in people with diabetes. 
 
5.5 The use of ultrasound in LH assessment 
Another important contribution made by this study has been in developing a protocol 
for the use of US in assessing and detecting LH, which could be utilised clinically or in 
future studies. As outlined in the discussion on the characterisation of LH the study 
has revealed important insights into LH. While this study was not designed to test or 
consider the clinical application of using US for LH detection, it has shown that with 
access to the appropriate equipment and with training diabetes professionals could 
undertake such assessments reliably. The Standard Operating Procedure (SOP) for 
the scanning, developed with an international expert in sonography with expertise in 
training health professionals, could provide a basis for the clinical use of US in LH 
detection and management. The SOP provides a framework, detailing: equipment  
specifications and settings; procedure for scanning anatomical sites; classifications for 
determining LH lesions; and a process for measuring, recording and reporting LH 
(Appendix 13.1). It was also used to show participants which areas were free of LH so 
they could inject in those areas. There has only been one other study group who have 
reported a protocol for assessing LH. Perciun and Mihu (2014) presented a protocol 
for US assessment of LH, which included some similar features to the SOP used in 
this study. This included, mapping and characterising lesions as nodular and diffuse, 
and providing children and their parents with a map of unaffected areas for future 
injections. However, their protocol was designed for use in a paediatric context, and 
they observed high degree of variability relatable to the age and development of the 
child. 
The learning from this study suggests that the SOP, together with a training package 
could be tested clinically by training diabetes health professionals. While the 
practicalities of doing this would challenging particularly in accessing scanning 






that could be used in any diabetes clinic. However, it is important to emphasise that 
the primary objective for future research is still to provide more evidence on the clinical 
hazards of LH (hyper and hypoglycaemia) and the benefits of a more systematic 
approach to its assessment and clinical management, to justify the costs of introducing 
such a procedure. As part of the cost benefit analysis for assessing clinical effect 
consideration could also be given to whether preventing and avoiding LH, will reduce 
the amount of insulin used by participants, In this study, the overall reduction in insulin 
in terms of TDI was 6%, in the participants who provided the data (n=48). Although, it 
is important to note that estimate was only at six weeks follow-up and participants 
were advised to reduce doses following the US assessment. Therefore, future studies 
need to consider the impact of LH avoidance on insulin doses over a longer period of 
time. A further consideration would be the need to develop robust systems to support 
and reinforce injection behaviours that would prevent the development of further 
lesions and avoid existing LH areas, as discussed in the previous section.   
 
5.6 Process evaluation findings 
 
One of the objectives of this study was to evaluate and consider the study design in 
terms of recruitment and retention of participants and their experiences in the study. 
As outlined in Chapter 3 processes evaluations are important in exploratory phase 
studies as they can help inform the design of future larger studies. 
 
In terms of recruitment and retention to the GV arm of the study, around 42% of 
screened participants were eligible (SD of mean glucose ³ 4mmol/L) for the study, and 
a third of these agreed to participate in the study. While this represents a reasonable 
level of recruitment for a relatively involved clinical study, the study also struggled to 
meet its recruitment target. The reasons for this were not fully identified, although it is 
likely that the frequency of visits involved in the study may have been seen as  
challenging for a population of working adults; particularly when people with T1DM  
also have to attend frequent outpatient appointments. In hindsight, greater attention 






with a larger PPI group. In addition, it would have been useful to have conducted either 
a survey or short interviews with people who decided not to participate in the study. 
 
In terms of potential bias to the study, while bias in a small exploratory study is 
somewhat inevitable, it would have been useful to look in more detail at those who 
declined participation to establishing factors that may impact on study findings. Some 
indication of these factors was gained from the retention data. Participants who exited 
the GV study without completing (40% of those recruited), tended to be male by a 
margin of two to one (male to female). Non-completers were also likely to be older with 
longer diabetes duration. Hence, prior to another trial study it would be important to 
model and optimise strategies for both recruitment and retention to reduce this 
potential bias. A further consideration would be whether participants should be 
financially compensated for their participation.  
 
Another important learning for the study was the way participants were recruited to the 
study. Referring clinicians were aware of the purpose of the study but were advised 
not to reveal this to the participants prior to recruitment so we could observe their 
glucose regulation following their usual insulin management behaviours. However, 
some participants revealed they had been given recent LH advice by their clinician. 
While this was partially compensated for by instructing participants to take their insulin 
as normal in Condition 1, this advice may have either consciously or unconsciously 
moderated their behaviour. It is quite challenging to consider how this potential 
contamination might be overcome in future studies exploring the association between 
LH and GV, although one possibility would be to recruit a random sample of people 
with diabetes with a high SD from clinic registries and directly invite them to participate. 
The assumption based on known prevalence of LH would be that at least 40-60% of 
people with diabetes would have significant LH. Participants would then be monitored 
with CGM  and then assessed for LH, this would potentially provide GV data on people 
with and potentially without LH for comparison. Although this study showed that in a 
sample of participants with a SD of mean glucose ³4mmol/L, all bar 3 people had 






Bearing in mind that there are many other factors particularly the number and timing 
of blood tests performed that determine SD; and there may also be bias in the sample 
as those with an elevated glucose SD with LH may have been more likely to participate 
in the study. Hence, further consideration needs to be given to the utility of SD in mean 
glucose as a possible indicator for LH.  
 
Other process related findings included: a small number of CGM sensor failures, which 
occurred in six observations, three were in Condition 1 and three in Condition 2 (this 
failure level could be modelled in sample size estimations for future studies involving 
CGM); and no significant adverse events were recorded, which was important given 
the potential risk of hypoglycaemia.  
 
Finally, the exit interviews gave some useful insights in respect of the process 
evaluation, in addition to the points already discussed in relation to insulin injecting 
behaviours. The participants provided comments on site rotation and some of the 
perceived benefits of changing their injection sites. While most participants reported 
that the adhered to their new sites for the study, they also reported that observing and 
potentially sustaining rotation can be challenging. Hence, it would seem to be a priority 
that future studies consider more optimal strategies to support people with site 
rotation. 
 
5.7 Insulin antibodies and LH 
 
A novel and very tentative observation made in the study (given the small sample 
size), was potential association between LH severity and insulin antibodies. While 
previous studies have shown that insulin antibodies are associated with lipoatrophy 
(Raile et al. 2001, Reeves et al. 1980), only one previous study in children with 
diabetes has found an association between insulin antibodies and LH (Raile et al. 
2001). In this study participants with strong GAD antibodies had the most severe LH 
based on size and number of LH nodules, followed by those with IA2 antibodies. 






confounding variables which may also mediate the development of LH for example 
duration of insulin exposure. It is likely therefore that if antibodies do play a role in the 
development of LH that contribution is likely to be minimal. Therefore, further study, in 
a larger sample of people with T1DM, is required to consider whether there is an 
interaction between insulin antibodies and the development/severity of LH. Such 
studies could also consider whether the association is related to an antibody mediated 
inflammatory reaction to subcutaneous insulin exposure or insulin resistance resulting 
in higher insulin requirements. Although, in relation to the latter point, the participants 
in this study with high antibody levels did not have high insulin requirements, with the 
exception of one participant (GV-27) who had high ZnT8 antibodies and a TDI dose 
13 units above the physiological estimation (0.6 units per kilogramme).  
 
5.8 Insulin satisfaction, diabetes distress and quality of life 
 
In relation to insulin satisfaction, diabetes distress and quality-of-life, the results 
showed little impact on these measures, with the exception of a slight improvement in 
the visual analogue scale of EQ-5D-5L. This was largely related to the size of the 
sample which precluded any estimation of change in the GV study arm, although the 
observations were same when the data from participants of the LH characterisation 
study was pooled. There have been very few previous studies looking at the 
association between LH and these measures. In a cross sectional study of participants 
(n=215) with T1DM, Hernar et al. (2017) group participants by LH severity (based on 
the number of LH nodules) and compared their diabetes distress (DDS) and insulin 
satisfaction scores (ITSQ). They found no differences in either measure between 
people: with no LH (n=95); one nodule(n=86); or two of more nodules (n=25). The 
median values they reported for the ITSQ and DDS in those with two or more nodules 
were 61.4  and  2.4 respectively, this compares to median values at baseline of 57.4 
(ITQS_total) and 2.0 (DDS_total) in this study (combining the GV and LH arms of the 
study). A correlation was performed to explore further whether the number of LH 
lesions or the severity index of LH associated with the EQ-5D-5L, ITSQ or DDS scores 






One secondary observation in relation to the survey instruments was that they had 
good completion rates, which would support their use in larger future studies, although 
it may be necessary to consider some more sensitive measures such as patient 
centred individualised outcome measures that could incorporate specific patient 
selected outcomes (Paterson 1996). In addition, it may be useful to develop some 
questions specific to LH, including injection behaviours and activation in managing 
injection sites. Such measures would be useful in establishing the impact of site 
management education.  
 
5.9 Strength and limitations of the study  
 
In conducting a study, it is important to recognise its limitations. In the context of this 
study which was exploratory in nature this is particularly important so as to inform 
future studies as well was identifying potential bias in the study observations. This 
section considers some of  the main strength and potential limitations of the study.  
 
An important limitation was recruitment and retention, only 10% of participants  
screened for eligibility (n=226) were recruited to the GV study, as the majority were 
ineligible due to inadequate testing. While 34 participants were recruited as suggested 
by the power calculation, only 27 of these entered Condition 1 and full data following 
Condition 2 was only available on 15 participants. Therefore, the study was ultimately 
underpowered. The fact that so many participants had to be assessed for eligibility 
meant that there was insufficient time to recruit further. Nevertheless, the study has 
provided some important insights and has shown that more consideration needs to be 
given to elements of the research process in determining the impact of LH of GV as 
outlined in the previous sections. This limitation also suggests that in advance of a 
future study the recruitment protocol may need further intensification particularly in 
identifying eligible participants and in making the study more attractive to people with 
diabetes. It may be that with the increasing use of Flash Glucose Monitoring, the blood 







As has been already been discussed another limitation of the study was the wash-out 
phase in which insulin levels were adjusted to prevent hypoglycaemia. While this was 
an important consideration for participant safety, the study has shown that actioning 
this and re-adjusting insulin doses may need more to consider individual factors such 
as BMI and patient preferences, participants may need more active support with this 
without altering the insulin delivery model or type of insulin. An alternative approach 
would be to consider whether an overt clinical intervention involving LH assessment, 
and insulin injection site education led to improved glucose regulation and improved 
glycaemia in a RCT; with the control and intervention groups both being given some 
education on managing insulin doses.  
 
A further limitation of the study was the short follow-up duration of six weeks. While 
this suited the assessment of short-term effects such as TIR and GV, it limited others 
such as glycaemic control as measured by Hb1Ac, although 1,5AG was used to 
compensate for this as a short term glycaemic marker, a longer follow-up period may 
provide greater insights into the impact of LH sites on metabolic control and also 
establish whether participants can sustain the changes. Again, this may be suited to 
a clinical intervention study with adequate follow-up (6-12 months).  
 
Perhaps the most important limitations of this study are in respect of measurement, 
particularly in relation to GV. Considering GV in a real world setting with people with 
diabetes, particularly with relatively short periods or observation, can be influenced by 
multiple extraneous factors. Dietary intake, carbohydrates, fats and proteins all impact 
on glucose levels. While people with diabetes generally only use insulin to compensate  
for carbohydrates, fat and protein based foods also elevated glucose levels. Mixed 
meals and the type of carbohydrates consumed can alter glucose responses. Other 
factors that can impact on glucose levels and variability include: activity and exercise 
levels (anaerobic and aerobic); stress mental or physical due to illness; alcohol 
consumption; menstruation; and many more. Hence, attempting to measure GV in two 
six day windows may not be adequate to assess the impact of LH on GV. The intention 






insulin model consistent and sticking with their normal routines. As has been 
highlighted the former was problematic, as is the latter without prescribing a fixed diet 
and routine. Although we asked participants to record their activities and did consider 
evidence of insulin action by looking at the glucose response to bolus injections in 
Conditions 1 and 2, this may not have been enough to compensate for these 
extraneous factors. A potential solution to this problem would be to use other glucose 
sensing technologies that provide data over longer time periods. In a study considering 
the validity and reliability of GV measures using CGM, it was identified that a minimum 
12 day period was required to ensure an acceptable level of data variability (Neylon et 
al. 2014). Therefore, the study had insufficient glucose data for a reliable analysis and 
this may explain the case to case variation observed. There are now a number of CGM 
and flash glucose monitoring systems available and these could be used to deliver 
longer-duration data, although not all have extractable glucose data and only a few 
are available blinded. This study set out with intention of providing some insights into 
the clinical relevance of LH by considering is impact on glucose regulation. While, the 
findings of this study are limited as identified above, the learning generated by this 
study will hopefully inform future studies. Identifying the clinical impact of LH remains 
an important objective, without this understanding gaging the risk to people with 
diabetes is problematic and risks either over or under considering the problem of LH 
clinically. It is also important to estimate the hazard to justify expanding or intensifying 
LH screening and the use of more expensive time consuming activities such as using 
portable US.  
 
There may also have been a contamination issue, with some participants having been 
informed by clinical staff to change injection sites prior to the CGM assessment of 
Condition 1 (as relayed in section 5.6). This may have meant that the opportunity to 
observe the full LH effect on TIR and GV in all participants was reduced. Hence, in 
future studies it would be important to screen people with diabetes to ascertain if they 
had changed their injections in anyway in the last month prior to starting the study, or 







Equipment availability was a significant limiting factor, particularly in respect of 
recruitment. There was only one US machine allocated for the study and it was only 
available one day per week. This limited the number of recruitments as it excluded 
people who may have a preference for other days and it also complicated scheduling 
participants’ clinical visits which affected retention. The inflexible timing contributed to 
significant drop out of participants as the study progressed. Going forward the use of 
portable US equipment with a designated scanner for studies should be considered. 
These technologies are becoming more affordable and available, with the equivalent 
scanning power and functionality of the larger machines.  
 
The fact that the study was quite involved in terms of participant commitment may 
have biased recruitment and reduced the potential to observe the interaction between 
LH and GV in a larger pool of people with diabetes. Participants in the study had to 
test and report their blood glucose levels regularly and completing their CGM diary. 
The study also involved multiple clinic visits which might be difficult for some, and 
perhaps the £50 voucher was not adequate compensation for their time. In addition, 
some of participants showed limited compliance in avoiding the LH sites, potentially 
reducing the estimation of the LH effect on GV. In addition, six participants from the 
GV study (approximately 20%) had no CGM data in Condition 1 or 2. Generally, in a 
parallel-group study, this can lead to an imbalance between groups. However, as the 
participants in this study acted as their own controls this was less of a problem, 
although it did reduce the power of the study significantly. For future studies some 
form of electronic data recording may make this easier for participants making fidelity 
monitoring more accurate. 
 
Despite these limitations the study has yielded some important insights shedding light 
on the complex relationship between LH and the action of insulin on glucose levels. 
The study has also exposed some of the many challenges in conducting studies to 
consider the clinical effect of LH on people with diabetes. It is hoped that these insights 







5.10 Implications for future research and clinical practice  
 
The research has identified a number of new insights into LH and its potential clinical 
relevance. The study has also shown that LH is a prevalent and under addressed 
clinical issue. In order to advance further the study of LH to generate evidence to 
support clinical guidelines further research is required as follows: 
 
Ø Studies to assess the clinical impact of LH on diabetes outcomes are required 
these should include both acute and long-term outcomes. Studying the impact 
of LH on GV is also useful in determining the clinical effects of LH, from the 
experience of this study such studies need: carefully designed recruitment 
protocols to encourage greater participation this would be enhanced with more 
PPI involvement; if blinding is included in the design then robust procedures for 
concealment of study intention need to be developed and referring clinicians 
need to adhere to the procedure; methods for the maintenance of usual 
injecting behaviours for baseline observations need to be developed and for 
monitoring adherence; more individualised insulin adjustment protocols with 
more active support during the wash-out phase should be considered; and 
longer periods of glucose monitoring (optimally 12 days) or use alternative 
monitoring systems such as flash-glucose monitoring.  
 
Ø Studies looking at insulin doses would be useful. Such studies could look at TDI 
doses before and after LH assessment and consider other outcomes such as 
glycaemic control and incident hypoglycaemia. 
 
Ø More studies on individual behaviours in respect of injection site practices and 
preferences are needed, these could be qualitative or observational studies. 
Such data will be useful in designing individual injection behaviour change 
interventions, as it is clear from the literature review and from this study that 
attending to injection sites can be challenging for people with T1DM. 
 
 
Ø Robust assessment of different methods of LH detection should be undertaken. 






performed and whether screening should consider all people with diabetes or 
only those exhibiting potential insulin absorption issues; the application of new 
technologies in routine clinical assessment such as portable US technology 
should also be considered, including cost-benefit analysis; and further 
validation work is required to identify an optimal grading model in terms of 
clinical utility.  
 
Ø More studies on the natural history of LH may be useful, considering how 
quickly lesions develop and when or if affected tissues return to normal and 
recover equivalence with normal tissue in terms of insulin absorption.  
 
Ø Studies examining LH tissue samples might be useful as there have been very 
few studies examining the histological characteristics of LH. Such studies could 
consider provide more insight into the necrotic of inflamed tissues observed on 
US. As part of these studies or in parallel it may be worth measuring  
inflammatory cytokines which could impact on insulin signalling or other 
metabolic pathways. 
 
Ø Studies of different site rotation methods together with technologies to support 
people with diabetes in managing their insulin sites to reduce the risk of LH are 
important, as the ultimate mediator for the development of LH is individual  
behaviour. There are currently a number of mobile applications and adapted 
insulin pen technologies in development which need evaluating in respect of 
this. A key factor in sustaining the rotation will be that the method is achievable 
and that the people with diabetes can recognise the benefits of it. As with all 
studies requiring people to change a frequent behaviours this may be best 
achieved through a co-design process.  
 
Ø Studies considering the interface between people with diabetes and 
professional perspectives on managing LH may help inform interventions that 
will engage both groups. Again co-design studies that consider the nature of a 
problem form people with diabetes and professional perspectives may yield 







Ø Finally, an area that is currently significantly understudied is the interaction of 
LH and insulin action in CSII users. As the number of people with diabetes 
using CSII increases this may be an important consideration as insulin 
exposure in one site can be quite extended with set changes only occurring 
every third day.  
 
In terms of clinical implications, this study provides some useful new learning and 
confirms many established truths about LH. The study reinforces the fact that LH is a 
very common clinical finding in people with T1DM, and that it is often under considered 
by health professionals. While the participants may have had some education on LH 
and site management it is clear that the education provided does not necessarily 
resonate with them. Hence, it is important that diabetes health professionals address 
LH and reinforce messages about site management with people with diabetes 
frequently. Some of the other specific clinical considerations, include: 
Ø Physical or visual examination of LH may significantly underestimate the 
presence of LH lesions even when current best practice is observed. This 
suggests that new approaches are required and if cost-effective US could play 
a role in LH detection. 
 
Ø Changing injection sites can significantly alter insulin requirement in some 
people with diabetes and insulin adjustments are important when sites are 
being changed. It is an important area for future development that standard 
methods or considerations are used to support this. 
 
Ø The classical view, held by many health professionals, of LH as a defined fatty 
lump needs to be reconsidered. This study allied with others shows that LH is 
heterogeneous in nature with changes to the skin and surrounding 











This exploratory study has generated some important and useful insights into LH in 
relation to its characteristics (presentation, grade, prevalence) and its impact on insulin 
action. While the number of participants studies was small, it was possible to observe 
some impact on insulin response in relation to LH when participants changed their 
sites. Hence, the study has exposed that the relationship between LH insulin action 
and glucose regulation is complex and difficult to measure in a real-world setting. The 
impression given by the observations gleaned in the studies suggests that LH 
management strategies will need to carefully consider insulin management in the 
transitioning injection sites away from LH affected areas. Overall the study has 
identified a number of important questions that need to be addressed in future studies 
to identify the evidence needed to prevent and manage LH more effectively. The study 
has also provided some useful insights into how future studies may be more optimally 
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Appendix 1 Systematic Review Search Terms 
 
Appendix 1.1 Web of Science  
TOPIC: (Diabetes Mellitus OR Diabetes mellitus type 1 OR insulin dependent diabetes 
mellitus OR Insulin-dependent diabetes patients OR Insulin-dependent diabetic 
patients OR Type 1 diabetes OR Type 1 diabetic OR T1D OR T1DM OR DM type 1 
OR IDDM OR Juvenile diabetes OR Diabetes mellitus type 2 OR Type 2 diabetes OR 
Type 2 diabetic OR T2D OR T2DM OR DM type 2 OR diabetic patient OR Diabetic 
patients OR Diabetes OR Diabetic OR Insulin treated patients)  
AND 
TOPIC: (Lipohypertrophy OR lypohypertrophy OR Diabetic lipohypertrophy OR 
Diabetes lipohypertrophy OR lipohypertrophic OR Lipohypertrophied OR 
lipohypertrophies OR Insulin dystrophy OR dystrophy OR Dystrophies OR 
Subcutaneous Dystrophy OR Subcutaneous dystrophies OR Subcutaneous tissue 
dystrophies OR lipodystrophy OR Lipodystrophies OR Lipodystrophic OR hypertrophy 
OR Fat hypertrophy)  
NOT 
TOPIC: (CARDIOVASCULAR DISEASE OR HEART DISEASE OR HYPERTENSIVE 
OR HYPERTENSION OR MYOCARDIAL DISEASE)  
NOT 
TOPIC: (GROWTH HORMONE)  
NOT  
TOPIC: (LIVER DISEASE OR HEPATIC DISEASE) NOT TOPIC: (AIDS)  
NOT 







TOPIC: (PREGNANCY OR GESTATIONAL DIABETES)  
NOT 
TOPIC: (VITAMIN D) 
Refined by: [excluding] RESEARCH AREAS: ( BIOCHEMISTRY MOLECULAR 
BIOLOGY OR HISTORY OR RESPIRATORY SYSTEM OR GENETICS HEREDITY 
OR MEDICAL INFORMATICS OR UROLOGY NEPHROLOGY OR 
RHEUMATOLOGY OR HISTORY PHILOSOPHY OF SCIENCE OR PUBLIC 
ENVIRONMENTAL OCCUPATIONAL HEALTH OR CARDIOVASCULAR SYSTEM 
CARDIOLOGY OR ENVIRONMENTAL SCIENCES ECOLOGY OR BUSINESS 
ECONOMICS OR TRANSPLANTATION OR NEUROSCIENCES NEUROLOGY OR 
MATHEMATICAL COMPUTATIONAL BIOLOGY OR IMMUNOLOGY OR 
PARASITOLOGY OR PLANT SCIENCES OR ENGINEERING OR ZOOLOGY OR 
VETERINARY SCIENCES OR NUTRITION DIETETICS OR DENTISTRY ORAL 
SURGERY MEDICINE OR GASTROENTEROLOGY HEPATOLOGY OR 
OTORHINOLARYNGOLOGY OR INFECTIOUS DISEASES OR SPORT SCIENCES 
OR OBSTETRICS GYNECOLOGY OR OPHTHALMOLOGY OR TOXICOLOGY OR 
SURGERY OR MICROSCOPY OR WOMEN APOS S STUDIES OR URBAN 
STUDIES OR FOOD SCIENCE TECHNOLOGY OR TELECOMMUNICATIONS OR 
ANESTHESIOLOGY OR FILM RADIO TELEVISION OR HEMATOLOGY OR 
REHABILITATION OR EVOLUTIONARY BIOLOGY OR ONCOLOGY OR 
EMERGENCY MEDICINE OR AGRICULTURE OR CULTURAL STUDIES OR 
ORTHOPEDICS OR COMMUNICATION OR VIROLOGY OR REPRODUCTIVE 
BIOLOGY )  
Timespan=All years 










































































































Appendix 2 Data extraction tool 
 
Data extraction tool - LH and glycaemic control (HbA1c) and /or GV studies  
 
Extraction items Details 
Citation   
Aims and objectives or research question  




Participants characteristics   
Study design   
Description of the method (detection of LH)  






































Blanco et al 
(2013) 




Hauner et al. 
(1996) 
McNally et al. 
(1988) 
1 + + + + + + + + + 
2 + + + + + + + + + 
3 CD + + + + CD CD CD CD 
4 + + + + + + - - + 
5 - + + - - + - - - 
6 + + + + - + + + + 
7 + + + + - + + + + 
8 + + + + NA + + + NA 
9 + + + + + + + + + 
10 - - - - - - - + - 
11 + + + + + - - + - 
12 NA NA NA NA + NA NA NA NA 
13 NA NA + NA NA + NA NA + 
14 - + + + - + + + - 
Total 8 out of 14 11 out of 14 12 out of 14 10 out of 14 7 out of 14 10 out of 14 7 out of 14 9 out of 14 7 out of 14 




















The Titanic Studies 
We would like to recruit people you think may have LH e.g. people with any 
of the following: erratic control, sudden unexplained hypo, running high to 
avoid sudden lows. With or without palpable areas or lumps, and meet the 
following criteria: 
 
Testing regularly > 4 = possible 
CGM study – (pink info sheet) (n34) 
Testing < 4 times a day = US study – 
(yellow info sheet) (n70) 
Age> 20 years 
Diagnosed T1DM and using insulin for >3 years 
Taking multiple daily injections ≥4 per/day 
Using the same insulin type and delivery method for the past 6 months 
Able to speak and read English 
Contact details: 
Henri(etta) Mulnier and Rabab Hashem 
Mobile: 075 0454 5384    






Appendix 5 Participant Information Sheets 
 
Appendix 5.1 Glucose Variability Study- Condition 1 
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Appendix 5.1 Glucose Variability Study- Condition 1 
 
Glucose Variability Study 
Invitation to take part in a research study 
We would like to invite you to take part in a research study looking at the variations in 
blood glucose (sugar) that can occur during the day. This information sheet will explain 
why this study is being done and what we would like you to do if you wish to take part. 
We will be happy to answer any questions you may have. Taking part is completely 
voluntary and you can decide to withdraw at any time. This study is being conducted 
as part of a PhD study in collaboration with Guy's and St Thomas' NHS Foundation 
Trust and King’s College London. 
 
Purpose of the study 
We want to understand more about why blood glucose levels can vary day-to-day. 
The study would measure your glucose variability, which means the changes (swings) 
that take place in the amount of glucose in your blood over a given period of time. To 
do this we will use a special sensor called a Continuous Glucose Monitor (CGM) for 
six days. The sensor will record your glucose automatically and painlessly the whole 
time you are wearing it. You will not be able to see the results, but when we download 
the readings at the end of the week it will provide us and you with: 
• An assessment of how much variation there is in your blood glucose 
• An understanding of how food, physical activity, and your insulin influence your 










Why have I been invited? 
You are being invited to take part in this study because: 
• You have had type 1 diabetes for more than 3 years 
• You have had some significant swings in blood glucose level in the past four 
weeks 
• You take four or more insulin injections per-day 
• You test your glucose at least four times a day 
 
Taking part in the study 
It is up to you to if you would like to take part in the study or not. If you do decide to 
take part you are free to withdraw from the study at any time without giving a reason. 
This decision will not affect the care you receive at the hospital in any way. 
 
What will happen to me if I take part? 
Following attendance at clinic today with your permission a diabetes specialist nurse 
will contact you by phone within the next few days. They will be able to answer any 
questions you may have and arrange an appointment with you at the clinical research 
centre at St Thomas’ Hospital to explain the study further and ask you for your consent 
to take part.  
If you agree to take part, we will arrange for the sensor to be put on. The sensor and 
recording device is small - the size of a £2 coin. It has a tiny plastic tube that lies just 
under the skin to record your glucose continuously. It is secured to your tummy area 
with tape and the whole thing is covered with a waterproof adhesive film, which means 
you can bath or shower, and continue activities as normal.  
You will still need to measure your blood glucose with a regular glucose meter at least 
four times a day. You will also need to keep a diary recording your blood glucose 






the sensor. We will ask your permission to access some of your medical records such 
as your current medication, recent blood test results, your blood pressure and weight.  
We would also like to ask you to complete a few brief questionnaires that assess how 
people with diabetes feel about their diabetes and its treatment. There are no right or 
wrong answers to any of these and you can choose to answer all or none of the 
questions. 
 
Benefits of taking part 
The results of the glucose monitoring will be shared with you and discussed in detail, 
so that we can look at the variability, what might be causing it, and possible ways to 
reduce this. 
 
Risks of taking part 
While the sensor is painless to wear, there may be some mild discomfort when it is 
inserted. There is a possible risk of skin irritation, inflammation, infection and bleeding 
at the sensor insertion site, although this is unusual. Please let the researcher know if 
you have any skin allergies before they insert the sensor. If you have any problems 
while wearing the sensor it can easily be removed without any assistance or medical 
help. 
 
What if there is a problem? 
If you have any concerns during the study you can contact the research team on the 
telephone numbers you will be provided with. If you have concerns regarding the study 
or you are unhappy in anyway and wish to complain formally, you can do this by 
contacting the Patients Advice and Liaison Service (PALS): phone: 020 7188 8801 
email: pals@gstt.nhs.uk. The PALS team is based in the main entrance on the ground 







In the event that something does go wrong and you are harmed during the research 
you may have grounds for legal action for compensation against Guy’s and St Thomas’ 
NHS Foundation Trust and/or King’s College London but you may have to pay your 
legal costs. The normal National Health Service complaints mechanisms will still be 
available to you (If appropriate). 
 
Will my taking part in the study be kept confidential? 
All data will be kept confidential and used anonymously. Information will be stored 
securely and only the research team will have access to it. 
 
Involvement of the general practitioner/family doctor 
Your GP will be informed, with your consent, that you are taking part in the study. 
 
Participation in future research 
 
The researchers will request permission to contact you again for future 
investigation. This is an optional request and if you do not wish to give consent to be 
contacted for future investigations, it will not impact your participation in this study nor 
will it impact your clinical care. 
  
Further information and contact details  
Thank you for reading this participant information sheet. If you have any questions, or 
would like to find out more about our studies please contact the study diabetes 
specialist nurse who will be happy to discuss this study with you: 
 
Contact name and address inserted here  
Tel:( contact details inserted here) 






Appendix 5.2 The Effect of Changing Injection Site- Condition 2 
 
UlTrasound classIficaTion and grAdiNg of lIpohypertrophy and its ImpaCt on glucose 
variability in type 1 diabetes (the TITANIC studies): the effect of changing injection site 
Invitation to take part in a research study 
We would like to invite you to take part in a research study looking at the relationship 
between fatty lumps that can occur under the skin when injecting insulin at the same 
area, and their effect on insulin and blood glucose (sugar) levels. These fatty lumps 
are known as Lipohypertrophy and are sometimes referred to as ‘lipos’. This 
information sheet will explain why this study is being done and what we would like you 
to do if you wish to take part. Taking part is completely voluntary. This study is being 
conducted as Doctorate study in collaboration with Guy's and St Thomas' NHS 
Foundation Trust and King’s College London. 
 
Purpose of the study 
The lipohypertrophy lumps develop because insulin can cause local fat cells to 
enlarge. They can sometimes be seen as large raised areas on the skin, felt as harder 
patches or small lumps under the skin. These small lumps can be difficult to feel, so 
you may not realise they are there. We think the lumps can affect how the insulin works 
causing the glucose level to vary unexpectedly. We want to understand what this 
changed tissue looks like using ultrasound and to describe it. We also want to measure 
the lumps to see if we can establish a way of grading the lumps and if some lumps or 
patches might affect glucose variability more than others. 
Why have I been invited? 
You are being invited because you have already done the Glucose variability study 








Do I have to take part? 
It is up to you to if you would like to take part in the study. If you do decide to take part 
you are free to withdraw from the study at any time without giving a reason. This 
decision will not affect the care you receive at the hospital in any way. 
What will happen to me if I take part? 
The researcher will explain to you the purpose of the study and answer any questions 
you may have. If you are interested in taking part, you will be asked to sign a new 
consent form. We will then examine your insulin injection sites using ultrasound. 
Before we do the scan, we will feel for any lumps in your injection sites, which is the 
current way of assessing for lipos in clinical practice. The ultrasound is a harmless and 
painless procedure, which uses high frequency sound waves to produce images. An 
external probe is held on the surface of the skin and images are recorded. The scan 
takes around 30 minutes to complete. We would like to scan your arms, abdomen, 
buttocks and thighs. We will then show you were your lumps are and identify some 
new areas where you can inject avoiding any lumps. When we have done this with 
people with diabetes in the past we have found that they need less insulin than when 
they were using their ‘old sites’, so the study diabetes nurse will discuss this with you 
and agree a reduced insulin dose with you. During the next six weeks from your scan 
you will be supported by the 
study DSN, to help ensure that your glucose does not go too high or too low in 
response to the new calculated dose. We will not change the type of your insulin or 
any other aspects of your treatment.  
We would like to take a blood sample to check your glycated haemoglobin (the test 
that tells us what your glucose has been like in recent weeks) and another test that 
can show us glucose variability. This blood samples will be collected by a needle into 
a vein in your arm and only needs 2 teaspoons (10ml) of blood collected in 2 or 3 vials. 
After five weeks of injecting into the new area we will ask you to return so that the 
continuous glucose monitor (CGM) sensor can be fitted for another weeks recording. 






a regular glucose meter and keep a diary recording your blood glucose levels, your 
insulin and what you eat, so we can check and interpret the readings from the sensor. 
When you return to have the sensor taken off and downloaded, the diabetes nurse will 
look at the data with you and discuss any differences from your first CGM recording. 
They will also ask you about your experiences of injecting into the different area (lipo 
free sites) during a short interview and to complete some of the questionnaires you 
completed at the beginning of the study. We would also like to repeat the blood test at 
this final visit. 
What will I have to do? 
Avoid injecting into your old lipohypertrophy areas 
Continue to monitor your glucose in your normal way 
Five weeks after the scan you would wear a CGM sensor for six days and keep 
a monitoring diary including activity and food intake 
Return for the final visit to have the sensor downloaded, complete post study 
questionnaires and have a blood sample taken 
What will happen to my blood sample? 
Blood samples collected for the purposes of the research will be used immediately 
and at the end of the study the samples will be disposed of in accordance with HTA 
policies. 
Will I be paid for my involvement? 
To say thank you for taking part in the study, we will give you a £50.00 gift voucher 
Benefits of taking part  
This study may not directly benefit you, but it does give you an opportunity to have 
your injection sites examined and scanned by ultrasound. The information you get 
from participating in the study will may help raise your awareness around lipos. It also 






insulin. In the future your participation may help us develop better ways of supporting 
people with diabetes to regulate their glucose levels. 
Risks of taking part 
There may be a small chance that your glucose may rise or fall when you change to 
the new injection sites and we have adjusted the dose of your insulin. You will be given 
advice on what to do if this happens and a contact number for the study diabetes 
nurse. There are no known risks from the type of ultrasound scan you are having. 
What if there is a problem? 
If you have any concerns during the study you can contact the research team on the 
telephone number provided and they will do their best to answer your questions or 
manage your concerns. If you have concerns regarding the study or you are unhappy 
in anyway and wish to complain formally, you can do this by contacting the Patients 
Advice and Liaison Service (PALS): phone: 020 7188 8801, email: pals@gstt.nhs.uk. 
The PALS team is based in the main entrance on the ground floor at St Thomas’ 
Hospital and on the ground floor at Guy’s Hospital in the Tower Wing.  
In the event that something does go wrong and you are harmed during the research 
you may have grounds for legal action for compensation against Guy’s and St Thomas’ 
NHS Foundation Trust and/or King’s College London but you may have to pay your 
legal costs. The normal National Health Service complaints mechanisms will still be 
available to you (If appropriate). 
Will my taking part in the study be kept confidential?    
Yes, you will only be identified by an anonymous code and your name will not be 
included in any reports of the study. All information will be stored securely and only 
the research team will have access to it and your personal details. 
What will happen to the results of the research study? 
Part of the research will be written up as a thesis for a Doctorate at King’s College 
London. On successful submission, the thesis will available in the University archives. 






internationally in meetings for healthcare professionals and via diabetes related 
support groups. Papers will be published in health journals associated with diabetes 
and newsletters for people with diabetes. 
Participation in future research 
The researchers will request permission to contact you again for future investigation. 
This is an optional request and if you do not wish to give consent to be contacted for 
future investigations, it will not impact your participation in this study nor will it impact 
your clinical care. 
Further information and contact details  
Thank you for reading this participant information sheet. If you have any questions, or 
would like to find out more about our studies please contact the study diabetes 
specialist nurse who will be happy to discuss this study with you: 
Contact name and address inserted here  
Tel:( contact details inserted here) 

















Appendix 5.3 Lipohypertrophy Characterisation Study  
 
UlTrasound classIficaTion and GrAdiNg of lIpohypertrophy and its ImpaCt on glucose 
variability in type 1 diabetes (the TITANIC studies): characterisation of 
lipohypertrophy. 
Invitation to take part in a research study 
We would like to invite you to take part in a research study to understand more about 
the fatty lumps that can occur under the skin when you inject insulin, and how they 
affect your blood glucose (sugar) levels. These fatty lumps are known as 
lipohypertrophy and are sometimes referred to as ‘lipos’. This information leaflet 
explains why this study is being done and what we would like you to do if you wish to 
take part. We will be happy to answer any questions you may have. Taking part is 
completely voluntary and you can decide to withdraw at any time. This study is being 
conducted in collaboration with Guy's and St Thomas' NHS Foundation Trust and 
King’s College London. 
Purpose of the study 
The lipohypertrophy lumps develop because insulin can cause local fat cells to 
enlarge. They can sometimes be seen as large raised areas on the skin, felt as harder 
patches or small lumps under the skin. These small lumps can be difficult to feel, so 
you may not realise they are there. We think the lumps can affect how the insulin works 
causing the glucose level to vary unexpectedly. We want to understand what this 
changed tissue looks like using ultrasound. We also want to measure the lumps to 
establish a way of grading the lumps and see if some lumps or patches might affect 
glucose control more than others. 
Why have I been invited? 
You are being invited to take part in this study because you have reported glucose 







Taking part in the study 
It is up to you to if you would like to take part in the study. If you do decide to take part 
you are free to withdraw from the study at any time without giving a reason. This 
decision will not affect the care you receive at the hospital in any way. 
What will happen to me if I take part? 
With your agreement, a study nurse will contact you by telephone and arrange to meet 
with you to discuss the study. If you agree to take part, you will be asked to sign a 
consent form. We will ask your permission to access some of your medical records 
such as your current medication and recent blood tests and arrange an appointment 
to examine your injection sites with ultrasound and by touch. When you come for this 
appointment and before we do the scan, we will feel for any lumps in your injection 
sites, which is the current way of assessing for lipos in clinical practice. The ultrasound 
is a harmless and painless procedure, which uses high frequency sound waves to 
produce images. An external scanner (probe) is held on the surface of the skin and 
images are recorded. The scan takes around 30 minutes to complete. We would like 
to scan your arms, abdomen, buttocks and thighs. We will show you were your lumps 
are and identify some new areas where you can inject avoiding any lumps. When we 
have done this with people with diabetes in the past, they often find that they need 
less insulin than when they were using their old sites, so the diabetes nurse will 
discuss this with you and agree a reduced insulin dose with you. We would also like 
to ask you to complete a few brief questionnaires that assess how people with diabetes 
feel about their diabetes and its treatment. There are no right or wrong answers to any 
of these and you can choose to answer all or none of the questions. We will take an 
additional blood test (about 5ml or one teaspoonful of extra blood) to check what your 
glucose levels have been in recent weeks – your glycated haemoglobin. Finally, we 
would like you to return to the clinic for a very short appointment six weeks after the 
scan to check your glycated haemoglobin again and to complete some of the 
questionnaires again. If you need ongoing review by your diabetes team after taking 







What will happen to my blood sample? 
Blood samples collected for the purposes of the research will be used immediately 
and at the end of the study the samples will be disposed of in accordance with Human 
Tissue Authority (HTA) policies. 
Benefits of taking part 
This study may not directly benefit you, but it does give you an opportunity to have 
your injection sites examined and scanned by ultrasound. This information may help 
you to reduce the variations in blood glucose you experience. 
Risks of taking part 
There may be a small chance that your glucose may rise or fall when you change to 
the new injection sites and we have adjusted the dose of your insulin. You will be given 
advice on what to do if this happens and a contact number for the study diabetes 
nurse. There are no known risks from the type of ultrasound scan you are having. 
What if there is a problem? 
If you have any concerns during the study you can contact the research team on the 
telephone numbers provided. If you have concerns regarding the study or are unhappy 
in anyway, you can do this by contacting the Patients Advice and Liaison Service 
(PALS): phone: 020 7188 8801, email: pals@gstt.nhs.uk.  The PALS team is based in 
the main entrance on the ground floor at St Thomas’ Hospital and on the ground floor 
at Guy’s Hospital in the Tower Wing. 
In the event that something does go wrong and you are harmed during the research 
you may have grounds for legal action for compensation against Guy’s and St Thomas’ 
NHS Foundation Trust and/or King’s College London but you may have to pay your 
legal costs. The normal National Health Service complaints mechanisms will still be 








Will my taking part in the study be kept confidential? 
All data will be kept confidential and used anonymously. Information will be stored 
securely and only the research team will have access to it. 
Involvement of the general practitioner/family doctor 
Your GP will be informed, with your consent, that you are taking part in the study. 
What will happen to the results of the research study? 
The results of the TITANIC studies will be disseminated locally, nationally and 
internationally in meetings for healthcare professionals and via diabetes related 
support groups. Papers will be published in health journals associated with diabetes 
and newsletters for people with diabetes. 
Participation in future research 
The researchers will request permission to contact you again for future investigation. 
This is an optional request and if you do not wish to give consent to be contacted for 
future investigations, it will not impact your participation in this study nor will it impact 
your clinical care. 
Further information and contact details  
Thank you for reading this participant information leaflet. If you have any questions, or 
would like to find out more about our studies please contact the study diabetes 
specialist nurse who will be happy to discuss this study with you: 
Contact name and address inserted here  
Tel:( contact details inserted here) 









Appendix 6 Study Consent Forms 
 
Appendix 6.1 Glucose Variability Study- Condition 1 
Appendix 6.2 The Effect of Changing Injection Site- Condition 2 

























Appendix 6.1 Glucose Variability Study- Condition 1 
PARTICIPANT CONSENT FORM 
Please tick the boxes below 
 Yes  No 
1. I confirm that I have read and understand the information sheet (GV 
Study-PI1 Version.3/date….) for the above study and have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
  
2. I understand that my participation is strictly voluntary and that I may 
withdraw at any time without the need to justify my decision and that 
this will not affect my medical care in any way. 
 
  
3. I understand that all information obtained during this study will be 




4. I understand that relevant sections of my medical notes may be 
looked at by individuals from King’s College London, where it is 
relevant to my taking part in this research. I give permission for 
these individuals to have access to my records. 
 
  
5. In the event of an abnormality being discovered as a result of the 
scan; I agree that I should be informed of the abnormality, that a 
relevant medical practitioner may be contacted and that I may be 
referred if necessary to the appropriate clinician. 
 
  
6. I agree to participate in this study. 
  
7. I agree to my GP being informed of my participation in the study 
   
8. I am happy to be contacted in the future regarding follow-on 
relevant ethically approved research studies. 
 
  
9. I would like to receive a summary of the findings from the study 




_________________                       _______________                            ____________ 
Name of Participant Date Signature 
 
________________                        _______________                          _____________ 






Appendix 6.2 The Effect of Changing Injection Site- Condition 2 
PARTICIPANT CONSENT FORM 
Please tick the boxes below 
 Yes  No 
1. I confirm that I have read and understand the information sheet 
(GV Study--PI2sVersion.3/date….) for the above study and have 
had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily. 
 
  
2. I understand that my participation is strictly voluntary and that I 
may withdraw at any time without the need to justify my decision 
and that this will not affect my medical care in any way. 
 
  
3. I understand that all information obtained during this study will 
be kept strictly confidential and that any results will not be linked 
to my personal details. 
 
  
4. I understand that relevant sections of my medical notes may be 
looked at by individuals from King’s College London, where it is 
relevant to my taking part in this research. I give permission for 
these individuals to have access to my records. 
 
  
5. In the event of an abnormality being discovered as a result of 
the scan; I agree that I should be informed of the abnormality, 
that a relevant medical practitioner may be contacted and that I 
may be referred if necessary to the appropriate clinician. 
 
  
6. I agree to participate in this study. 
  
7. I agree to my GP being informed of my participation in the study 
   
8. I am happy to be contacted in the future regarding follow-on 
relevant ethically approved research studies. 
 
  
9. I would like to receive a summary of the findings from the study 




_________________                       _______________                            ____________ 
Name of Participant Date Signature 
 
________________                        _______________                          _____________ 






Appendix 6.3 Lipohypertrophy Characterisation Study 
PARTICIPANT CONSENT FORM 
Please tick the boxes below 
 Yes  No 
1. I confirm that I have read and understand the information sheet 
(USScanStudyPI2b Version.3/date….) for the above study and 
have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
  
2. I understand that my participation is strictly voluntary and that I 
may withdraw at any time without the need to justify my decision 
and that this will not affect my medical care in any way. 
 
  
3. I understand that all information obtained during this study will 
be kept strictly confidential and that any results will not be linked 
to my personal details. 
 
  
4. I understand that relevant sections of my medical notes may be 
looked at by individuals from King’s College London, where it is 
relevant to my taking part in this research. I give permission for 
these individuals to have access to my records. 
 
  
5. In the event of an abnormality being discovered as a result of 
the scan; I agree that I should be informed of the abnormality, 
that a relevant medical practitioner may be contacted and that I 
may be referred if necessary to the appropriate clinician. 
 
  
6. I agree to participate in this study. 
  
7. I agree to my GP being informed of my participation in the study 
   
8. I am happy to be contacted in the future regarding follow-on 
relevant ethically approved research studies. 
 
  
9. I would like to receive a summary of the findings from the study 




_________________                       _______________                            ____________ 
Name of Participant Date Signature 
 
________________                        _______________                          _____________ 






Appendix 7 Schedule of Procedures  
Appendix 7.1 Case-crossover Study 
Case-crossover study OPA  Screen visit  
Visit 1 
Visit 2 Visit 3  Visit 4 
Participant information sheet- Glucose 
variability study  
X X    
Inclusion and exclusion check X X    
People with diabetes who meet the study inclusion criteria 
Informed consent  X X   
Demographics  X    
DDS, ITSQ, Gold score, quality of life 
questionnaires 
 X   X 
Blood sample    X  X 
CGM fitted  X  X  
Participant information sheet - GV    X   
Physical examination  
(digital palpation) 
  X   
Ultrasound scan   X   
Body map (Injection sites)     X   
CGM diary   X  X  
Insulin stabilisation, advice about injection site 
and agree which new injection areas to use 
  X   
Tel contact   Telephone support from 
the diabetes specialist 
nurse to ensure participant 
safety 
CGM removed    X  X 















Lipohypertrophy characterisation Study OPA  Screen visit  
Visit 1 
Visit 2 
Participant information sheet –  
LH characterisation study  
X X  
Inclusion and exclusion check X X  
People with diabetes who do not meet the study inclusion criteria 
Informed consent  X  
Demographics  X  
DDS, ITSQ, Gold score, quality of life questionnaires  X X 
Blood sample   X X 
Ultrasound scan  X  
Physical examination (digital palpation)  X  
Body map (Injection sites)   X X 
Insulin stabilisation, advice about injection site and 
agree which new injection areas to use 
 X  
Tel contact  Telephone support from the 
diabetes specialist nurse to 
ensure participant safety 






Appendix 8 Study Questionnaire 
 
Dear Participant, 
We would be very grateful if you could take some time to complete the below 
information about you and your diabetes, and questionnaires about: insulin, 
hypoglycaemia, and your health in general. 
 
We really value your time in completing this and encourage you to express your 
answers freely whether they are positive or negative. The questionnaire will be kept 
anonymous and your responses will in no way prejudice the care you receive.  
Please try and answer all the questions if you can. However, if you think a question is 
inappropriate or does not apply to you then you may choose not to give an answer.   






















CODE: __ __ __ __ 
 
Section 1.   In this section, we will ask you some questions about you and your 
diabetes 
1.   Date of birth: __ __ __ __ __ 
2.   Are you?     Male    or    Female 
3.  How would you describe your 
ethnic origin? (check one box) 
 
 White 
 Black        
 Asian  
 Chinese  
 Mixed 
 Other ________________ please specify     
4. Is English your first language?  Yes        No 
5. What is the highest level of 
education you have completed? 
(check one box) 
 
 Some secondary school   
 Secondary school graduate 
 Some college 
 University graduate           
 Some postgraduate education  
 Post graduate degree 
 Advanced Graduate work or Ph.D.        
 Not Sure 
6. What is your current weight?       __ __ __ kg  
7.  What is your height? __ __ __     cm   
8. Which insulins do you use? Long acting (basal insulin) name: ________________      
Do you take this once daily  or twice :  
What dose do you take 
  Once daily dose:  ______      or   
  Twice daily doses:  _______/______        
 
Quick acting (bolus) insulin name: __________ 
What is your usual 1st meal/breakfast dose? 
__________ 
What is your usual 2nd meal/lunch dose? 
 __________ 
What is your usual 3rd meal/evening dose? 
__________ 
9. Do you use carbohydrate 
counting? 
 Yes          My insulin / carb ratio is;      
                             Breakfast      ____ /____ 
                             Lunch           ____ /____ 
                             Dinner         ____ /____ 
 No       






10. Do you take any other 
medication?                                                                                  
Name of 
medication
Dosage  Frequency  
   
   
   
   
   
   
 
11. Do you have any other long 
term conditions/illnesses? 

































Your diabetes and treatment 
13. When was your diabetes diagnosed? __ __ __ __  (Please enter the year)   
14.  Have you attended any diabetes education 
or self-management course/s? 
 Yes name of course____________ 
e.g. DAFNE BERTIE other   
 No                                                    
15.  How many times do you usually check your 
blood glucose in a day? 
 1     
 2     
 3      
 4    
  more than 4 times per day 
16. Have you EVER had a low blood glucose 
where you have needed assistance to get some 




Yes              No (go to Q 18)                
 
17. How many of these severe hypos have you 
had in the last year? 
 1    
 2     
 3      
 4    
 more than 4 times 
18. Do you know when your hypos are 
commencing? 
 1    Always aware  
 2     
 3      
 4    
 5 
 6 
 7 Never aware 
19. Which needle length do you use? 
 
 4 mm 
 5 mm    
 6 mm      
 8 mm  
 12.7 mm 
20. What and when was your last HbA1c result?    __ __ __ %/mmol    date ___/ ___ / ____ 
     I don’t know 
21.  Do you have any complications related to 
diabetes? 
 Kidney problems 
 Foot problems 
 Nerve damage 
 Eye problems 
 Stroke 
 Heart disease (e.g. heart attack, heart 







Section 2. This section contains some specific questionnaires about, insulin, diabetes 
distress, hypoglycaemia, and your health in general 
The following questions are about your perceptions of your current insulin treatment and how 
it affects you in your daily life.  When you think of your insulin treatment, please keep in mind 
the type of insulin you take, the dose or amount of insulin, your schedule for taking insulin, 
and the device or method you use to give yourself insulin.  
Please think about your experiences during the past 4 weeks when you answer the questions. 
If you are unsure about how to answer a question, please give the best answer you can. 
1. How much of a bother is it for you to take all your daily insulin doses as prescribed? 
No bother at all             A tremendous bother 
1              2            3           4           5          6          7 
 
2. How much does your current insulin treatment interfere with your ability to enjoy social or 
leisure activities? 
Does not interfere at all                                           Interferes tremendously 
 
1              2            3           4           5          6          7           
 
3. How much does your current insulin treatment interfere with your work or school 
activities? (If you do not work or attend school, think about your regular daily activities). 
Does not interfere at all                                   Interferes tremendously 
 
1              2            3           4           5          6          7 
 
4. How much do you have to plan the timing of your meals or snacks around the insulin you 
currently use?                                                                                                     
                                                                                                              A tremendous 
No planning at all                                         amount of planning 
1              2            3           4           5          6          7 
 
 
5. How much do you have to plan what you eat with your current insulin treatment? 
                            A tremendous 
No planning at all                                      amount of planning 











6. How much do you have to plan your physical activities (such as exercise or strenuous 
household chores) around your current insulin treatment? 
                                            A tremendous 
No planning at all                                         amount of planning 
1              2            3           4           5          6          7 
 
7. How confident are you that you can avoid symptoms of low blood glucose (such as 
sweating, trembling, dizziness, blurred vision) with your current insulin treatment? 
Extremely confident                                                        Not at all confident 
1              2            3           4           5          6          7 
 
8. How confident are you that you can avoid severe episodes of low blood glucose that result 
in loss of consciousness (fainting or passing out) with the insulin you currently use? 
Extremely confident                                                          Not at all confident 
1              2            3           4           5          6          7 
 
9. In general, how bothered are you by symptoms of low blood glucose (such as sweating, 
trembling, dizziness, blurred vision) due to the insulin you currently use? 
Not at All Bothered                                                                    Extremely Bothered 
1              2            3           4           5          6          7 
 
10. How much do you feel that the insulin you are currently using increases the chances that 
you will experience low blood glucose? 
     Extremely                                                                                                Not at All                                                                                                                                          
                    1              2            3           4           5          6          7 
 
 
11. How worried are you about experiencing low blood glucose during the night with the 
insulin you currently use? 
Not at All Worried                                                                           Extremely Worried 
1              2            3           4           5          6          7 
 
 
12. How confident are you that you can avoid symptoms of high blood glucose (such as dry 
mouth, thirst, frequent urination, fatigue, increased appetite) with your current insulin 
treatment? 
Extremely confident                                                  Not at All confident 











13. How satisfied are you with the stability of your blood glucose levels with your current 
insulin treatment? 
Extremely satisfied                                                                         Not at All satisfied 
1              2            3           4           5          6          7 
 
14. Overall, how pleased are you with the blood glucose control you achieve with your current 
insulin treatment? 
Extremely pleased                                                                         Not at All pleased 
1              2            3           4           5          6          7 
 
15. In general, how stressful is it for you to manage taking your current insulin treatment? 
Not at all stressful                                                                       Extremely stressful 
1              2            3           4           5          6          7 
 
16. How burdensome is it for you to manage your current insulin treatment? 
Not at all burdensome                                                     Extremely burdensome 
1              2            3           4           5          6          7 
 
 
The following questions are about your perceptions of your current method of taking 
insulin and how it affects you in your daily life.  For these questions, you should only 
think about the device or method you use to give yourself insulin. 
 
17. How easy is it for you to take the correct amount of insulin each time with your current 
method of taking insulin? 
Extremely easy                                                                                        Not at all easy     
1              2            3           4           5          6          7 
 
18. How convenient is your current method of taking insulin when you are away from 
home? 
Extremely convenient                                                                     Not at all convenient 
1              2            3           4           5          6          7 
 
19. How much pain or other physical discomfort do you experience with your current method 
of taking insulin? 
                            A tremendous amount   
No pain or discomfort                                                          of pain or discomfort 










20. How comfortable are you taking insulin in a public place (where people might see you with 
your current method of taking insulin)? 
Extremely comfortable                                                                  Not at all comfortable 
1              2            3           4           5          6          7 
 
21. How much emotional distress or anxiety do you experience related to your method of taking 
insulin? 
                      A tremendous amount 
No distress or anxiety                                                                  of distress or anxiety 
1              2            3           4           5          6          7 
 
 
22. Overall, how satisfied are you with your current method of taking insulin? 
Extremely satisfied                                                                              Not at all satisfied 

























Living with diabetes can sometimes be tough. There may be many problems and hassles 
concerning diabetes and they can vary greatly in severity. Problems may range from minor 
hassles to major life difficulties. Listed below are 17 potential problem areas that people with 
diabetes may experience. Consider the degree to which each of the 17 items may have 
distressed or bothered you DURING THE PAST MONTH and circle the appropriate 
number.  
Please note that we are asking you to indicate the degree to which each item may be 
bothering you in your life, NOT whether the item is merely true for you. If you feel that 
a particular item is not a bother or a problem for you, you would circle "1". If it is very 









































1. Feeling that my doctor 
doesn't know enough 
about diabetes and 
diabetes care. 
1 2 3 4 5 6 
2. Feeling that diabetes 
is taking up too much of 
my mental and physical 
energy every day. 
1 2 3 4 5 6 
3. Not feeling confident 
in my day-to-day ability 
to manage diabetes. 
1 2 3 4 5 6 
4. Feeling angry, scared 
and/or depressed when I 
think about living with 
diabetes. 
1 2 3 4 5 6 
5. Feeling that my doctor 
doesn't give me clear 
enough directions on 
how to manage my 
diabetes. 
1 2 3 4 5 6 
6. Feeling that I am not 
testing my blood sugars 
frequently enough. 
1 2 3 4 5 6 
7. Feeling that I will end 
up with serious long-term 
complications, no matter 
what I do. 























8. Feeling that I am often 
failing with my diabetes 
routine. 
1 2 3 4 5 6 
9. Feeling that friends or 
family are not supportive 
enough of self-care 
efforts (e.g. planning 
activities that conflict with 
my schedule, 
encouraging me to eat 
the "wrong" foods).  
1 2 3 4 5 6 
10. Feeling that diabetes 
controls my life.  
1 2 3 4 5 6 
11. Feeling that my 
doctor doesn't take my 
concerns seriously 
enough.  
1 2 3 4 5 6 
12. Feeling that I am not 
sticking closely enough 
to a good meal plan.  
1 2 3 4 5 6 
13. Feeling that friends 
or family don't appreciate 
how difficult living with 
diabetes can be.  
1 2 3 4 5 6 
14. Feeling overwhelmed 
by the demands of living 
with diabetes.  
1 2 3 4 5 6 
15. Feeling that I don't 
have a doctor who I can 
see regularly enough 
about my diabetes.  
1 2 3 4 5 6 
16. Not feeling motivated 
to keep up my diabetes 
self-management.  
1 2 3 4 5 6 
17. Feeling that friends 
or family don't give me 
the emotional support 
that I would like.  






Under each heading, please tick the ONE box that best describes your health TODAY  
 
MOBILITY 
I have no problems in walking about q 
I have slight problems in walking about q 
I have moderate problems in walking about q 
I have severe problems in walking about q 




I have no problems washing or dressing myself q 
I have slight problems washing or dressing myself    q 
I have moderate problems washing or dressing myself q 
I have severe problems washing or dressing myself   q 
I am unable to wash or dress myself q 
 
USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities) 
I have no problems doing my usual activities q 
I have slight problems doing my usual activities q 
I have moderate problems doing my usual activities q 
I have severe problems doing my usual activities q 
I am unable to do my usual activities q 
 
PAIN / DISCOMFORT 
I have no pain or discomfort q 
I have slight pain or discomfort   q 
I have moderate pain or discomfort q 
I have severe pain or discomfort   q 
I have extreme pain or discomfort   q 
 
ANXIETY / DEPRESSION  
I am not anxious or depressed q 
I am slightly anxious or depressed q 
I am moderately anxious or depressed q 
I am severely anxious or depressed   q 
I am extremely anxious or depressed   q 
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The best health you can imagine 
We would like to know how good or bad your health is TODAY.                    
This scale is numbered from 0 to 100.  
100 means the best health you can imagine, 0 means the worst 
health you can imagine. 
Mark an X on the scale to indicate how your health is TODAY.  
Now, please write the number you marked on the scale in the 
box below.  
 
                                                                                The worst health you can imagine 
YOUR HEALTH TODAY = __________________ 




Thank you for your time in completing this questionnaire 
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Appendix 9 Clinical Data Forms 
 
Appendix 9.1 Digital Palpation  
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Appendix 9.1 Digital Palpation  
 
Palpation Examination             























LLA   
RAT   
LAT   
RLT   
LLT   
RGM   

















Appendix 9.2 Ultrasound Examination 
 
 




None Injection area    DL/SC 
  RTr                                                                                                                      
LTr 
 












   
RLA 
 
   
LLA    
 
RTA                                                                                        
 LTA    
RLT                                                                                                
LLT                                                                                            
 









RTr, Right Triceps; LTr, Left Triceps; RUA, Right upper abdomen; LUA, Left upper abdomen; RLA, 
Right lower abdomen; LLA, Left lower abdomen; RTA, Right anterior thigh; LTA, Left anterior 
thigh; RLT, Right lateral thigh; LLT, Left lateral thigh; RGM, Right gluteal region; LGM, Left gluteal 












Appendix 10 Continuous Glucose Monitor Diary  
Glucose Variability Study 
(Participant Instructions) 













Care and wearing of CGM sensor 
Ø Please live your life as you would do normally and do not change the 
way you manage your diabetes in any way. If you normally exercise, 
then exercise etc. and do everything as you would usually do. 
Ø Make sure the tape is over the CGM device and sensor to prevent 
accidental removal or sensor movement. If new tape is needed, just 
put it over the existing tape. 
Ø If the CGM device looks like it has come apart from the sensor, then 
please try to gently push it together. 
Ø Check the site for signs of irritation and contact the study nurse (mobile 
phone No) if you have any concerns regarding this. Removal of the 
sensor is simple should you need to, in which case, or if it falls out then 
please place the whole thing tape included into a resalable bag. 
Ø You can bathe, shower and swim while wearing the CGM. The device 
is watertight at a depth of up to 2.4 meters (8 feet) for 30 minutes. There 
is no time limit if you are swimming on the surface of a pool in bath or 
showering. 
Ø The device must be disconnected from the sensor prior to an x-ray, CT 
scan or MRI, so please contact the study nurse if this is an issue 
(Mobile phone no). 
 
 
On the first day: 
Ø Take your first BG meter reading 1 hour after the CGM 
sensor has been inserted 
Ø Take a second BG meter 3 hours after the device has been 
connected. 
Ø Take a reading before each meal 
Ø Collect at least one-meter reading before bed 
Ø To calibrate properly when downloaded at the end of the 
week we need at least four BG meter readings each day – 
ideally before breakfast, before lunch, before evening meal 
and before bed 
Ø Do not change any settings on your meter during the study 
–even if the clocks go forward or back 
Ø Use the same blood glucose meter for all BG meter readings 
Ø Do not let anyone else use your meter during the study 
 
Diary sheet entries 
Ø Write down your BG meter readings, the time you took your 
insulin and the dosage, the food (a photo may be easier) and/ 
or drink you had, and the carb content if you are used to 
estimating this), any physical activity you do – the time and 
duration, and any other symptoms or things of note you may 
experience. 
 
Ø Keep the diary sheet with you at all times. So, you can write 
down the information immediately after each event. 
 
We know the above is a big ask, but it will help us and you tremendously 
at the end of the week to see what is happening with your blood sugar, 





Glucose Variability Study 
(Participant log sheet) 
                                                                                               
Participant’s Study ID______________ 
 







QA     LA 
BG Meals or snacks 
Please describe 
and estimate CHO 
– e.g. fried fish with 
mash, grilled fish 
with chips, or take 




or event e.g. hypo, 
running for 20 




you gave the 
injection 
09:15 QA7 LA 12 7.2 70g two large 
slices of toast and 
some peanut 
butter 
Went swimming for 
20 mins 
 




12:00 QA 6 5.5 60g sandwich and 
crisps 
Stressful 
afternoon, so went 
for a long walk  
18:00 QA 6 8.2 60g avocado and 




22:00 QA6 LA 12 9.2 40g cheese and 
biscuits 
Off to bed 
 
For the next six days: please test your 
blood glucose at least four times and when 
it might be at its lowest, for example: 
before breakfast, lunch, dinner, and 
bedtime. 
 
Please bring your glucose meter with you 












BG Meals or snacks 
Please describe and estimate CHO – e.g. fried fish with 
mash, grilled fish with chips, or take a picture if that is 
easier. 
Comments 
Exercise, activity or event e.g. Went running 
for 20 mins. Really hot day. Had a hypo. 
Please mark roughly 
where you gave the 
injection 
   On day 1 please test your glucose one hour after the 




     
 
     
 
     
 
     
 





Appendix 11 Injection Site and Dose Calculation Form  
 






Dose calculation for use when injection into new area 
 
Current dose    







Appendix 12 Exit Interview Guide 
 
1. General introduction: (mention confidentiality) 
Prompts: 
• Remind me how long have you had Type 1? 
• Where did you have LH (lumps)? 
• Where did we suggest you inject? 
 
• How many units of long acting are you using now? 
• How many units of short acting are you using now? 
• Is that less than you used to be on? Yes/No 
• Is it more?    Yes/No 
• Is it the same?    Yes/No 
 
2. Can you tell me about how you found changing your injection sites? 
Prompts:  
• Was it difficult to move? Yes/No 
• Did you feel you wanted to go back? Yes/No 
• Was the new site painful in comparison?                Yes/No 
• Have you had less swings? Yes/No 
• Do you feel the insulin is more efficient/reliable?     Yes/No 
 
3. What advice or teaching have you been given about your injection sites in the 
past? 
Prompts: How long ago? 
 
• Did you use a grid/guide?     Yes/No 
• Did you divide your sites into quadrants   Yes/No 





4. When you have attended your routine diabetes visits in the past two years 
have health professionals…. 
• Palpated your sites?    Yes/No 
• Looked at your sites visually?  Yes/No 
• Asked you about your sites?   Yes/No 
 





6. LH takes three months to start building up. If we suggested you inject all over 
four large sites/areas (e.g. 1) your upper abdomen, or 2) lower abdomen, or 3) 
flanks, or 4 upper thighs), and inject into one site for three months and then 
move to the next, and so on, so that each has nine months to recover: 
 
• Do you think that would be do-able/achievable?  
 Yes/No 
• What about using the seasons to remind you to change sites?
 Yes/No 
 




8. (If the interviewer feels it is appropriate) Would you like some further support?  










Appendix 13 Standard Operator Procedures  
 
Appendix 13.1 Standard Operator Procedures 1- Physical examination and ultrasound 
scan technique 
Appendix 13.2 Standard Operator Procedures 2- Insertion Technique for the IPro2 
Continuous Glucose Monitor 
Appendix 13.3 Standard Operator Procedures 3- Identification of lipohypertrophy free 




























Appendix 13.1 Standard Operator Procedures 1- Physical examination and 
ultrasound scan technique 
 
This SOP describes the procedure of the physical examination and ultrasound scan 
technique, and the steps that will be followed by the clinicians/researchers, to inform 
and prepare the participant for the data collection.  
A) Physical examination using inspection & digital palpation 
The visual inspection and digital palpation will be carried out by one of the two study 
research nurses. 
Equipment (for examination):  
• Marker pen 
• Gel  
• Examination lamp with an adjustable neck 
Prior to the examination 
• Ensure the room is warm to prevent participant chilling (this ensures participant 
comfort and also prevents shivering and muscle tension, which can interfere with 
the examinations). 
• Explain the procedure to the participant and check informed consent has been 
provided 
• Reminded the participant they are welcome to ask any questions – before, during 
or after the procedure – whether they relate to the science or the procedure 
• Participants will be made aware that the researchers will adhere to universal 
precautions to ensure safety during this data collection 











• Supine position (lying down):  
The participant should initially be lying down on their back (to relax abdominal 
muscles) with knees bent (to relax thigh {quadriceps} muscles), and arms 
folded over chest (to relax arm muscles). 
• Standing position: ask the participant to stand and arms folded over chest, to 
ensure that further LH is not identified. 
Method:  
• Inspect the site with the lamp first. The light should be shined onto the skin surface 
at an angle of 30-45 degrees (obliquely – not overhead) adjusting its angle to be 
able to detect any subtle risings or depressions across the surface of the skin. 
• Ensure hands are washed and warm, apply a water based gel to the site to facilitate 
palpation of the area especially if there are no visible changes or lumps in the site. 
• Palpate the area using slow circular and vertical fingertip movements followed by 
repeated horizontal attempts on the same spot (see figure x). 
• Start with light pressure and increase thereafter to ensure that deeper tissue 
changes are felt. 
• Perform the ‘pinch’ maneuver shown in Figure A to further identify LH changes. 
Comparing the thickness of the suspected spot to that of surrounding areas  

















Figure A. Digital palpation of injection sites. Perform repeated vertical and horizontal 
fingertip movements over and around the area (a–c), ‘pinch’ gently vertically and 
horizontally across the area to further facilitate identification of LH (d–f). Marking (g) 
and measure it if not continuing to ultrasound (h) Gentile et al. (2016a). 
 
Ultrasound Scan  
This SOP is to be used only after the researcher/clinician has completed basic training 
in the use of ultrasound 
The ultrasound scans will be performed by a trained and experienced 
ultrasonographer. 
Equipment 
• SonoSite X-Porte with high-frequency linear probe (6–13 MHz)  






1) Upper arm scan 
Start with asking the participant to rest both arms across the chest or, alternatively, 
both arms resting on the abdomen. Place the transducer in a transverse plane on 
the posterior and lateral aspect of the upper arm (right and left), two finger-widths 
below the acromion and sweep up and down to two to four finger-widths 
(depending on individual limb length and extent of soft tissue in the area) above 
the elbow (Images A and B). 
Image A: Arrows: lateral side of the upper arm; lines: two fingers below acromion and two or four 
fingers above elbow 
 
                                Image B: Arrows: posterior side of the upper arm; lines: two fingers below acromion  
                                          and two or four fingers above elbow                                                                             










Image C: Arrows: midline of the posterior and lateral aspect of the upper arm 
Images will be recorded of any tissue changes thought to be LH. Nodules or diffuse 
areas will be measured and recorded. An image will also be recorded for the posterior 
and lateral side of both arms, on the midline of the upper arm (Image C). If the arm is 
being used as an injection site and tissue changes are measured, then an area 
showing normal skin and tissue depth and type will also be recorded either above or 





2) Abdominal scan 
With the individual in a supine position, place the transducer in a longitudinal plane 
over the outer margin of the right hypochondrial region to examine the upper abdominal 
area, and then sweep side-to-side to the outer margin of the left hypochondriac region. 
When the transducer is moved by sliding, the angle of entry should remain fixed so 
that a series of parallel planes can be scanned. 
The transducer should continue to the lower abdominal area and begin scanning 
from the outer margin of the right lumbar region to the outer margin of the left lumbar 





Image D: Arrows: RT and LT hypochondriac region and RT and LT lumbar region 
 
Image E: Arrows: at the midsternal line and the height of the iliac crest avoiding the umbilicus 
 
Images will be recorded of any tissue changes thought to be LH. Nodules or diffuse 
areas will be measured and recorded. An image will also be recorded and saved of 
the tissue in the midline at the height of the iliac crest (image E). If this is being used 
as an injection site – an area of none injected tissue as close as possible to this will 








3) Thigh scan 
With the individual in a supine position, place the transducer in a transverse plane, 
two to four finger-widths above the knee (depending on limb length and soft tissue 
area), and sweep up and down to the base of the iliac region to scan the anterior 
side of the thigh (right and left) (Image F). 
To scan the lateral side of the thigh (right and left), the individual should be in a 
lateral recumbent position. 
Image F: Arrows: two to four finger-widths above the 




Images will be recorded of any tissue changes thought to be LH. Nodules or diffuse 
areas will be measured and recorded. An image will also be recorded for the anterior 
and lateral side of both thighs, on the midline of the midline of the thigh (Image F). If 
the thigh is being used as an injection site and tissue changes are measured, then an 
area showing normal skin and tissue depth and type will also be recorded either above 














 4)  Gluteal region scans: 
With the individual on lateral (Right or Left) decubitus position, place the transducer 
in a longitudinal plane, over the outer side of the right gluteal area and sweep it side 
to side to the midline. Follow the same technique to scan the left gluteal area (As 








Image H: The midline at the right and left of the posterior 
inferior iliac spine 
 
Images will be recorded of any tissue changes thought to be LH. Nodules or diffuse 
areas will be measured and recorded. An image will also be recorded and saved of 
the tissue in the midline at the right and left of the gluteal area (image H). If this is 
being used as an injection site – an area of none injected tissue as close as possible 












Accuracy of measurement 
The distance from skin surface to muscle fascia will be measured from inner to inner 
side. The normal subcutaneous tissue and skin thickness will be measured for all 
identified injection site. 
Dermis layer: measured from the lower border of the epidermis and to the upper 
border of the subcutaneous tissue. 
Subcutaneous tissue (SC): The layer between the dermis and the muscle fascia. The 
fat tissue acts to preserve neutral fat, cushioning against external physical pressure, 
retaining moisture and generating heat. 
The subcutaneous layer will be measured from the lower border of the dermis layer to 
the upper border of the muscle. 
  
Image I. (+) the distance from the lower border of the epidermis and to the upper border of the SC. (x) 










Lipohypertrophy (LH): When the site of LH is identified, the nodule may not have 
clear edges. For that reason, images should be obtained in both longitudinal and 
transverse planes to maximize information and accuracy of localization (Kaplan et al. 
1990). 
  
Image J. LH measure 
Risks  
Participants-There is a risk of discomfort during the physical examination and 
ultrasound scan. This discomfort will be related to examination.  
Researchers-There are no known risks to the researchers implementing the SOP as 
a result of the protocol itself, or the equipment. 
Ultrasound scan- There are no known risks from the sound waves used in an 
ultrasound scan. It does not involve exposure to radiation. External ultrasound scans 
are generally painless 
SOP created by:  
Prof. Angus Forbes, Dr. Henrietta Mulnier, Ms. Susan Halson-Brown, Rabab Hashem 
(PhD student). 
 [ X ] I acknowledge that as the principal investigator/faculty supervisor I am 
responsible for updating this SOP and notifying the Ethic committees if any of the 




Appendix 13.2 Standard Operator Procedures 2- Insertion Technique for the 
IPro2 Continuous Glucose Monitor 
 
This SOP describes the procedure for inserting the iPro2 continuous glucose monitor 
(CGM) device, and the steps that will be followed to inform and prepare the participant 
for the data collection.  
Prior to insertion 
• Check informed consent has been provided 
• Discuss the positioning of the monitor with the participant to ensure it will not 
interfere with their daily activities. As a guide this should be above the waistband, 
slightly to one side (5-10cm) and on the opposite side from usual sleep position 
or bag/briefcase carriage.  
• Participants are reminded to ask any questions – before, during or after the 
procedure – whether they relate to the science or the procedure.  
• Participants will be made aware that the researchers will adhere to universal 
precautions to ensure safety during this data collection. 
Equipment (for insertion):  
• Gloves 
• Glucose sensor and serter (device that introduces the sensor) 
• Fully charge recording device    
• Sharps bin  
• Cannula Dressings x5  
Preparation for sensor insertion 
• Wash hands thoroughly 
• Wear gloves 





• The skin should be socially clean (shower or bath prior to attending clinic is 
sufficient). If the participant wishes use warm water to clean the area and 
thoroughly dry before inserting the sensor. 
Method:  
Part 1. Inserting a new Sensor 
Hold sensor by pedestal and place on table  
 
 
To load serter, push serter all the way down onto 




Be careful not to force serter too hard onto 




To remove pedestal, place two fingers on pedestal 




To insert sensor, press green button in and release it 
 
Hold serter against body and wait 5 seconds to allow 
time for pressure-sensitive adhesive to stick to skin 
 
Press and hold in green button. 
 
 
While continuing to hold in green button, slowly lift 













With one hand, hold sensor against your body. With other 
hand, hold needle housing at the tip 
 
 
Pull needle housing straight out and dispose of into sharps box 
 
Warning: If bleeding occurs at sensor site (under/around/or on 
top of sensor), apply steady pressure using sterile gauze or clean 
cloth placed on top of sensor for up to three minutes. If bleeding 
does not stop, then remove sensor and apply steady pressure 
until bleeding stops. 
Remove white paper underneath curved adhesive pad. Press 
entire adhesive to skin for several seconds. 
 







Part 2. Taping the Sensor 
Remove large paper backing from overtape. Do not remove 




Important: Attach overtape to both rounded part of sensor 
and skin in front of sensor. 
 
Apply rest of overtape, but do not block sensor connector 





Remove two paper tabs from sides of overtape. Press 
overtape against skin. 
 
 
Overtape covers both sensor and skin 
 
Part 3. Connecting the Transmitter 
With one hand, hold sensor in place. With other hand, connect 
transmitter to sensor 
You will hear a faint “click” when the two components are 
connected. Check for green light to flash on transmitter. 
 
Remove paper on adhesive tab. 
 
Fold adhesive tab over transmitter. Important: Be careful not to pull 









• Make the participant comfortable in a chair. 
• Check participant is feeling ok. 
• Go through the CGM information sheet and monitoring record with the participant 
to ensure that they know exactly what they need to do. In particular, they must be 
informed of what to do should they need to remove the device and also what 
information they need to record and when. Ensure that they fully understand and 
appreciate that the interpretation of the data download at the end of the week will 
only be successful if the blood glucose measurements have been taken as needed 
on the first day and at least four times a day on subsequent days. 
• Make sure the participant can review and reflect what they need to do in the coming 
week and that they feel confident in what they are doing (achieving 7 on a 0 – 10 
scale). 
• Ensure they have at least three spare dressings that they can put on top of the 
originals should they start to peel back. 
Equipment (for removal):  
• Gloves  
• Gauze 
• Plaster 
• Computer with CareLink iPro software installed 
• Download cable 
• Docking device for re-charging 
• Cleaning plug  
Procedure: 
• Explain procedure to participant.  
• Get participant to sit or lie down.  
• Loosen adhesive dressings and when ready remove device and sensor together 
and place in a receptacle.  
• Apply pressure for a short period to the area where the sensor was placed with a 




• Clean the area around sensor of any dried-on blood/dirt with a cleansing wipe.  
• Place a small plaster over the puncture area. 
Cleaning the iPro2 
• Remove the sensor and tape from the device. 
• Insert the cleaning plug and use cleaning solution containing alcohol supplied by 
the manufacturing company. 
• Remove the plug and download the data onto the computer. 
• Insert cleaning plug back in and ensure thoroughly clean and free of previous 
adhesive. Remove the cleaning plug and place on the dock to charge for the next 
participant. Usually 30 minutes. 
Risks  
• Participants  
There is a risk of discomfort during the insertion of the sensor. This discomfort will be 
similar to the prick of a needle that would be obtained from a glucometer. Irritation 
and bleeding at the site may also occur but is rare. These risks will have been 
explained to the participant before consent and before insertion. 
• Researchers  
There is a risk of sharps contamination after insertion of the sensor. To reduce 
this risk the sharp is disposed of directly into a sharps box after insertion. 
SOP created by:  
Prof. Angus Forbes, Dr. Henrietta Mulnier, Rabab Hashem PhD Candidate. 
 [ X ] I acknowledge that as the principal investigator/faculty supervisor I am 
responsible for updating this SOP and notifying the Ethic committees if any of the 







Appendix 12.3 Standard operating procedure 3: Identification of 
lipohypertrophy free injection sites and safety issues regarding use of these 
new injection sites 
 
This SOP describes the steps that will be followed by the study diabetes specialist 
nurse (DSN) to ensure participant safety during their transition to injecting into 
lipohypertrophy (LH) free areas. The DSN will help prepare participants for changing 
to LH free injection areas, by: agreeing their insulin dose; giving advice on blood 
glucose monitoring; and ensuring participants are aware of and can access ongoing 
support. The hazard of greatest risk is hypoglycaemia following a change in injection 
site. The method for insulin dose calculation and reduction to minimise this risk are set 
out below. It is important to emphasise that other than agreeing this dose change no 
additional adjustments will be made to the participant’s insulin delivery technique, so 
that the validity of the study observations is maintained. The DSN will observe the 
following steps for each participant: 
 
Step 1 Identifying LH sites and LH free areas for future injection 
The study DSN will review the ultrasound (US) scan findings with the 
ultrasonographer. Areas of LH will be identified and marked in detail on the case report 
form and on a schema for the participant to take home. The US images will also be 
shown to the participant to reinforce the importance of avoiding these areas. The DSN 
will also print the participants’ CGM traces or for those in the grading arm of the study 
their blood glucose data, to help further reinforce the need to avoid their LH areas. The 












Step 2 set new insulin dose 
A detailed discussion looking at the participant’s glucose monitoring profile and current 
insulin dose will then take place. A weight based dose will be calculated as it would 
for a person starting insulin at diagnosis. Injecting into a new site can result in 
increased insulin sensitivity to a similar state to a new diagnosis, when a safe, but 
effective dose is calculated and agreed. The participant and DSN with then agree a 
safe and cautious reduced insulin dose. This will be documented, and a paper version 
given to the participant to take home for reference. If the participant is at all anxious 
about the dose adjustment, then the study clinician will be contacted to agree a dose 
with the participant. 
 
Example dose calculation 
Participants current 
total daily dose (TDD) 
 
 
50% given as basal 
Rapid 8 10 10 
Basal 14 14  
TDD = 56 units 
 
Current basal = 28 
(14 units am and 14 
units pm) 
Weight calculate total 
daily dose based on 0.6 
units per Kilogram 
 
 
50% given as basal 
80Kg x 0.6units 
= TDD 48 units 
 
 
Basal = 24 
(12 units am 
and 12 units pm 
Recommended 
reduction depending 
on hypoglycaemia risk 
10% to 20% 
20%  10% 
CHO ratio/usual meal 
dose 
1 unit :8g  1 unit: 10g 
Comment 
 
Participant (patient) is confident to take a 10% reduction using the 
calculated dose based on their weight, and use 1:10g 









Participants will be advised by the DSN to monitor and record their blood glucose 
levels at least four times per day. They will ensure that the participant has a fully 
functioning blood glucose monitor and provide them with a second device in case the 
first device fails.  
NB. The DSN will not make any other recommendations or changes to the participant’s 
current insulin delivery model, unless there was a significant clinical hazard in which 
case the adjustments would be advised and the participant would be clinically followed 
up, but they would be excluded from the study.  
 
The participants will be given the study DSN’s mobile phone number and encourage 
to ring this number for advice over the following days. This may be held by other 
experienced DSNs employed by GSTFT to allow cover for holidays and illness. They 
will also be given a second number, which will be for the on-call diabetes medical team 
who are available 24hrs 7 days 
 
Step 3 Insulin safety monitoring phase 
The DSN will contact participants daily to discuss their glucose readings and make 
increases or further reductions in the insulin dose if their glucose levels were 
>12mmols at any time point, <5mmols/l pre-breakfast or <4mmols/l pre meals or 
<6mmols/l pre-bed. Daily contact will continue until the participant’s glucose remains 
within the parameters for three consecutive days. Participants will then be given a 
weekly call to reinforce continuing to inject into LH free tissue and to check for any 
additional hypo or hyperglycaemic episodes. They will also be advised to contact the 
team should they have any queries or concerns. After five weeks for the GV study they 
will return for their follow-up CGM insertion. Then at six weeks all the participants will 
return for a final blood test and the final data collection visit. 
 
NB. While the amount of insulin reduction proposed is not likely to lead to hazardous 






Step 4 Ongoing follow-up 
At the final visit the DSN and participant will discuss the current glucose control and 
insulin doses. Based on this information the DSN will advise the participant on how to 
prevent further problems with LH and re-view the participants entire injection technique 
including needle length in case there are any additional changes that could help the 
participant avoid glucose variability and hypos e.g. taking meal time insulin at the 
optimal time. With the participants permission, the DSN will prepare a clinical summary 
of the results and adjustments made for the participant’s diabetes team and ongoing 





























































Appendix 15: Publications arising from this project 
 

































































15.2 Published abstracts 
The data from this project have been presented at the following conferences as oral 
and poster presentation  
Year Activity  Title  Organisation 
2019 Poster presentation Characterisation of lipohypertrophy: A case 
study using Ultrasound to describe 
lipohypertrophy in different insulin injection 
sites 
FEND* 
2017 Oral presentation  
 
Subcutaneous tissue changes and dermal 
inflammation at insulin injections sites: a 
feasibility study using ultrasound to describe 
characterise and grade lipohypertrophy  
EASD 
2017 Poster presentation Clinical impact of lipohypertrophy on 
glycaemic control: A systematic review and 
meta-analysis 
ADA 
*FEND, Foundation of European Nurses in Diabetes 
 
 
15.3 Publications to prepare 
1. Ultrasound characterisation of LH in T1DM 
2. Standard operator procedure for using Ultrasound to assess LH 
3. Clinical impact of LH on glycaemic control: A systematic review and meta-
analysis 
4. Impact of LH on glucose variability in T1DM 










Characterisation of lipohypertrophy: A case study using Ultrasound to describe 





Subcutaneous tissue changes and dermal inflammation at insulin injections 
sites: a feasibility study using ultrasound to describe characterise and grade 
lipohypertrophy 
 
 
 
